WO2013080156A1 - 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics - Google Patents

3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics Download PDF

Info

Publication number
WO2013080156A1
WO2013080156A1 PCT/IB2012/056829 IB2012056829W WO2013080156A1 WO 2013080156 A1 WO2013080156 A1 WO 2013080156A1 IB 2012056829 W IB2012056829 W IB 2012056829W WO 2013080156 A1 WO2013080156 A1 WO 2013080156A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrido
oxazin
methoxy
dihydro
octahydro
Prior art date
Application number
PCT/IB2012/056829
Other languages
French (fr)
Inventor
Christian Hubschwerlen
Georg Rueedi
Jean-Philippe Surivet
Cornelia Zumbrunn Acklin
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to CN201280058091.3A priority Critical patent/CN103958525A/en
Priority to CA2854266A priority patent/CA2854266A1/en
Priority to US14/362,026 priority patent/US9029368B2/en
Priority to JP2014544023A priority patent/JP2014533747A/en
Priority to EP12813981.3A priority patent/EP2785721A1/en
Publication of WO2013080156A1 publication Critical patent/WO2013080156A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to 3,7-disubstituted octahydro-2H-pyrido[4,3-e][l,3]oxazin- 2-one antibiotic derivatives, pharmaceutical antibacterial compositions containing them and the use of these compounds in the manufacture of a medicament for the treatment of infections (e.g. bacterial infections).
  • infections e.g. bacterial infections
  • These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram positive and Gram negative aerobic and anaerobic bacteria and mycobacteria.
  • Enterobacteriacea are cephalosporin and quinolone resistant;
  • - P. aeruginosa are ⁇ -lactam and quinolone resistant.
  • the present invention describes for the first time trafts-3,7-disubstituted octahydro- 2H-pyrido[4,3-e][l,3]oxazin-2-one derivatives having antibiotic activity.
  • the invention relates to the compounds of formula I wherein the relative configuration of the octahydro-pyrido[4,3-e][l,3 oxazinone moiety is trans
  • K represents the group Ka
  • R la represents alkoxy, halogen or cyano (especially alkoxy);
  • U a , V a , W a represent(s) N and the remaining each represent CH;
  • X a represents CR a wherein R a represents hydrogen or halogen (especially fluorine);
  • A represents CHR b wherein R b represents hydrogen or hydroxyl; or K represents the group Kb
  • R represents hydrogen, alkoxy, halogen or cyano (especially alkoxy); one or two of U b , V b , and W b (especially of U b or W b ) represent(s) N and the remaining each represent CH; or K represents the group Kc or Kd wherein
  • R LC and R LD independently represent H or F
  • V c , V d , W c and W d independently represent CH or N;
  • G represents one of the groups Ga, Gb, Gc and Gd
  • Ga Gb Gc Gd wherein M represents CH or N; and Q and Q' independently represent O or S.
  • the compounds of formula I may contain further stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
  • the compounds of formula I may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • alkyl refers to a saturated straight or branched chain alkyl group containing from one to four carbon atoms.
  • Representative examples of alkyl groups include methyl, ethyl, propyl, /so-propyl, ft-butyl, z ' so-butyl, sec -butyl and tert-butyl.
  • (C x -C y )alkyl (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms.
  • alkoxy refers to a straight or branched chain alkoxy group containing from one to four carbon atoms.
  • (C x -C y )alkoxy refers to an alkoxy group as defined before containing x to y carbon atoms.
  • a (Ci-C3)alkoxy group contains from one to three carbon atoms.
  • Representative examples of alkoxy groups include methoxy, ethoxy, ⁇ -propoxy and /so-propoxy. Preferred are methoxy and ethoxy.
  • halogen refers to fluorine, chlorine, bromine or iodine, preferably to fluorine or chlorine.
  • hydroxy or “hydroxyl” refers to a -OH group.
  • enriched for example when used in the context of enantiomers, is understood in the context of the present invention to mean especially that the respective enantiomer is present in a ratio (mutatis mutandis: purity) of at least 70:30, and notably of at least 90: 10 (mutatis mutandis: purity of 70% / 90%) with respect to the respective other enantiomer.
  • the term refers to the respective essentially pure enantiomer.
  • essentially for example when used in a term such as "essentially pure” is understood in the context of the present invention to mean especially that the respective stereoisomer / composition / compound etc. consists in an amount of at least 90, especially of at least 95, and notably of at least 99 per cent by weight of the respective pure stereoisomer / composition / compound etc.
  • the present invention also relates to pharmacologically acceptable salts and to compositions and formulations of compounds of formula I.
  • Any reference to a compound of formula I in this text (and notably in the embodiments presented above) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
  • pharmaceutically acceptable salts refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
  • room temperature refers to a temperature of 25°C.
  • the term “about” placed before a numerical value "X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X.
  • the term “about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10°C to Y plus 10°C, and preferably to an interval extending from Y minus 5°C to Y plus 5°C.
  • a second embodiment relates to the compounds of formula I according to embodiment 1) which are also compounds of formula I :
  • a third embodiment relates to the compounds of formula I according to embodiment 1) which are also compounds of formula I :
  • K represents the group Ka or Kb.
  • the compounds of formula I according to embodiment 4) will be such that K represents the group Ka wherein R la represents methoxy, or such that K represents the group Kb wherein R lb represents methoxy.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to
  • a further embodiment relates to the compounds according to any one of embodiments 1) to
  • R la represents alkoxy (especially methoxy);
  • U a represents N, or U a and V a both represent N, or, especially, U a and W a both represent N; and the remaining of V a and W a each represent CH;
  • X a represents CR a wherein R a represents hydrogen or fluorine (especially R a represents fluorine);
  • A represents CHR b wherein R b represents hydrogen or hydroxyl (especially R b represents hydrogen).
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 7) wherein, in case K represents the group Ka, A represents CHR b and R b represents hydroxyl, the absolute configuration of the carbon atom to which R b is attached to being (R).
  • a further embodiment relates to the compounds according to any one of embodiments 1) to
  • K represents the group Ka and A represents CHR b wherein R b represents hydrogen.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 6) wherein K represents the group Ka, A represents CHR b wherein R b represents hydroxyl, and the absolute configuration of the carbon atom to which R b is attached to is (R).
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 6) wherein K represents the group Ka wherein R la represents methoxy, U a and W a each represent N and V a and X a each represent CH, X a represents CR a wherein R a represents fluorine and A represents CHR b wherein R b represents hydrogen or hydroxyl.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 5) wherein K represents the group Kb. 13) A further embodiment relates to the compounds according to embodiment 12) wherein R lb represents methoxy, U b represents N, V b represents CH and W b represents CH or N.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 4) and 12) wherein, in case K represents Kb, at least one of the following characteristics (in any combination) is present:
  • ⁇ R lb represents hydrogen or alkoxy (notably alkoxy, especially methoxy);
  • U b represents N, or U b and W b both represent N, or U b and V b both represent N; and the remaining of V b and W b each represent CH.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 3) wherein K represents the group Kc or Kd.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 3) and 15) wherein, in case K represents Kc or Kd, at least one of the following characteristics (in any combination) is present:
  • R lc or respectively, R ld represents F
  • V c and W c both represent CH, V c represents N and W c represents CH, or W c represents N and V c represents CH, or V c and W c both represent N (in a sub-embodiment: V c and W c both represent CH, or V c represents N and W c represents CH); or respectively
  • V d and W d both represent CH, V d represents N and W d represents CH, or W d represents N and V d represents CH, or V d and W d both represent N (in a sub-embodiment: V d and W d both represent CH, or V d represents N and W d represents CH). 17)
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 16) wherein G represents one of the groups Ga, Gb, Gc and Gd
  • Ga Gb Gc Gd wherein M represents CH and Q' represent O or S, or M represents N and Q' represents S, and Q represents O or S.
  • a further embodiment relates to the compounds according to any one of embodiments 1) to 17) wherein G represents Gd, wherein M represents CH and Q' represent O or S, or M represents N and Q' represents S.
  • a further embodiment relates to compounds according to any one of embodiments 1) to 17) wherein G represents Ga, Gb or Gc, wherein Q represents O or S.
  • a further embodiment relates to compounds of formula I according to one of embodiments 1) to 3), wherein:
  • R la represents methoxy
  • U a and W a each represent N and V a and X a each represent CH;
  • X a represents CR a wherein R a represents fluorine
  • A represents CHR b wherein R b represents hydrogen or hydroxyl
  • R represents methoxy
  • U b represents N
  • V b represents CH
  • W b represents CH or N
  • the compounds of formula I according to embodiment 20) will be such that K represents the group Ka, wherein Ka and R la , U a , V a , W a , X a and A are as defined in embodiment 20).
  • the compounds of formula I according to embodiment 20) will be such that K represents the group Kb, wherein Kb and R lb , U b , V a and W b are as defined in embodiment 20).
  • the compounds of formula I according to one of embodiments 20) to 22) will be such that G represents the group Gb, wherein Gb is as defined in embodiment 20).
  • the compounds of formula I according to one of embodiments 20) to 22) will be such that G represents the group Gc, wherein Gc and Q are as defined in embodiment 20).
  • a further embodiment of the present invention relates to the compounds of formula I according to embodiment 1), which are selected from the group consisting of:
  • the above listed compounds having the relative configuration (4aR*,8aR*) preferably are enantiomerically enriched, having either the absolute configuration (4aR,8aR), or the absolute configuration (4aS,8aS).
  • a further embodiment of the present invention relates to the compounds of formula I according to embodiment 1), which are selected from the group consisting of:
  • the above listed compounds having the relative configuration (4aR*,8aR*) preferably are enantiomerically enriched, having either the absolute configuration (4aR,8aR), or the absolute configuration (4aS,8aS).
  • the invention furthermore relates to the groups of compounds of formula I selected from the group consisting of the compounds listed in embodiments 25) and 26), which groups of compounds furthermore correspond to one of embodiments 2) to 24), as well as to the salts (in particular the pharmaceutically acceptable salts) of such compounds.
  • the invention moreover relates to any individual compound of formula I selected from the group consisting of the compounds listed in embodiments 25) and 26), and to the salts (in particular the pharmaceutically acceptable salts) of such individual compound.
  • the present invention also includes isotope labelled, especially 2 H (deuterium) labelled compounds of formula I as defined in any one of embodiments 1) to 28), which compounds are identical to the compounds of formula I except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • Isotope labelled, especially 2 H (deuterium) labelled compounds of formula I and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g.
  • the compounds of formula I are not isotope labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula I are not isotope labelled at all. Isotope labelled compounds of formula I may be prepared in analogy to the methods described hereinafter, but using the appropriate isotope variation of suitable reagents or starting materials.
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula I or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
  • compositions comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient / carrier material.
  • a pharmaceutical composition according to the present invention contains at least one compound of formula I (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants, and may also contain additional known antibiotics.
  • the administered amount is comprised between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day.
  • the production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, CO, USA, 2001 ; Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science) by bringing the described compounds of formula I and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the compounds of formula I according to this invention, or the pharmaceutically acceptable salts thereof may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of a bacterial infection.
  • Another aspect of the invention concerns a method for the prevention or the treatment of a bacterial infection in a patient comprising the administration to said patient of a pharmaceutically active amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
  • bacterial infections can also be treated using compounds of formula I (or pharmaceutically acceptable salts thereof) in other species like pigs, ruminants, horses, dogs, cats and poultry.
  • the compounds of formula I may also be used for cleaning purposes, e.g. to remove pathogenic microbes and bacteria from surgical instruments or to make a room or an area aseptic.
  • the compounds of formula I could be contained in a solution or in a spray formulation.
  • the compounds of formula I according to the invention are suitable for the use as substances for preserving inorganic and organic materials in particular all types of organic materials for example polymers, lubricants, paints, fibres, leather, paper and wood.
  • the compounds of formula I according to the invention are particularly active against bacteria and bacteria-like organisms. They are therefore particularly suitable in human and veterinary medicine for the prophylaxis and chemotherapy of local and systemic infections caused by these pathogens as well as disorders related to bacterial infections comprising pneumonia, otitis media, sinusitis, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E. faecium, E. casseliflavus, S. epidermidis, S.
  • strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracyclines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S. epidermidis, S.
  • Streptococcus pyogenes Streptococcus agalactiae
  • Streptococcal groups C-F minute colony streptococci
  • viridans streptococci Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae
  • uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp.
  • urethritis and cervicitis sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiseria gonorrhoeae; toxin diseases related to infection by S.
  • aureus food poisoning and toxic shock syndrome
  • Groups A, B, and C streptococci ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H.
  • MAC Mycobacterium avium complex
  • chelonei gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by B or detella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylori or Chlamydia pneumoniae.
  • the compounds of formula I according to any one of embodiments 1) to 28) are further useful for the preparation of a medicament for the treatment of infections that are mediated by Gram negative bacteria, such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp. including Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Neisseria meningitidis, and Bacteroides spp.
  • Gram negative bacteria such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp. including Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Neisseria meningitidis, and Bacteroides spp.
  • the compounds of formula I according to any one of embodiments 1) to 28) are further useful for the preparation of a medicament for the treatment of infections that are mediated by Gram positive bacteria such as Bacillus cereus, Bacillus anthracis, Clostridium difficile, Corynebacterium spp. and Propionibacterium acnes.
  • Gram positive bacteria such as Bacillus cereus, Bacillus anthracis, Clostridium difficile, Corynebacterium spp. and Propionibacterium acnes.
  • the compounds of formula I according to any one of embodiments 1) to 28) are further useful to treat protozoal infections caused by Plasmodium malaria, Plasmodium falciparum, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma brucei and Leishmania spp.
  • the present list of pathogens is to be interpreted merely as examples and in no way as limiting.
  • any preferences indicated for the compounds of formula I (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of formula 3 ⁇ 4i and 1 ⁇ 2 ⁇
  • This invention thus, relates to the compounds of formula I as defined in embodiment 1), or further limited under consideration of their respective dependencies by the characteristics of any one of embodiments 2) to 28), and to pharmaceutically acceptable salts thereof. It relates furthermore to the use of such compounds as medicaments, especially for the prevention or treatment of bacterial infections (i.e. infections that are mediated by Gram negative bacteria or infections that are mediated by Gram positive bacteria), in particular for the prevention or treatment of bacterial infections caused by Staphylococcus aureus bacteria, and notably caused by quinolone -resistant Staphylococcus aureus bacteria.
  • bacterial infections i.e. infections that are mediated by Gram negative bacteria or infections that are mediated by Gram positive bacteria
  • Staphylococcus aureus bacteria i.e. infections that are mediated by Staphylococcus aureus bacteria, and notably caused by quinolone -resistant Staphylococcus aureus bacteria.
  • the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures. Sections a) to f) hereafter describe general methods for preparing compounds of formula I.
  • the compounds of formula I can be manufactured by a) reacting a compound of formula II
  • K is as defined in formula I, provided that when K is Ka, A is CH 2 , using general reaction technique 3; or d) reacting a compound of formula II with a compound of formula VI
  • LG represents chloro, bromo, iodo, OTf, OTs or OMs.
  • the reaction can be performed in various solvents such as DMF, DMA, NMP, in presence of a base such as DIPEA or TEA at a temperature ranging between 20°C and 100°C; or e) reacting a compound of formula VII
  • PG represents 4-methoxybenzyl or 2,4- dimethoxybenzyl or 3,4-dimethoxybenzyl.
  • the deprotection reaction can be performed using acidic conditions such as TFA, TfOH, or a combination of TFA and TfOH at a temperature ranging between 20°C and 100°C.
  • the compounds of formula I thus obtained may be, if desired, converted into their salts, and notably into their pharmaceutically acceptable salts.
  • the diastereomers can be separated using methods known to one skilled in the art, e.g. by HPLC over a chiral stationary phase such as a Regis Whelk-Ol(R,R) (10 ⁇ ) column, a Daicel ChiralCel OD-H (5-10 ⁇ ) column, or a Daicel ChiralPak IA (10 ⁇ ) or AD-H (5 ⁇ ) column.
  • a chiral stationary phase such as a Regis Whelk-Ol(R,R) (10 ⁇ ) column, a Daicel ChiralCel OD-H (5-10 ⁇ ) column, or a Daicel ChiralPak IA (10 ⁇ ) or AD-H (5 ⁇ ) column.
  • Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as TEA or diethylamine) and eluent B (Hex), at a flow rate of 0.8 to 150 mL/min.
  • EtOH eluent A
  • Hex eluent B
  • the mixtures of diasteromers may also be separated by an appropriate combination of silica gel chromatography, HPLC and crystallization techniques.
  • PG 1 is an amine protecting group, such as a Boc, Cbz, Alloc or Fmoc and L 1 represents CI, Br, I or OTf.
  • the compounds of formula Ilia can be prepared as described in WO 02/08224, WO 2004/058144, WO 2006/021448, WO 2007/016610, WO 2007/107965 and WO 2010/041194 or by analogy to these reported methods.
  • the compounds of formula Illb can be prepared as described in WO 2007/071936 and WO 2010/041194 or by analogy to these reported methods.
  • the compounds of formulae IVa, IVb and IVc can be prepared as described in WO 00/78748, WO 02/08224, WO 2006/02047, WO 2006/21448 and WO 2006/032466.
  • the compounds of formula V wherein K represents Kb can be prepared as described in WO 2006/137485, WO 2007/138974, WO 2009/09700 and WO 2009/69589.
  • the compounds of formula V wherein K represents Kc can be prepared by oxidation of the corresponding primary alcohols using general reaction technique 7.
  • the compounds of formula V wherein K represents Kd can be prepared by oxidation of the corresponding primary alcohols using general reaction technique 7.
  • LG represents OTf, OMs, OTf or halogen such as bromine, chlorine or iodine.
  • G is as defined in formula VII
  • PG 1 is an amine protecting group, such as a Boc, Cbz, Alloc or Fmoc and K is as defined in formula I, provided that A represents CH 2 .
  • the compounds of formula III-l can be deprotected (Scheme 3) using general reaction technique 6, leading to the intermediates of formula III-2.
  • the formation of the compounds of formula VII can then be achieved using methods which have been described for the preparation of compounds of formula I wherein A is CH 2 , section a), c), d) and f) using respectively precursors of formulae Ilia, Illb, V and VI.
  • PG represents 4-methoxybenzyl, 2,4-dimethoxybenzyl or 3,4-dimethoxybenzyl
  • PG 1 is an amine protecting group, such as a Boc, Cbz, Alloc or Fmoc
  • L 2 represents OTf or a halogen such as CI, Br or I.
  • the compounds of formula 1-1 can be reacted (Scheme 4) with the compounds of formula IV-1, wherein L represents OTf or a halogen such as CI, Br or I using general reaction technique 5.
  • L represents OTf or a halogen such as CI, Br or I
  • the protecting group PG 1 in the intermediates of formula IV-2 is removed using general reaction technique 6 affording the intermediates of formula IV-3 which are further transformed into the derivatives of formula IX using methods which have been described for the preparation of compounds of formula I wherein A is CH 2 , section a), c), d) and f), using respectively precursors of formulae Ilia, Illb, V and VI.
  • PG 1 represents an amino protecting group such Boc or Cbz.
  • the compounds of formula II- 1 wherein K represents Ka can be obtained by reduction of the corresponding aldehydes using general reaction technique 9.
  • the required aldehydes can be made according to J. Chem. Soc. (1957), 3066-3071, WO 02/089749, WO 2003/050132, WO 2005/108389, WO 2005/016916 or in analogy to methods reported therein.
  • the compounds of formula II- 1 wherein K represents Kb can be obtained according to WO 2006/137485, WO 2007/138974, WO 2008/009700 and WO 2009/069589.
  • the compounds of formula II- 1 wherein K represents Kc are obtained by reduction of the corresponding aldehydes using general reaction technique 9.
  • the required aldehydes are made according to WO 2010/41194 or in analogy to the method reported therein.
  • the compounds of formula II- 1 wherein K represents Kd can be obtained by reduction of the corresponding aldehydes using general reaction technique 9.
  • the required aldehydes can be made according to WO 2008/03690 and WO 2009/104147 or in analogy to the methods reported therein.
  • G is as defined in formula I.
  • PG 1 and PG 2 are orthogonal amine protecting groups, such as a Boc, alloc, Cbz or Fmoc.
  • L is CI, Br, I, OMs, OTs or OTf.
  • the compounds of formula VI-2 can be obtained (Scheme 6) from the compounds of formula VI-1 (commercially available when PG 1 represents Cbz or Boc) using general technique reaction 8.
  • the sodio anion of compounds of formula VI-3 which are formed by reacting the compounds of formula VI-3 with sodium hydride in an appropriate solvent such as DMF are subsequently reacted with the compound of formula VI-2 at a temperature ranging between 25 °C and 100°C and especially at 60°C to afford directly the compounds of formula III- 1.
  • the protecting group PG can be removed using general reaction technique 6.
  • L 2 is CI, Br or I.
  • PG is an amine protecting group such as a 4-methoxybenzyl or 3,4-dimethoxybenzyl
  • Q' represents O or S and M is N or CH.
  • the compounds of formula VII- 1 can be reacted with 4-methoxybenzyl, 2,4-dimethoxybenzyl or 3,4-dimethoxybenzyl chloride in the presence of a base such as CS 2 CO 3 in a solvent such as DMF at a temperature ranging between 20°C and 100°C, affording the compound of formula IV- 1.
  • a base such as CS 2 CO 3
  • solvent such as DMF
  • the compound of formula V-l wherein PG 1 is Boc is commercially available.
  • the other analogues can be made from (3R,4R)-4-(aminomethyl)-3-piperidinol (prepared according to WO 2005/000838) using general reaction technique 10.
  • the compound of formula VI-3 wherein G represents Gc and PG represents Boc can be prepared from the corresponding acids of formula VIII- 1 via a Curtius reaction.
  • the compounds of formula VIII- 1 can for instance be reacted with DPPA in 2-methyl-2-propanol in presence of TEA at a temperature between 50°C and reflux.
  • the compounds of formula VI-3 can be prepared from the compounds of formula VIII-2 using general reaction technique 10.
  • the compounds of formula VIII- 1 are either commercially available or can be prepared according to WO 2004/58144, WO 02/56882, WO 2006/105289, WO 2007/16610 or J. Org. Chem. (1968), 33(1), 456-457.
  • G represents Gc
  • they can also be obtained by saponification of the corresponding ester using general reaction technique 1 1 as shown in Scheme 9 hereafter.
  • the required esters can be prepared according to WO 2007/081597.
  • IPr 1.3 bis(2,6-diisopropylphenyl)-l,3-dihydro-2H-imidazol-2-ylidene
  • JosiPhos ligands (R)-l-[(SP)-2-(di-tert-butylphosphino)ferrocenyl]ethylbis(2-methyl- phenyl)phosphine or (R)-l-[(SP)-2-(di-tert-butyl- phosphino)ferrocenyl]ethyldiphenylphosphine or
  • PEPPSITM-IPr [ 1 ,3-bis(2,6-diisopropylphenyl)imidazol- 2-ylidene](3-chloropyridyl)palladium(II) di chloride
  • reaction . technique . 1 (addition of . piperidine derivative onto . an a . lkene) :
  • a piperidine derivative onto an alkene can be accomplished in various solvents such as DMF, DMA or NMP in presence of a promoter such a TMG at a temperature ranging between 60°C and 100°C.
  • a piperidine derivative onto an epoxide can be accomplished in various solvent such as DMF, DMA, NMP in presence of a mineral base such as K 2 CO 3 and a Lewis acid such as LiC10 4 at a temperature ranging between 60°C and 100°C.
  • the reaction between an amine and an aldehyde is performed in a solvent system allowing the removal of the formed water through physical or chemical means (e.g. distillation of the solvent-water azeotrope or presence of drying agents such as molecular sieves, MgS0 4 or Na 2 S0 4 ).
  • solvent is typically toluene, Hex, THF, NMP, DCM or DCE or a mixture of solvents such as DCE/MeOH.
  • the reaction can be catalyzed by traces or a stoichiometric amount of acid (usually AcOH or /?-TsOH).
  • the intermediate imine is reduced with a suitable reducing agent (e.g.
  • reaction is carried out between -10° and +110°C, preferably between 0°C and 60°C.
  • the reaction can also be carried out in one pot. It can also be performed in protic solvents such as MeOH or water in the presence of a picoline-borane complex (Tetrahedron (2004), 60, 7899-7906).
  • the aminoalcohol derivative was reacted with phosgene, diphosgene, triphosgene, carbonyldiimidazole or di-O-succinyl carbonate.
  • the reaction is preferably carried out in a dry aprotic solvent such as DCM or THF in presence of an organic base such as TEA or pyridine and at a temperature range between -78°C and +80°C.
  • halide or triflate aromatic partner is reacted with the required 7-protected octahydro- 2H-pyrido[4,3-e][l,3]oxazin-2-one derivative in the presence of a palladium catalyst in a solvent such as toluene, THF, dioxane, DME or DMF.
  • a palladium catalyst in a solvent such as toluene, THF, dioxane, DME or DMF.
  • typical palladium catalysts are triarylphosphine palladium complexes such as Pd(PPh 3 ) 4 .
  • These catalysts can also be prepared in situ from a common palladium source such as Pd(OAc) 2 or Pd 2 (dba) 3 and a ligand such as trialkylphosphines (e.g.
  • PCy 3 or P(tBu) 3 dialkylphosphinobiphenyls (e.g. X-Phos or BrettPhos), chelating diphosphines (e.g. ⁇ , XantPhos) or ferrocenylphosphines (e.g. Q-phos).
  • dialkylphosphinobiphenyls e.g. X-Phos or BrettPhos
  • chelating diphosphines e.g. ⁇ , XantPhos
  • ferrocenylphosphines e.g. Q-phos
  • a commercially available precatalyst based on palladacycle e.g. SK-CC02-A
  • N-heterocyclic carbene complexes e.g. PEPPSITM-IPr
  • a copper catalysed coupling reaction between the above mentioned partners can be performed using a copper (I) source such as copper iodide, a ligand such as trans-N,N'-dimethyl-l,2-cyclohexanediamine, a base such as K 2 CO 3 in a solvent such as dioxane at a temperature ranging between 50°C and reflux.
  • a copper (I) source such as copper iodide
  • a ligand such as trans-N,N'-dimethyl-l,2-cyclohexanediamine
  • a base such as K 2 CO 3
  • a solvent such as dioxane
  • reaction technique . 6 (removal , of amine . protecting . groups) . : .
  • the benzyl carbamates are deprotected by hydrogenolysis over a noble metal catalyst (e.g. Pd/C or Pd(OH) 2 /C).
  • a noble metal catalyst e.g. Pd/C or Pd(OH) 2 /C.
  • the Boc group is removed under acidic conditions such as HC1 in an organic solvent such as MeOH or dioxane, or TFA neat or diluted in a solvent such DCM.
  • the Alloc group is removed by the action of tetrakis(triphenylphosphine)palladium(0) in presence of an allyl cation scavenger such as morpholine, dimedone or tributyltin hydride between 0°C and +50°C in a solvent such as THF.
  • the Fmoc group is removed under mild basic conditions such as piperidine in DMF.
  • the N-acetyl protecting group is removed under basic conditions such as Na 2 CO 3 , LiOH or NaOH in aq. MeOH or THF, or under acidic conditions such as aq. HC1 in THF.
  • the N-benzyl protected amines are deprotected by hydrogenolysis over a noble catalyst (e.g. Pd(OH) 2 ).
  • the 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl or 4-methoxybenzyl protecting group can be removed by reaction with TFA. Further general methods to remove amine protecting groups have been described in Protecting Groups in Organic Synthesis, 3 rd Ed 1999, 494-653; T.W. Greene, P.G.M. Wuts (Publisher: John Wiley and Sons, Inc., New York).
  • the alcohol is reacted with MsCl, TfCl or TsCl in presence of a base such as TEA in a dry aprotic solvent such as Pyr, THF or DCM between -30°C and +50°C.
  • a base such as TEA
  • a dry aprotic solvent such as Pyr, THF or DCM between -30°C and +50°C.
  • Tf 2 0 or Ms 2 0 can also be used.
  • These sulfonates can be reacted with a sodium halogenide such as Nal or NaBr in MeCN or DMF between 40°C and 120°C delivering the corresponding iodide derivatives.
  • the corresponding bromides or chlorides can also be obtained by reaction of the corresponding alcohol derivatives with PBr 3 or PC1 3 respectively.
  • a ketone or an aldehyde is reduced with a boron or aluminium hydride reducing agent such as LiBH 4 , NaBH 4 or LAH in a solvent such as THF between -20°C and +40°C.
  • a boron or aluminium hydride reducing agent such as LiBH 4 , NaBH 4 or LAH
  • a solvent such as THF between -20°C and +40°C.
  • Amines are usually protected as carbamates such as Alloc, Cbz, Boc or Fmoc. They are obtained by reacting the amine with allyl- or benzyl- chloroformate, di tert-butyl dicarbonate or Fmoc chloride in presence of a base such as NaOH, TEA, DMAP or imidazole. Further strategies to introduce other amine protecting groups have been described in Protecting Groups in Organic Synthesis, 3rd Ed (1999), 494-653; T.W. Greene, P.G.M. Wuts; (Publisher: John Wiley and Sons, Inc., New York, N.Y.).
  • the methyl and ethyl esters are deprotected by saponification with an alkali hydroxide such as NaOH, LiOH or KOH, benzyl ester by hydrogeno lysis over a noble metal catalyst such as Pd/C.
  • the tert-butyl esters are deprotected by treatment with TFA (neat or diluted in an organic solvent such as DCM) or a solution of HC1 in an organic solvent such as dioxane.
  • UV/Vis and/or MS and/or ELSD UV/Vis and/or MS and/or ELSD.
  • Methyl triphenyl phosphonium bromide (154 g, 430 mmol) was suspended in THF (1 L) and cooled to 0°C.
  • KOtBu (44.4 g, 400 mmol) was added in one portion and the yellow suspension was stirred at 0°C for 15 min before a solution of 6-fluoro-3-methoxyquinoxaline- 5-carbaldehyde (71 g, 340 mmol) in THF (550 mL) was added dropwise over 70 min. The mixture was stirred at 0°C for 60 min. Sat. NH 4 C1 solution (250 mL) and water (250 mL) were added and the phases were separated. The org.
  • Example 3 (4aR*, « R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(2RS)-2-hydroxy- 2-(6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one (mixture of stereoisomers): Typical procedure for an epoxide opening with an oxazinone moiety
  • Example 4 rac-(4aR *,8aR *)-3-(2,3-dih dro-benzo [1,4] dioxin-6-yl)-7- [2-(6-methoxy- [l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one: Starting from 2-methoxy-8-vinyl-l,5-naphthyridine (0.0215 g, 0.115 mmol) and intermediate B.ii.
  • the title compound was obtained as an off-white foam (0.017 g, 31% yield) using the procedure described in Examples 1 and 2, step 1/2. i.
  • the crude material was purified by CC (DCM/MeOH 19: 1 + 0.5% aq. NH 4 OH).
  • Example 7 r c-( R*,5 R*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]- 3-(3-oxo-3,4-dihy dro-2H-benzo [ 1,4] thiazin-6-yl)-octahy dro-py rido [4,3-e] [ 1,3 ] oxazin-
  • Example 9 rac-(4aR *,8aR *)-3-(2,3-dihy dro-benzo [1,4] dioxin-6-yl)-7- [2-(7-methoxy- 2-oxo-2H-quinoxalin-l-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one:
  • Example 12 r c-( R*,5 R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-methoxy- 6-oxo-6H-pyrido [2,3-6] pyrazin-5-yl)-ethyl] -octahy dro-pyrido [4,3-e] [1,3] oxazin-2-one: Starting from 2-(3-methoxy-6-oxopyrido[2,3-b]pyrazin-5(6H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.04 g, 0.161 mmol) and intermediate B.ii (0.050 g, 0.172 mmol), the title compound was obtained as a yellowish foam (0.046 g, 54% yield) using the procedure described in Example 8.
  • Example 17 (4aR *,8aR *)-3-(2,3-dihydro-benzo [1,4] dioxin-6-yl)-7-[(2RS)-2-(6-fluoro- 3-methoxy-quinoxalin-5-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one (mixture of stereoisomers):
  • Example 19 r c-( ⁇ aR*,*aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]- 3-(3-oxo-3,4-dihydro-2H-pyrido [3,2-6] [1,4] oxazin-6-yl)-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
  • Example 23 r c-( R*,5 R*)-3-(6,7-dihydro-[l,4]dioxino[2,3-c]pyridazin-3-yl)- 7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one: Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.023 g, 0.11 mmol) and intermediate K (0.033 g, 0.11 mmol), the title compound was obtained as a yellowish foam (0.037 g, 66%o yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH 4 OH).
  • Example 24 r c-( ⁇ aR*, «aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-c]pyridin-7-yl)- 7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
  • Example 32 (4aR*, « R*)-7-(( ⁇ RS)-2-(3-fluoro-6-methoxy-l,5-naphthyridin-4-yl)- 2-hydroxyethyl)-3-(3-oxo-3,4-dihydro-2H-benzo [b] [1,4] oxazin-6-yl)octahydro- 2H-pyrido [4,3-e] [1,3] oxazin-2-one:
  • Bacterial growth minimal inhibitory concentrations Experimental methods: Minimal inhibitory concentrations (MICs; mg/1) were determined in cation-adjusted Mueller- Hinton Broth by a microdilution method following the description given in "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically", Approved standard, 7 th ed., Clinical and Laboratory Standards Institute (CLSI) Document M7-A7, Wayne, PA, USA, 2006. All Example compounds were tested against several Gram positive and Gram negative bacteria. Typical antibacterial test results are given in the table hereafter (MIC in mg/1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to antibacterial compounds of Formula (I) wherein G and K are as defined in the description; and salts of such compounds.

Description

3,7-disubstituted octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one antibiotics
The present invention relates to 3,7-disubstituted octahydro-2H-pyrido[4,3-e][l,3]oxazin- 2-one antibiotic derivatives, pharmaceutical antibacterial compositions containing them and the use of these compounds in the manufacture of a medicament for the treatment of infections (e.g. bacterial infections). These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram positive and Gram negative aerobic and anaerobic bacteria and mycobacteria.
The intensive use of antibiotics has exerted a selective evolutionary pressure on micro-organisms to produce genetically based resistance mechanisms. Modern medicine and socio-economic behaviour exacerbates the problem of resistance development by creating slow growth situations for pathogenic microbes, e.g. in artificial joints, and by supporting long-term host reservoirs, e.g. in immuno-compromised patients.
In hospital settings, an increasing number of strains of Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp., and Pseudomonas aeruginosa, major sources of infections, are becoming multi-drug resistant and therefore difficult if not impossible to treat:
- S. aureus is resistant to β-lactams, quinolones and now even to vancomycin;
- S. pneumoniae is becoming resistant to penicillin or quinolone antibiotics and even to new macrolides;
- Enteroccocci are quinolone and vancomycin resistant and β-lactam antibiotics are inefficacious against these strains;
- Enterobacteriacea are cephalosporin and quinolone resistant;
- P. aeruginosa are β-lactam and quinolone resistant.
Further new emerging organisms like Acinetobacter spp. or Clostridium difficile, which have been selected during therapy with the currently used antibiotics, are becoming a real problem in hospital settings. In addition, microorganisms that are causing persistent infections are increasingly being recognized as causative agents or cofactors of severe chronic diseases like peptic ulcers or heart diseases. The present invention describes for the first time trafts-3,7-disubstituted octahydro- 2H-pyrido[4,3-e][l,3]oxazin-2-one derivatives having antibiotic activity.
Various embodiments of the invention are presented hereafter:
1) The invention relates to the compounds of formula I wherein the relative configuration of the octahydro-pyrido[4,3-e][l,3 oxazinone moiety is trans
Figure imgf000003_0001
wherein
K represents the group Ka
Figure imgf000003_0002
Ka
wherein Rla represents alkoxy, halogen or cyano (especially alkoxy);
one or two (especially two) of Ua, Va, Wa represent(s) N and the remaining each represent CH;
Xa represents CRa wherein Ra represents hydrogen or halogen (especially fluorine);
A represents CHRb wherein Rb represents hydrogen or hydroxyl; or K represents the group Kb
Figure imgf000003_0003
wherein R represents hydrogen, alkoxy, halogen or cyano (especially alkoxy); one or two of Ub, Vb, and Wb (especially of Ub or Wb) represent(s) N and the remaining each represent CH; or K represents the group Kc or Kd wherein
Figure imgf000004_0001
Kc Kd wherein RLC and RLD independently represent H or F;
Vc, Vd, Wc and Wd independently represent CH or N; and
G represents one of the groups Ga, Gb, Gc and Gd
Figure imgf000004_0002
Ga Gb Gc Gd wherein M represents CH or N; and Q and Q' independently represent O or S.
The relative configuration of the octahydro-pyrido[4,3-e][l,3]oxazinone moiety is trans; i.e. the compounds of formula I are either compounds of formula IE1, or compounds of formula IE2, or any mixture thereof (such as racemates):
Figure imgf000004_0003
IEI IE2 The relative configuration of stereoisomers is denoted as follows: for example, (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-methoxy-6-oxo- 6H-pyrido[2,3-b]pyrazin-5-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one, if not explicitly mentioned as racemate, denominates (4aR,SaR)-3-(2,3-dihydro- benzo[l,4]dioxin-6-yl)-7-[2-(3-methoxy-6-oxo-6H-pyrido[2,3-b]pyrazin-5-yl)-ethyl]- octahydro-pyrido[4,3-e][l,3]oxazin-2-one or (^aS,5aS)-3-(2,3-dihydro-benzo[l,4]dioxin- 6-yl)-7-[2-(3-methoxy-6-oxo-6H-pyrido[2,3-b]pyrazin-5-yl)-ethyl]-octahydro- pyrido[4,3-e][l,3]oxazin-2-one, or any mixture of these two enantiomers (including the racemic mixture). The compounds of formula I may contain further stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. The compounds of formula I may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
The following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and other expressions used in this text and are intended to apply uniformly throughout the specification and claims, unless an otherwise expressly set out definition provides a broader or narrower definition.
The term "alkyl", used alone or in combination, refers to a saturated straight or branched chain alkyl group containing from one to four carbon atoms. Representative examples of alkyl groups include methyl, ethyl, propyl, /so-propyl, ft-butyl, z'so-butyl, sec -butyl and tert-butyl. The term "(Cx-Cy)alkyl" (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms.
The term "alkoxy", used alone or in combination, refers to a straight or branched chain alkoxy group containing from one to four carbon atoms. The term "(Cx-Cy)alkoxy" (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example, a (Ci-C3)alkoxy group contains from one to three carbon atoms. Representative examples of alkoxy groups include methoxy, ethoxy, ^-propoxy and /so-propoxy. Preferred are methoxy and ethoxy.
The term "halogen" refers to fluorine, chlorine, bromine or iodine, preferably to fluorine or chlorine. The term "hydroxy" or "hydroxyl" refers to a -OH group.
In this text, a bond interrupted by a wavy line shows a point of attachment of the radical drawn to the rest of the molecule. For exam le, the radical drawn below
Figure imgf000006_0001
is the 2,3-dihydro-[l,4]dioxino[2,3-c]pyridin-7-yl group.
The term "enriched", for example when used in the context of enantiomers, is understood in the context of the present invention to mean especially that the respective enantiomer is present in a ratio (mutatis mutandis: purity) of at least 70:30, and notably of at least 90: 10 (mutatis mutandis: purity of 70% / 90%) with respect to the respective other enantiomer. Preferably the term refers to the respective essentially pure enantiomer. The term "essentially", for example when used in a term such as "essentially pure" is understood in the context of the present invention to mean especially that the respective stereoisomer / composition / compound etc. consists in an amount of at least 90, especially of at least 95, and notably of at least 99 per cent by weight of the respective pure stereoisomer / composition / compound etc.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases or the like, this is intended to mean also a single compound, salt, disease or the like.
The present invention also relates to pharmacologically acceptable salts and to compositions and formulations of compounds of formula I. Any reference to a compound of formula I in this text (and notably in the embodiments presented above) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
Besides, the term "room temperature" as used herein refers to a temperature of 25°C. Unless used regarding temperatures, the term "about" placed before a numerical value "X" refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term "about" placed before a temperature "Y" refers in the current application to an interval extending from the temperature Y minus 10°C to Y plus 10°C, and preferably to an interval extending from Y minus 5°C to Y plus 5°C.
Whenever the word "between" is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range. For example: if a temperature range is described to be between 40°C and 80°C, this means that the end points 40°C and 80°C are included in the range; or if a variable is defined as being an integer between 1 and 4, this means that the variable is the integer 1, 2, 3, or 4.
2) A second embodiment relates to the compounds of formula I according to embodiment 1) which are also compounds of formula I :
Figure imgf000007_0001
wherein the absolute configuration of the octahydro-pyrido[4,3-e][l,3]oxazinone moiety is as depicted in formula IE1 [i.e. the absolute configuration of the octahydro- pyrido[4,3-e][l,3]oxazinone moiety is (4aS,8aS)].
3) A third embodiment relates to the compounds of formula I according to embodiment 1) which are also compounds of formula I :
Figure imgf000007_0002
wherein the absolute configuration of the octahydro-pyrido[4,3-e][l,3]oxazinone moiety is as depicted in formula IE2 [i.e. the absolute configuration of the octahydro- pyrido[4,3-e][l,3]oxazinone moiety is (4aR,8aR)]. 4) A further embodiment relates to the compounds according to any one of embodiments 1) to
3) wherein K represents the group Ka or Kb.
5) In particular, the compounds of formula I according to embodiment 4) will be such that K represents the group Ka wherein Rla represents methoxy, or such that K represents the group Kb wherein Rlb represents methoxy.
6) A further embodiment relates to the compounds according to any one of embodiments 1) to
5) wherein K represents the group Ka.
7) A further embodiment relates to the compounds according to any one of embodiments 1) to
4) and 6) wherein, in case K represents Ka, at least one of the following characteristics (in any combination) is present:
• Rla represents alkoxy (especially methoxy);
• Ua represents N, or Ua and Va both represent N, or, especially, Ua and Wa both represent N; and the remaining of Va and Wa each represent CH;
• Xa represents CRa wherein Ra represents hydrogen or fluorine (especially Ra represents fluorine);
• A represents CHRb wherein Rb represents hydrogen or hydroxyl (especially Rb represents hydrogen).
8) A further embodiment relates to the compounds according to any one of embodiments 1) to 7) wherein, in case K represents the group Ka, A represents CHRb and Rb represents hydroxyl, the absolute configuration of the carbon atom to which Rb is attached to being (R).
9) A further embodiment relates to the compounds according to any one of embodiments 1) to
6) wherein K represents the group Ka and A represents CHRb wherein Rb represents hydrogen.
10) A further embodiment relates to the compounds according to any one of embodiments 1) to 6) wherein K represents the group Ka, A represents CHRb wherein Rb represents hydroxyl, and the absolute configuration of the carbon atom to which Rb is attached to is (R).
1 1) A further embodiment relates to the compounds according to any one of embodiments 1) to 6) wherein K represents the group Ka wherein Rla represents methoxy, Ua and Wa each represent N and Va and Xa each represent CH, Xa represents CRa wherein Ra represents fluorine and A represents CHRb wherein Rb represents hydrogen or hydroxyl.
12) A further embodiment relates to the compounds according to any one of embodiments 1) to 5) wherein K represents the group Kb. 13) A further embodiment relates to the compounds according to embodiment 12) wherein Rlb represents methoxy, Ub represents N, Vb represents CH and Wb represents CH or N.
14) A further embodiment relates to the compounds according to any one of embodiments 1) to 4) and 12) wherein, in case K represents Kb, at least one of the following characteristics (in any combination) is present:
· Rlb represents hydrogen or alkoxy (notably alkoxy, especially methoxy);
• Ub represents N, or Ub and Wb both represent N, or Ub and Vb both represent N; and the remaining of Vb and Wb each represent CH.
15) A further embodiment relates to the compounds according to any one of embodiments 1) to 3) wherein K represents the group Kc or Kd. 16) A further embodiment relates to the compounds according to any one of embodiments 1) to 3) and 15) wherein, in case K represents Kc or Kd, at least one of the following characteristics (in any combination) is present:
• Rlc, or respectively, Rld represents F;
• Vc and Wc both represent CH, Vc represents N and Wc represents CH, or Wc represents N and Vc represents CH, or Vc and Wc both represent N (in a sub-embodiment: Vc and Wc both represent CH, or Vc represents N and Wc represents CH); or respectively
• Vd and Wd both represent CH, Vd represents N and Wd represents CH, or Wd represents N and Vd represents CH, or Vd and Wd both represent N (in a sub-embodiment: Vd and Wd both represent CH, or Vd represents N and Wd represents CH). 17) A further embodiment relates to the compounds according to any one of embodiments 1) to 16) wherein G represents one of the groups Ga, Gb, Gc and Gd
Figure imgf000010_0001
Ga Gb Gc Gd wherein M represents CH and Q' represent O or S, or M represents N and Q' represents S, and Q represents O or S.
18) A further embodiment relates to the compounds according to any one of embodiments 1) to 17) wherein G represents Gd, wherein M represents CH and Q' represent O or S, or M represents N and Q' represents S.
19) A further embodiment relates to compounds according to any one of embodiments 1) to 17) wherein G represents Ga, Gb or Gc, wherein Q represents O or S.
20) A further embodiment relates to compounds of formula I according to one of embodiments 1) to 3), wherein:
• K represents the group Ka
Figure imgf000010_0002
wherein Rla represents methoxy;
Ua and Wa each represent N and Va and Xa each represent CH;
Xa represents CRa wherein Ra represents fluorine;
A represents CHRb wherein Rb represents hydrogen or hydroxyl;
Figure imgf000011_0001
Kb
wherein R represents methoxy;
Ub represents N, Vb represents CH and Wb represents CH or N; and
• G represents one of the groups Gb and Gc
Figure imgf000011_0002
wherein Q represents O or S.
21) According to one variant of embodiment 20), the compounds of formula I according to embodiment 20) will be such that K represents the group Ka, wherein Ka and Rla, Ua, Va, Wa, Xa and A are as defined in embodiment 20).
22) According to another variant of embodiment 20), the compounds of formula I according to embodiment 20) will be such that K represents the group Kb, wherein Kb and Rlb, Ub, Va and Wb are as defined in embodiment 20).
23) According to a particular embodiment, the compounds of formula I according to one of embodiments 20) to 22) will be such that G represents the group Gb, wherein Gb is as defined in embodiment 20).
24) According to another particular embodiment, the compounds of formula I according to one of embodiments 20) to 22) will be such that G represents the group Gc, wherein Gc and Q are as defined in embodiment 20). 25) A further embodiment of the present invention relates to the compounds of formula I according to embodiment 1), which are selected from the group consisting of:
• (^aR,5aR)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
· (4aS,Sa>S)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-hydroxy-2-(6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
• (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(6-methoxy-[ 1 ,5]naphthyridin- 4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-benzo[ 1 ,4]oxazin-6-yl)-octahydro-pyrido[4,3-e] [1 ,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy-
[ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one; · (^aR^5aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-
3,4-dihydro-2H-benzo[ 1 ,4]thiazin-6-yl)-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(7-methoxy-2-oxo-2H-quinolin- l-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(7-methoxy-2-oxo- 2H-quinoxalin-l-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(7-methoxy-2-oxo- 2H- [ 1 , 8]naphthyridin- 1 -yl)-ethyl] -octahydro-pyrido [4,3 -e] [ 1 ,3 ] oxazin-2-one ;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(6-methoxy-3-oxo- 3H-pyrido[2,3-b]pyrazin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
· (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(3-methoxy-6-oxo-
6H-pyrido[2,3-b]pyrazin-5-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(R)-2-(3-fluoro-6-methoxy-
[ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aS,SaS)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy- [1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR,5aR)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy-
[ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one; • (4aR* SaR*)-3-(2,3-dihydro-benzo[l,4]dw^
8-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(6-fluoro-3-methoxy- quinoxalin-5-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
· (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-hydroxy-2-(3-methoxy- quinoxalin-5-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR,5aR)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-3,4-dihydro- 2H-pyrido[3,2-b][l,4]thiazin-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aS,5aS)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-3,4-dihyd^ 2H-pyrido[3,2-b] [ 1 ,4]thiazin-6-yl)-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-b]pyridin-7-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
· (^aR^5aR*)-3-(6,7-dihydro-[l,4]dioxino[2,3-c]pyridazin-3-yl)-7-[2-(3-fluoro-
6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-c]pyridin-7-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
• (^aR^5aR*)-7-[2-(7-methoxy-2-oxo-2H-[l,8]naphthyridin-l-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR^5aR*)-7-[2-(7-methoxy-2-oxo-2H-[l,8]naphthyridin-l-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-pyrido[3,2-b][l,4]thiazin-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-3-(6,7-dihydro-8-oxa-5-thia-l,2-diaza-naphthalen-3-yl)-7-[2-(3-fluoro- 6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one; · (4aR *,8aR *)-3-(6,7-dihydro-8-oxa-5-thia- 1 ,2-diaza-naphthalen-3-yl)-7-[2-(6-methoxy-
3- oxo-3H-pyrido[2,3-b]pyrazin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (R)-2-[(^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-2-oxo-octahydro- pyrido[4,3-e][l,3]oxazin-7-ylmethyl]-9^
4- one; and
· 4-[(^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-2-oxo-octahydro- pyrido[4,3-e][l,3]oxazin-7-ylmethyl]-3-fluoro-4,5-dihydro- pyrrolo[3,2, 1 -de] [ 1 ,5]naphthyridin-7-one. In a sub-embodiment of embodiment 25), the above listed compounds having the relative configuration (4aR*,8aR*) preferably are enantiomerically enriched, having either the absolute configuration (4aR,8aR), or the absolute configuration (4aS,8aS).
26) A further embodiment of the present invention relates to the compounds of formula I according to embodiment 1), which are selected from the group consisting of:
• (^aR*,5aR*)-7-(2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)ethyl)-3-(3-oxo- 3,4-dihydro-2H-benzo[b][l,4]thiazin-6-yl)octahydro-2H-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR *,8aR *)-7-((2RS)-2-(3-fluoro-6-methoxy- 1 ,5-naphthyridin-4-yl)-2-hydroxyethyl)- 3-(3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl)octahydro- 2H-pyrido [4,3 -e] [ 1 ,3 ] oxazin-2-one ;
• (4aR *,8aR *)-7-(((R)-9-fluoro-4-oxo-2,4-dihydro- lH-pyrrolo[3,2, 1 - /']quinolin- 2-yl)methyl)-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-6-yl)octahydro- 2H-pyrido[4,3-e] [ 1 ,3]oxazin-2-one; and
• (^aR*,5aR*)-7-(2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)ethyl)-3-(3-oxo- 3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl)octahydro-2H-pyrido[4,3-e][l,3]oxazin-2-one.
In a sub-embodiment of embodiment 26), the above listed compounds having the relative configuration (4aR*,8aR*) preferably are enantiomerically enriched, having either the absolute configuration (4aR,8aR), or the absolute configuration (4aS,8aS).
27) The invention furthermore relates to the groups of compounds of formula I selected from the group consisting of the compounds listed in embodiments 25) and 26), which groups of compounds furthermore correspond to one of embodiments 2) to 24), as well as to the salts (in particular the pharmaceutically acceptable salts) of such compounds.
28) The invention moreover relates to any individual compound of formula I selected from the group consisting of the compounds listed in embodiments 25) and 26), and to the salts (in particular the pharmaceutically acceptable salts) of such individual compound.
The present invention also includes isotope labelled, especially 2H (deuterium) labelled compounds of formula I as defined in any one of embodiments 1) to 28), which compounds are identical to the compounds of formula I except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotope labelled, especially 2H (deuterium) labelled compounds of formula I and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formula I are not isotope labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula I are not isotope labelled at all. Isotope labelled compounds of formula I may be prepared in analogy to the methods described hereinafter, but using the appropriate isotope variation of suitable reagents or starting materials. The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula I or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
A further aspect of the invention are pharmaceutical compositions comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient / carrier material.
A pharmaceutical composition according to the present invention contains at least one compound of formula I (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants, and may also contain additional known antibiotics.
In a preferred embodiment of the invention, the administered amount is comprised between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day. The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, CO, USA, 2001 ; Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science) by bringing the described compounds of formula I and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants. The compounds of formula I according to this invention, or the pharmaceutically acceptable salts thereof, may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of a bacterial infection.
Another aspect of the invention concerns a method for the prevention or the treatment of a bacterial infection in a patient comprising the administration to said patient of a pharmaceutically active amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
As well as in humans, bacterial infections can also be treated using compounds of formula I (or pharmaceutically acceptable salts thereof) in other species like pigs, ruminants, horses, dogs, cats and poultry. Moreover, the compounds of formula I may also be used for cleaning purposes, e.g. to remove pathogenic microbes and bacteria from surgical instruments or to make a room or an area aseptic. For such purposes, the compounds of formula I could be contained in a solution or in a spray formulation.
Moreover, the compounds of formula I according to the invention are suitable for the use as substances for preserving inorganic and organic materials in particular all types of organic materials for example polymers, lubricants, paints, fibres, leather, paper and wood.
The compounds of formula I according to the invention are particularly active against bacteria and bacteria-like organisms. They are therefore particularly suitable in human and veterinary medicine for the prophylaxis and chemotherapy of local and systemic infections caused by these pathogens as well as disorders related to bacterial infections comprising pneumonia, otitis media, sinusitis, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E. faecium, E. casseliflavus, S. epidermidis, S. haemolyticus, or Pepto streptococcus spp. ; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Corynebacterium diphtheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; blood and tissue infections, including endocarditis and osteomyelitis, caused by S. aureus, S. haemolyticus, E. faecalis, E. faecium, E. durans, including strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracyclines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S. epidermidis, S. haemolyticus, etc.), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcal groups C-F (minute colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp. ; urethritis and cervicitis; sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiseria gonorrhoeae; toxin diseases related to infection by S. aureus (food poisoning and toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulars, infections caused by Mycobacterium tuberculosis, M. leprae, M. paratuberculosis, M. kansasii, or M. chelonei; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by B or detella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylori or Chlamydia pneumoniae.
The compounds of formula I according to any one of embodiments 1) to 28) are further useful for the preparation of a medicament for the treatment of infections that are mediated by Gram negative bacteria, such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp. including Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Neisseria meningitidis, and Bacteroides spp.
The compounds of formula I according to any one of embodiments 1) to 28) are further useful for the preparation of a medicament for the treatment of infections that are mediated by Gram positive bacteria such as Bacillus cereus, Bacillus anthracis, Clostridium difficile, Corynebacterium spp. and Propionibacterium acnes.
The compounds of formula I according to any one of embodiments 1) to 28) are further useful to treat protozoal infections caused by Plasmodium malaria, Plasmodium falciparum, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma brucei and Leishmania spp. The present list of pathogens is to be interpreted merely as examples and in no way as limiting.
Besides, any preferences indicated for the compounds of formula I (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of formula ¾i and ½■
This invention, thus, relates to the compounds of formula I as defined in embodiment 1), or further limited under consideration of their respective dependencies by the characteristics of any one of embodiments 2) to 28), and to pharmaceutically acceptable salts thereof. It relates furthermore to the use of such compounds as medicaments, especially for the prevention or treatment of bacterial infections (i.e. infections that are mediated by Gram negative bacteria or infections that are mediated by Gram positive bacteria), in particular for the prevention or treatment of bacterial infections caused by Staphylococcus aureus bacteria, and notably caused by quinolone -resistant Staphylococcus aureus bacteria. In particular, the following embodiments relating to the compounds of formula I according to embodiment 1) are thus possible and intended and herewith specifically disclosed in individualised form: 1, 2+1, 3+1, 4+1, 4+2+1, 4+3+1, 5+4+1, 5+4+2+1, 5+4+3+1, 6+1, 6+2+1, 6+3+1, 6+4+1, 6+4+2+1, 6+4+3+1 6+5+4+1, 6+5+4+2+1, 6+5+4+3+1, 7+1, 7+2+1, 7+3+1, 7+4+1, 7+4+2+1, 7+4+3+1, 7+6+1, 7+6+2+L 7+6+3+1, 7+6+4+1, 7+6+4+2+1, 7+6+4+3+1, 7+6+5+4+1, 7+6+5+4+2+1, 7+6+5+4+3+1, 8+1, 8+2+1, 8+3+L 8+4+1, 8+4+2+1, 8+4+3+1, 8+5+4+1, 8+5+4+2+1 , 8+5+4+3+1, 8+6+1, 8+6+2+1, 8+6+3+1, 8+6+4+1 8+6+4+2+1, 8+6+4+3+1, 8+6+5+4+1, 8+6+5+4+2+1, 8+6+5+4+3+1, 8+7+1, 8+7+2+1, 8+7+3+1, 8+7+4+ L 8+7+4+2+1, 8+7+4+3+1, 8+7+6+1, 8+7+6+2+1, 8+7+6+3+1, 8+7+6+4+1, 8+7+6+4+2+1, 8+7+6+4+3+L 8+7+6+5+4+1, 8+7+6+5+4+2+1, 8+7+6+5+4+3+1, 9+1, 9+2+1, 9+3+1, 9+4+1, 9+4+2+1, 9+4+3+1, 9+5+4+1 9+5+4+2+1, 9+5+4+3+1, 9+6+1, 9+6+2+1, 9+6+3+1, 9+6+4+1, 9+6+4+2+1, 9+6+4+3+1, 9+6+5+4+ L 9+6+5+4+2+1, 9+6+5+4+3+1, 10+1, 10+2+1, 10+3+1, 10+4+1, 10+4+2+1, 10+4+3+1, 10+5+4+1 10+5+4+2+1, 10+5+4+3+1, 10+6+1, 10+6+2+1, 10+6+3+1, 10+6+4+1, 10+6+4+2+1, 10+6+4+3+1 10+6+5+4+1, 10+6+5+4+2+1, 10+6+5+4+3+1, 11+1, 11+2+1, 11+3+1, 11+4+1, 11+4+2+1, 11+4+3+1 11+5+4+1, 11+5+4+2+1, 11+5+4+3+1, 11+6+1, 11+6+2+1, 11+6+3+1, 11+6+4+1, 11+6+4+2+1, 11+6+4+3+1 11+6+5+4+1, 11+6+5+4+2+1, 11+6+5+4+3+1, 12+1, 12+2+1, 12+3+1, 12+4+1, 12+4+2+1, 12+4+3+1 12+5+4+1, 12+5+4+2+1, 12+5+4+3+1, 13+12+1, 13+12+2+1, 13+12+3+1, 13+12+4+1, 13+12+4+2+L 13+12+4+3+1, 13+12+5+4+1, 13+12+5+4+2+1, 13+12+5+4+3+1, 14+1, 14+2+1, 14+3+1, 14+4+1, 14+4+2+1 14+4+3+1, 14+12+1, 14+12+2+1, 14+12+3+1, 14+12+4+1, 14+12+4+2+1, 14+12+4+3+1, 14+12+5+4+1 14+12+5+4+2+1, 14+12+5+4+3+1, 15+1, 15+2+1, 15+3+1, 16+1, 16+2+1, 16+3+1, 16+15+1, 16+15+2+1 16+15+3+1, 17+1, 17+2+1, 17+3+1, 17+4+1, 17+4+2+1, 17+4+3+1, 17+5+4+1, 17+5+4+2+1, 17+5+4+3+1 17+6+1, 17+6+2+1, 17+6+3+1, 17+6+4+1, 17+6+4+2+1, 17+6+4+3+1, 17+6+5+4+1, 17+6+5+4+2+ L 17+6+5+4+3+1, 17+7+1, 17+7+2+1, 17+7+3+1, 17+7+4+1, 17+7+4+2+1, 17+7+4+3+1, 17+7+6+1 17+7+6+2+1, 17+7+6+3+1, 17+7+6+4+1 , 17+7+6+4+2+1, 17+7+6+4+3+1, 17+7+6+5+4+1 17+7+6+5+4+2+1, 17+7+6+5+4+3+1, 17+8+1, 17+8+2+1, 17+8+3+1, 17+8+4+1, 17+8+4+2+1, 17+8+4+3+L 17+8+5+4+1, 17+8+5+4+2+1, 17+8+5+4+3+1, 17+8+6+1, 17+8+6+2+1, 17+8+6+3+1, 17+8+6+4+1 17+8+6+4+2+1, 17+8+6+4+3+1, 17+8+6+5+4+1, 17+8+6+5+4+2+1, 17+8+6+5+4+3+1, 17+8+7+1 17+8+7+2+1, 17+8+7+3+1, 17+8+7+4+1, 17+8+7+4+2+1, 17+8+7+4+3+1, 17+8+7+6+1, 17+8+7+6+2+ L 17+8+7+6+3+1, 17+8+7+6+4+1, 17+8+7+6+4+2+1, 17+8+7+6+4+3+1, 17+8+7+6+5+4+1 17+8+7+6+5+4+2+1, 17+8+7+6+5+4+3+1, 17+9+1, 17+9+2+1, 17+9+3+1, 17+9+4+1, 17+9+4+2+1 17+9+4+3+1, 17+9+5+4+1, 17+9+5+4+2+1, 17+9+5+4+3+1, 17+9+6+1, 17+9+6+2+1, 17+9+6+3+1 17+9+6+4+1, 17+9+6+4+2+1, 17+9+6+4+3+1, 17+9+6+5+4+1, 17+9+6+5+4+2+1, 17+9+6+5+4+3+L 17+10+1, 17+10+2+1, 17+10+3+1, 17+10+4+1, 17+10+4+2+1, 17+10+4+3+1, 17+10+5+4+1 17+10+5+4+2+1, 17+10+5+4+3+1, 17+10+6+1, 17+10+6+2+1, 17+10+6+3+1, 17+10+6+4+1 17+10+6+4+2+1, 17+10+6+4+3+1, 17+10+6+5+4+1, 17+10+6+5+4+2+1, 17+10+6+5+4+3+1, 17+11+L 17+11+2+1, 17+11+3+1, 17+11+4+1, 17+11+4+2+1, 17+11+4+3+1, 17+11+5+4+1, 17+11+5+4+2+1 17+11+5+4+3+1, 17+11+6+1, 17+11+6+2+1, 17+11+6+3+1, 17+11+6+4+1, 17+11+6+4+2+1 17+11+6+4+3+1, 17+11+6+5+4+1, 17+11+6+5+4+2+1, 17+11+6+5+4+3+1, 17+12+1, 17+12+2+1 17+12+3+1, 17+12+4+1, 17+12+4+2+1, 17+12+4+3+1, 17+12+5+4+1, 17+12+5+4+2+1, 17+12+5+4+3+1 17+13+12+1, 17+13+12+2+1, 17+13+12+3+1, 17+13+12+4+1, 17+13+12+4+2+1, 17+13+12+4+3+1 17+13+12+5+4+1, 17+13+12+5+4+2+1, 17+13+12+5+4+3+1, 17+14+1, 17+14+2+1, 17+14+3+1, 17+14+4+1 17+14+4+2+1, 17+14+4+3+1, 17+14+12+1, 17+14+12+2+1, 17+14+12+3+1, 17+14+12+4+1 17+14+12+4+2+1, 17+14+12+4+3+1, 17+14+12+5+4+1, 17+14+12+5+4+2+1, 17+14+12+5+4+3+1, 17+15+1 17+15+2+1, 17+15+3+1, 17+16+1, 17+16+2+1, 17+16+3+1, 17+16+15+1, 17+16+15+2+1, 17+16+15+3+1 18+1, 18+2+1, 18+3+1, 18+4+1, 18+4+2+1, 18+4+3+1, 18+5+4+1, 18+5+4+2+1, 18+5+4+3+1, 18+6+1 18+6+2+1, 18+6+3+1, 18+6+4+1, 18+6+4+2+1, 18+6+4+3+1, 18+6+5+4+1, 18+6+5+4+2+1, 18+6+5+4+3+L 18+7+1, 18+7+2+1, 18+7+3+1, 18+7+4+1, 18+7+4+2+1, 18+7+4+3+1, 18+7+6+1, 18+7+6+2+1, 18+7+6+3+ 1 18+7+6+4+1, 18+7+6+4+2+1, 18+7+6+4+3+1, 18+7+6+5+4+1, 18+7+6+5+4+2+1, 18+7+6+5+4+3+L 18+8+1, 18+8+2+1, 18+8+3+1, 18+8+4+1, 18+8+4+2+1, 18+8+4+3+1, 18+8+5+4+1, 18+8+5+4+2+ L 18+8+5+4+3+1, 18+8+6+1, 18+8+6+2+1, 18+8+6+3+1, 18+8+6+4+1, 18+8+6+4+2+1, 18+8+6+4+3+1 18+8+6+5+4+1, 18+8+6+5+4+2+1, 18+8+6+5+4+3+1, 18+8+7+1, 18+8+7+2+1, 18+8+7+3+1, 18+8+7+4+ L 18+8+7+4+2+1, 18+8+7+4+3+1, 18+8+7+6+1, 18+8+7+6+2+1, 18+8+7+6+3+1, 18+8+7+6+4+1 18+8+7+6+4+2+1, 18+8+7+6+4+3+1, 18+8+7+6+5+4+1, 18+8+7+6+5+4+2+1, 18+8+7+6+5+4+3+1, 18+9+1 18+9+2+1, 18+9+3+1, 18+9+4+1, 18+9+4+2+1, 18+9+4+3+1, 18+9+5+4+1, 18+9+5+4+2+1, 18+9+5+4+3+L 18+9+6+1, 18+9+6+2+1, 18+9+6+3+1, 18+9+6+4+1, 18+9+6+4+2+1, 18+9+6+4+3+1, 18+9+6+5+4+ L 18+9+6+5+4+2+1, 18+9+6+5+4+3+1, 18+10+1, 18+10+2+1, 18+10+3+1, 18+10+4+1, 18+10+4+2+1 18+10+4+3+1, 18+10+5+4+1, 18+10+5+4+2+1, 18+10+5+4+3+1, 18+10+6+1, 18+10+6+2+1, 18+10+6+3+1 18+10+6+4+1, 18+10+6+4+2+1, 18+10+6+4+3+1, 18+10+6+5+4+1, 18+10+6+5+4+2+1, 18+10+6+5+4+3+L 18+11+1, 18+11+2+1, 18+11+3+1, 18+11+4+1, 18+11+4+2+1, 18+11+4+3+1, 18+11+5+4+1 18+11+5+4+2+1, 18+11+5+4+3+1, 18+11+6+1, 18+11+6+2+1, 18+11+6+3+1, 18+11+6+4+1 18+11+6+4+2+1, 18+11+6+4+3+1, 18+11+6+5+4+1, 18+11+6+5+4+2+1, 18+11+6+5+4+3+1, 18+12+L 18+12+2+1, 18+12+3+1, 18+12+4+1, 18+12+4+2+1, 18+12+4+3+1, 18+12+5+4+1, 18+12+5+4+2+1 18+12+5+4+3+1, 18+13+12+1, 18+13+12+2+1, 18+13+12+3+1, 18+13+12+4+1, 18+13+12+4+2+1 18+13+12+4+3+1, 18+13+12+5+4+1, 18+13+12+5+4+2+1, 18+13+12+5+4+3+1, 18+14+1, 18+14+2+L 18+14+3+1, 18+14+4+1, 18+14+4+2+1, 18+14+4+3+1, 18+14+12+1, 18+14+12+2+1, 18+14+12+3+1 18+14+12+4+1, 18+14+12+4+2+1, 18+14+12+4+3+1, 18+14+12+5+4+1, 18+14+12+5+4+2+1 18+14+12+5+4+3+1, 18+15+1, 18+15+2+1, 18+15+3+1, 18+16+1, 18+16+2+1, 18+16+3+1, 18+16+15+1 18+16+15+2+1, 18+16+15+3+1, 18+17+1, 18+17+2+1, 18+17+3+1, 18+17+4+1, 18+17+4+2+1 18+17+4+3+1, 18+17+5+4+1, 18+17+5+4+2+1, 18+17+5+4+3+1, 18+17+6+1, 18+17+6+2+1, 18+17+6+3+1 18+17+6+4+1, 18+17+6+4+2+1, 18+17+6+4+3+1, 18+17+6+5+4+1, 18+17+6+5+4+2+1, 18+17+6+5+4+3+L 18+17+7+1, 18+17+7+2+1, 18+17+7+3+1, 18+17+7+4+1, 18+17+7+4+2+1, 18+17+7+4+3+1, 18+17+7+6+1 18+17+7+6+2+1, 18+17+7+6+3+1, 18+17+7+6+4+1, 18+17+7+6+4+2+1, 18+17+7+6+4+3+1 18+17+7+6+5+4+1, 18+17+7+6+5+4+2+1, 18+17+7+6+5+4+3+1, 18+17+8+1, 18+17+8+2+1, 18+17+8+3+L 18+17+8+4+1, 18+17+8+4+2+1, 18+17+8+4+3+1, 18+17+8+5+4+1, 18+17+8+5+4+2+1, 18+17+8+5+4+3+1 18+17+8+6+1, 18+17+8+6+2+1, 18+17+8+6+3+1, 18+17+8+6+4+1, 18+17+8+6+4+2+1, 18+17+8+6+4+3+L 18+17+8+6+5+4+1, 18+17+8+6+5+4+2+1, 18+17+8+6+5+4+3+1, 18+17+8+7+1, 18+17+8+7+2+1 18+17+8+7+3+1, 18+17+8+7+4+1, 18+17+8+7+4+2+1, 18+17+8+7+4+3+1, 18+17+8+7+6+1 18+17+8+7+6+2+1, 18+17+8+7+6+3+1, 18+17+8+7+6+4+1, 18+17+8+7+6+4+2+1, 18+ 17+8+7+6+4+3+ 1 : 18+17+8+7+6+5+4+1, 18+17+8+7+6+5+4+2+1, 18+17+8+7+6+5+4+3+1, 18+17+9+1, 18+17+9+2+1 18+17+9+3+1, 18+17+9+4+1, 18+17+9+4+2+1, 18+17+9+4+3+1, 18+17+9+5+4+1, 18+17+9+5+4+2+1 18+17+9+5+4+3+1, 18+17+9+6+1, 18+17+9+6+2+1, 18+17+9+6+3+1, 18+17+9+6+4+1, 18+17+9+6+4+2+ L 18+17+9+6+4+3+1, 18+17+9+6+5+4+1, 18+17+9+6+5+4+2+1, 18+17+9+6+5+4+3+1, 18+17+10+1 18+17+10+2+1, 18+17+10+3+1, 18+17+10+4+1, 18+17+10+4+2+1, 18+17+10+4+3+1, 18+17+10+5+4+1 18+17+10+5+4+2+1, 18+17+10+5+4+3+1, 18+17+10+6+1, 18+17+10+6+2+1, 18+17+10+6+3+1 18+17+10+6+4+1, 18+17+10+6+4+2+1, 18+17+10+6+4+3+1, 18+17+10+6+5+4+1, 18+17+10+6+5+4+2+1 18+17+10+6+5+4+3+1, 18+17+11+1, 18+17+11+2+1, 18+17+11+3+1, 18+17+11+4+1, 18+17+11+4+2+1 18+17+11+4+3+1, 18+17+11+5+4+1, 18+17+11+5+4+2+1, 18+17+11+5+4+3+1, 18+17+11+6+1 18+17+11+6+2+1, 18+17+11+6+3+1, 18+17+11+6+4+1, 18+17+11+6+4+2+1, 18+17+11+6+4+3+1 18+17+11+6+5+4+1, 18+17+11+6+5+4+2+1, 18+17+11+6+5+4+3+1, 18+17+12+1, 18+17+12+2+1 18+17+12+3+1, 18+17+12+4+1, 18+17+12+4+2+1, 18+17+12+4+3+1, 18+17+12+5+4+1 18+17+12+5+4+2+1, 18+17+12+5+4+3+1, 18+17+13+12+1, 18+17+13+12+2+1, 18+17+13+12+3+1 18+17+13+12+4+1, 18+17+13+12+4+2+1, 18+17+13+12+4+3+1, 18+17+13+12+5+4+1 18+17+13+12+5+4+2+1, 18+17+13+12+5+4+3+1, 18+17+14+1, 18+17+14+2+1, 18+17+14+3+1 18+17+14+4+1, 18+17+14+4+2+1, 18+17+14+4+3+1, 18+17+14+12+1, 18+17+14+12+2+1 18+17+14+12+3+1, 18+17+14+12+4+1, 18+17+14+12+4+2+1, 18+17+14+12+4+3+1, 18+17+14+12+5+4+1 18+17+14+12+5+4+2+1, 18+17+14+12+5+4+3+1, 18+17+15+1, 18+17+15+2+1, 18+17+15+3+1 18+17+16+1, 18+17+16+2+1, 18+17+16+3+1, 18+17+16+15+1, 18+17+16+15+2+1, 18+17+16+15+3+1 19+1, 19+2+1, 19+3+1, 19+4+1, 19+4+2+1, 19+4+3+1, 19+5+4+1, 19+5+4+2+1, 19+5+4+3+1, 19+6+1 19+6+2+1, 19+6+3+1, 19+6+4+1, 19+6+4+2+1, 19+6+4+3+1, 19+6+5+4+1, 19+6+5+4+2+1, 19+6+5+4+3+L 19+7+1, 19+7+2+1, 19+7+3+1, 19+7+4+1, 19+7+4+2+1, 19+7+4+3+1, 19+7+6+1, 19+7+6+2+1, 19+7+6+3+ 1 19+7+6+4+1, 19+7+6+4+2+1, 19+7+6+4+3+1, 19+7+6+5+4+1, 19+7+6+5+4+2+1, 19+7+6+5+4+3+L 19+8+1, 19+8+2+1, 19+8+3+1, 19+8+4+1, 19+8+4+2+1, 19+8+4+3+1, 19+8+5+4+1, 19+8+5+4+2+ L 19+8+5+4+3+1, 19+8+6+1, 19+8+6+2+1, 19+8+6+3+1, 19+8+6+4+1, 19+8+6+4+2+1, 19+8+6+4+3+1 19+8+6+5+4+1, 19+8+6+5+4+2+1, 19+8+6+5+4+3+1, 19+8+7+1, 19+8+7+2+1, 19+8+7+3+1, 19+8+7+4+L 19+8+7+4+2+1, 19+8+7+4+3+1, 19+8+7+6+1, 19+8+7+6+2+1, 19+8+7+6+3+1, 19+8+7+6+4+1 19+8+7+6+4+2+1, 19+8+7+6+4+3+1, 19+8+7+6+5+4+1, 19+8+7+6+5+4+2+1, 19+8+7+6+5+4+3+1, 19+9+1 19+9+2+1, 19+9+3+1, 19+9+4+1, 19+9+4+2+1, 19+9+4+3+1, 19+9+5+4+1, 19+9+5+4+2+1, 19+9+5+4+3+L 19+9+6+1, 19+9+6+2+1, 19+9+6+3+1, 19+9+6+4+1, 19+9+6+4+2+1, 19+9+6+4+3+1, 19+9+6+5+4+ L 19+9+6+5+4+2+1, 19+9+6+5+4+3+1, 19+10+1, 19+10+2+1, 19+10+3+1, 19+10+4+1, 19+10+4+2+1 19+10+4+3+1, 19+10+5+4+1, 19+10+5+4+2+1, 19+10+5+4+3+1, 19+10+6+1, 19+10+6+2+1, 19+10+6+3+1 19+10+6+4+1, 19+10+6+4+2+1, 19+10+6+4+3+1, 19+10+6+5+4+1, 19+10+6+5+4+2+1, 19+10+6+5+4+3+L 19+11+1, 19+11+2+1, 19+11+3+1, 19+11+4+1, 19+11+4+2+1, 19+11+4+3+1, 19+11+5+4+1 19+11+5+4+2+1, 19+11+5+4+3+1, 19+11+6+1, 19+11+6+2+1, 19+11+6+3+1, 19+11+6+4+1 19+11+6+4+2+1, 19+11+6+4+3+1, 19+11+6+5+4+1, 19+11+6+5+4+2+1, 19+11+6+5+4+3+1, 19+12+ L 19+12+2+1, 19+12+3+1, 19+12+4+1, 19+12+4+2+1, 19+12+4+3+1, 19+12+5+4+1, 19+12+5+4+2+1 19+12+5+4+3+1, 19+13+12+1, 19+13+12+2+1, 19+13+12+3+1, 19+13+12+4+1, 19+13+12+4+2+1 19+13+12+4+3+1, 19+13+12+5+4+1, 19+13+12+5+4+2+1, 19+13+12+5+4+3+1, 19+14+1, 19+14+2+L 19+14+3+1, 19+14+4+1, 19+14+4+2+1, 19+14+4+3+1, 19+14+12+1, 19+14+12+2+1, 19+14+12+3+1 19+14+12+4+1, 19+14+12+4+2+1, 19+14+12+4+3+1, 19+14+12+5+4+1, 19+14+12+5+4+2+1 19+14+12+5+4+3+1, 19+15+1, 19+15+2+1, 19+15+3+1, 19+16+1, 19+16+2+1, 19+16+3+1, 19+16+15+1 19+16+15+2+1, 19+16+15+3+1, 19+17+1, 19+17+2+1, 19+17+3+1, 19+17+4+1, 19+17+4+2+1 19+17+4+3+1, 19+17+5+4+1, 19+17+5+4+2+1, 19+17+5+4+3+1, 19+17+6+1, 19+17+6+2+1, 19+17+6+3+1 19+17+6+4+1, 19+17+6+4+2+1, 19+17+6+4+3+1, 19+17+6+5+4+1, 19+17+6+5+4+2+1, 19+17+6+5+4+3+L 19+17+7+1, 19+17+7+2+1, 19+17+7+3+1, 19+17+7+4+1, 19+17+7+4+2+1, 19+17+7+4+3+1, 19+17+7+6+1 19+17+7+6+2+1, 19+17+7+6+3+1, 19+17+7+6+4+1, 19+17+7+6+4+2+1, 19+17+7+6+4+3+1 19+17+7+6+5+4+1, 19+17+7+6+5+4+2+1, 19+17+7+6+5+4+3+1, 19+17+8+1, 19+17+8+2+1, 19+17+8+3+L 19+17+8+4+1, 19+17+8+4+2+1, 19+17+8+4+3+1, 19+17+8+5+4+1, 19+17+8+5+4+2+1, 19+17+8+5+4+3+1 19+17+8+6+1, 19+17+8+6+2+1, 19+17+8+6+3+1, 19+17+8+6+4+1, 19+17+8+6+4+2+1, 19+17+8+6+4+3+L 19+17+8+6+5+4+1, 19+17+8+6+5+4+2+1, 19+17+8+6+5+4+3+1, 19+17+8+7+1, 19+17+8+7+2+1 19+17+8+7+3+1, 19+17+8+7+4+1, 19+17+8+7+4+2+1, 19+17+8+7+4+3+1, 19+17+8+7+6+1 19+17+8+7+6+2+1, 19+17+8+7+6+3+1, 19+17+8+7+6+4+1, 19+17+8+7+6+4+2+1, 19+17+8+7+6+4+3+L 19+17+8+7+6+5+4+1, 19+17+8+7+6+5+4+2+1, 19+17+8+7+6+5+4+3+1, 19+17+9+1, 19+17+9+2+1 19+17+9+3+1, 19+17+9+4+1, 19+17+9+4+2+1, 19+17+9+4+3+1, 19+17+9+5+4+1, 19+17+9+5+4+2+1 19+17+9+5+4+3+1, 19+17+9+6+1, 19+17+9+6+2+1, 19+17+9+6+3+1, 19+17+9+6+4+1, 19+17+9+6+4+2+ L 19+17+9+6+4+3+1, 19+17+9+6+5+4+1, 19+17+9+6+5+4+2+1, 19+17+9+6+5+4+3+1, 19+17+10+1 19+17+10+2+1, 19+17+10+3+1, 19+17+10+4+1, 19+17+10+4+2+1, 19+17+10+4+3+1, 19+17+10+5+4+1 19+17+10+5+4+2+1, 19+17+10+5+4+3+1, 19+17+10+6+1, 19+17+10+6+2+1, 19+17+10+6+3+1 19+17+10+6+4+1, 19+17+10+6+4+2+1, 19+17+10+6+4+3+1, 19+17+10+6+5+4+1, 19+17+10+6+5+4+2+1 19+17+10+6+5+4+3+1, 19+17+11+1, 19+17+11+2+1, 19+17+11+3+1, 19+17+11+4+1, 19+17+11+4+2+1 19+17+11+4+3+1, 19+17+11+5+4+1, 19+17+11+5+4+2+1, 19+17+11+5+4+3+1, 19+17+11+6+1 19+17+11+6+2+1, 19+17+11+6+3+1, 19+17+11+6+4+1, 19+17+11+6+4+2+1, 19+17+11+6+4+3+1 19+17+11+6+5+4+1, 19+17+11+6+5+4+2+1, 19+17+11+6+5+4+3+1, 19+17+12+1, 19+17+12+2+1 19+17+12+3+1, 19+17+12+4+1, 19+17+12+4+2+1, 19+17+12+4+3+1, 19+17+12+5+4+1 19+17+12+5+4+2+1, 19+17+12+5+4+3+1, 19+17+13+12+1, 19+17+13+12+2+1, 19+17+13+12+3+1 19+17+13+12+4+1, 19+17+13+12+4+2+1, 19+17+13+12+4+3+1, 19+17+13+12+5+4+1
19+17+13+12+5+4+2+1, 19+17+13+12+5+4+3+1, 19+17+14+1, 19+17+14+2+1, 19+17+14+3+1 19+17+14+4+1, 19+17+14+4+2+1, 19+17+14+4+3+1, 19+17+14+12+1, 19+17+14+12+2+1 19+17+14+12+3+1, 19+17+14+12+4+1, 19+17+14+12+4+2+1, 19+17+14+12+4+3+1, 19+17+14+12+5+4+1 19+17+14+12+5+4+2+1, 19+17+14+12+5+4+3+1, 19+17+15+1, 19+17+15+2+1, 19+17+15+3+1 19+17+16+1, 19+17+16+2+1, 19+17+16+3+1, 19+17+16+15+1, 19+17+16+15+2+1, 19+17+16+15+3+1 20+1, 20+2+1, 20+3+1, 21+20+1, 21+20+2+1, 21+20+3+1, 22+20+1, 22+20+2+1, 22+20+3+1, 23+20+1 23+20+2+1, 23+20+3+1, 23+21+20+1, 23+21+20+2+1, 23+21+20+3+1, 23+22+20+1, 23+22+20+2+1 23+22+20+3+1, 24+20+1, 24+20+2+1, 24+20+3+1, 24+21+20+1, 24+21+20+2+1, 24+21+20+3+1 24+22+20+1, 24+22+20+2+1, 24+22+20+3+1, 25, 26, 27+2+1, 27+3+1, 27+4+1, 27+4+2+1, 27+4+3+1 27+5+4+1, 27+5+4+2+1, 27+5+4+3+1, 27+6+1, 27+6+2+1, 27+6+3+1, 27+6+4+1, 27+6+4+2+1, 27+6+4+3+L 27+6+5+4+1, 27+6+5+4+2+1, 27+6+5+4+3+1, 27+7+1, 27+7+2+1, 27+7+3+1, 27+7+4+1, 27+7+4+2+1 27+7+4+3+1, 27+7+6+1, 27+7+6+2+1, 27+7+6+3+1, 27+7+6+4+1, 27+7+6+4+2+1, 27+7+6+4+3+1 27+7+6+5+4+1, 27+7+6+5+4+2+1, 27+7+6+5+4+3+1, 27+8+1, 27+8+2+1, 27+8+3+1, 27+8+4+1 27+8+4+2+1, 27+8+4+3+1, 27+8+5+4+1, 27+8+5+4+2+1, 27+8+5+4+3+1, 27+8+6+1, 27+8+6+2+1 27+8+6+3+1, 27+8+6+4+1, 27+8+6+4+2+1, 27+8+6+4+3+1, 27+8+6+5+4+1, 27+8+6+5+4+2+1 27+8+6+5+4+3+1, 27+8+7+1, 27+8+7+2+1, 27+8+7+3+1, 27+8+7+4+1, 27+8+7+4+2+1, 27+8+7+4+3+L 27+8+7+6+1, 27+8+7+6+2+1, 27+8+7+6+3+1, 27+8+7+6+4+1, 27+8+7+6+4+2+1, 27+8+7+6+4+3+1 27+8+7+6+5+4+1, 27+8+7+6+5+4+2+1, 27+8+7+6+5+4+3+1, 27+9+1, 27+9+2+1, 27+9+3+1, 27+9+4+ L 27+9+4+2+1, 27+9+4+3+1, 27+9+5+4+1, 27+9+5+4+2+1, 27+9+5+4+3+1, 27+9+6+1, 27+9+6+2+1 27+9+6+3+1, 27+9+6+4+1, 27+9+6+4+2+1, 27+9+6+4+3+1, 27+9+6+5+4+1, 27+9+6+5+4+2+1 27+9+6+5+4+3+1, 27+10+1, 27+10+2+1, 27+10+3+1, 27+10+4+1, 27+10+4+2+1, 27+10+4+3+1 27+10+5+4+1, 27+10+5+4+2+1, 27+10+5+4+3+1, 27+10+6+1, 27+10+6+2+1, 27+10+6+3+1, 27+10+6+4+1 27+10+6+4+2+1, 27+10+6+4+3+1, 27+10+6+5+4+1, 27+10+6+5+4+2+1, 27+10+6+5+4+3+1, 27+11+1 27+11+2+1, 27+11+3+1, 27+11+4+1, 27+11+4+2+1, 27+11+4+3+1, 27+11+5+4+1, 27+11+5+4+2+1 27+11+5+4+3+1, 27+11+6+1, 27+11+6+2+1, 27+11+6+3+1, 27+11+6+4+1, 27+11+6+4+2+1 27+11+6+4+3+1, 27+11+6+5+4+1, 27+11+6+5+4+2+1, 27+11+6+5+4+3+1, 27+12+1, 27+12+2+1 27+12+3+1, 27+12+4+1, 27+12+4+2+1, 27+12+4+3+1, 27+12+5+4+1, 27+12+5+4+2+1, 27+12+5+4+3+1 27+13+12+1, 27+13+12+2+1, 27+13+12+3+1, 27+13+12+4+1, 27+13+12+4+2+1, 27+13+12+4+3+1 27+13+12+5+4+1, 27+13+12+5+4+2+1, 27+13+12+5+4+3+1, 27+14+1, 27+14+2+1, 27+14+3+1, 27+14+4+1 27+14+4+2+1, 27+14+4+3+1, 27+14+12+1, 27+14+12+2+1, 27+14+12+3+1, 27+14+12+4+1 27+14+12+4+2+1, 27+14+12+4+3+1, 27+14+12+5+4+1, 27+14+12+5+4+2+1, 27+14+12+5+4+3+1, 27+15+1 27+15+2+1, 27+15+3+1, 27+16+1, 27+16+2+1, 27+16+3+1 , 27+16+15+1, 27+16+15+2+1, 27+16+15+3+1 27+17+1, 27+17+2+1, 27+17+3+1, 27+17+4+1, 27+17+4+2+1, 27+17+4+3+1, 27+17+5+4+1 27+17+5+4+2+1, 27+17+5+4+3+1, 27+17+6+1, 27+17+6+2+1, 27+17+6+3+1, 27+17+6+4+1 27+17+6+4+2+1, 27+17+6+4+3+1, 27+17+6+5+4+1, 27+17+6+5+4+2+1, 27+17+6+5+4+3+1, 27+17+7+1 27+17+7+2+1, 27+17+7+3+1, 27+17+7+4+1, 27+17+7+4+2+1, 27+17+7+4+3+1, 27+17+7+6+1 27+17+7+6+2+1, 27+17+7+6+3+1, 27+17+7+6+4+1, 27+17+7+6+4+2+1, 27+17+7+6+4+3+1 27+17+7+6+5+4+1, 27+17+7+6+5+4+2+1, 27+17+7+6+5+4+3+1, 27+ 17+8+1, 27+17+8+2+1, 27+17+8+3+1 27+17+8+4+1, 27+17+8+4+2+1, 27+17+8+4+3+1, 27+17+8+5+4+1, 27+17+8+5+4+2+1, 27+17+8+5+4+3+L 27+17+8+6+1, 27+17+8+6+2+1, 27+17+8+6+3+1, 27+17+8+6+4+1, 27+17+8+6+4+2+1, 27+17+8+6+4+3+L 27+17+8+6+5+4+1, 27+17+8+6+5+4+2+1, 27+17+8+6+5+4+3+1, 27+17+8+7+1, 27+17+8+7+2+1 27+17+8+7+3+1, 27+17+8+7+4+1, 27+17+8+7+4+2+1, 27+17+8+7+4+3+1, 27+17+8+7+6+L 27+17+8+7+6+2+1, 27+17+8+7+6+3+1, 27+17+8+7+6+4+1, 27+17+8+7+6+4+2+1, 27+17+8+7+6+4+3+L 27+17+8+7+6+5+4+1, 27+17+8+7+6+5+4+2+1, 27+17+8+7+6+5+4+3+1, 27+17+9+1, 27+17+9+2+1 27+17+9+3+1, 27+17+9+4+1, 27+17+9+4+2+1, 27+17+9+4+3+1, 27+17+9+5+4+1, 27+17+9+5+4+2+1 27+17+9+5+4+3+1, 27+17+9+6+1, 27+17+9+6+2+1, 27+17+9+6+3+1, 27+17+9+6+4+1, 27+17+9+6+4+2+L 27+17+9+6+4+3+1, 27+17+9+6+5+4+1, 27+17+9+6+5+4+2+1, 27+17+9+6+5+4+3+1, 27+17+10+1 27+17+10+2+1, 27+17+10+3+1, 27+17+10+4+1, 27+17+10+4+2+1, 27+17+10+4+3+1, 27+17+10+5+4+1 27+17+10+5+4+2+1, 27+17+10+5+4+3+1, 27+17+10+6+1, 27+17+10+6+2+1, 27+17+10+6+3+1 27+17+10+6+4+1, 27+17+10+6+4+2+1, 27+17+10+6+4+3+1, 27+17+10+6+5+4+1, 27+17+10+6+5+4+2+1 27+17+10+6+5+4+3+1, 27+17+11+1, 27+17+11+2+1, 27+17+11+3+1, 27+17+11+4+1, 27+17+11+4+2+1 27+17+11+4+3+1, 27+17+11+5+4+1, 27+17+11+5+4+2+1, 27+17+11+5+4+3+1, 27+17+11+6+1 27+17+11+6+2+1, 27+17+11+6+3+1, 27+17+11+6+4+1, 27+17+11+6+4+2+1, 27+17+11+6+4+3+1 27+17+11+6+5+4+1, 27+17+11+6+5+4+2+1, 27+17+11+6+5+4+3+1, 27+17+12+1, 27+17+12+2+1 27+17+12+3+1, 27+17+12+4+1, 27+17+12+4+2+1, 27+17+12+4+3+1, 27+17+12+5+4+1 27+17+12+5+4+2+1, 27+17+12+5+4+3+1, 27+17+13+12+1, 27+17+13+12+2+1, 27+17+13+12+3+1 27+17+13+12+4+1, 27+17+13+12+4+2+1, 27+17+13+12+4+3+1, 27+17+13+12+5+4+1 27+17+13+12+5+4+2+1, 27+17+13+12+5+4+3+1, 27+17+14+1, 27+17+14+2+1, 27+17+14+3+1 27+17+14+4+1, 27+17+14+4+2+1, 27+17+14+4+3+1, 27+17+14+12+1, 27+17+14+12+2+1 27+17+14+12+3+1, 27+17+14+12+4+1, 27+17+14+12+4+2+1, 27+17+14+12+4+3+1, 27+17+14+12+5+4+1 27+17+14+12+5+4+2+1, 27+17+14+12+5+4+3+1, 27+17+15+1, 27+17+15+2+1, 27+17+15+3+1 27+17+16+1, 27+17+16+2+1, 27+17+16+3+1, 27+17+16+15+1, 27+17+16+15+2+1, 27+17+16+15+3+1 27+18+1, 27+18+2+1, 27+18+3+1, 27+18+4+1, 27+18+4+2+1, 27+18+4+3+1, 27+18+5+4+1 27+18+5+4+2+1, 27+18+5+4+3+1, 27+18+6+1, 27+18+6+2+1, 27+18+6+3+1, 27+18+6+4+1 27+18+6+4+2+1, 27+18+6+4+3+1, 27+18+6+5+4+1, 27+18+6+5+4+2+1, 27+18+6+5+4+3+1, 27+18+7+1 27+18+7+2+1, 27+18+7+3+1, 27+18+7+4+1, 27+18+7+4+2+1, 27+18+7+4+3+1, 27+18+7+6+1 27+18+7+6+2+1, 27+18+7+6+3+1, 27+18+7+6+4+1, 27+18+7+6+4+2+1, 27+18+7+6+4+3+1 27+18+7+6+5+4+1, 27+18+7+6+5+4+2+1, 27+18+7+6+5+4+3+1, 27+18+8+1, 27+18+8+2+1, 27+18+8+3+1 27+18+8+4+1, 27+18+8+4+2+1, 27+18+8+4+3+1, 27+18+8+5+4+1, 27+18+8+5+4+2+1, 27+18+8+5+4+3+L 27+18+8+6+1, 27+18+8+6+2+1, 27+18+8+6+3+1, 27+18+8+6+4+1, 27+18+8+6+4+2+1, 27+18+8+6+4+3+L 27+18+8+6+5+4+1, 27+18+8+6+5+4+2+1, 27+18+8+6+5+4+3+1, 27+18+8+7+1, 27+18+8+7+2+1 27+18+8+7+3+1, 27+18+8+7+4+1, 27+18+8+7+4+2+1, 27+18+8+7+4+3+1, 27+18+8+7+6+L 27+18+8+7+6+2+1, 27+18+8+7+6+3+1, 27+18+8+7+6+4+1, 27+18+8+7+6+4+2+1, 27+18+8+7+6+4+3+ L 27+18+8+7+6+5+4+1, 27+18+8+7+6+5+4+2+1, 27+18+8+7+6+5+4+3+1, 27+18+9+1, 27+18+9+2+1 27+18+9+3+1, 27+18+9+4+1, 27+18+9+4+2+1, 27+18+9+4+3+1, 27+18+9+5+4+1, 27+18+9+5+4+2+1 27+18+9+5+4+3+1, 27+18+9+6+1, 27+18+9+6+2+1, 27+18+9+6+3+1, 27+18+9+6+4+1, 27+18+9+6+4+2+L 27+18+9+6+4+3+1, 27+18+9+6+5+4+1, 27+18+9+6+5+4+2+1, 27+18+9+6+5+4+3+1, 27+18+10+1 27+18+10+2+1, 27+18+10+3+1, 27+18+10+4+1, 27+18+10+4+2+1, 27+18+10+4+3+1, 27+18+10+5+4+1 27+18+10+5+4+2+1, 27+18+10+5+4+3+1, 27+18+10+6+1, 27+18+10+6+2+1, 27+18+10+6+3+1 27+18+10+6+4+1, 27+18+10+6+4+2+1, 27+18+10+6+4+3+1, 27+18+10+6+5+4+1, 27+18+10+6+5+4+2+1 27+18+10+6+5+4+3+1, 27+18+11+1, 27+18+11+2+1, 27+18+11+3+1, 27+18+11+4+1, 27+18+11+4+2+1 27+18+11+4+3+1, 27+18+11+5+4+1, 27+18+11+5+4+2+1, 27+18+11+5+4+3+1, 27+18+11+6+1 27+18+11+6+2+1, 27+18+11+6+3+1, 27+18+11+6+4+1, 27+18+11+6+4+2+1, 27+18+11+6+4+3+1 27+18+11+6+5+4+1, 27+18+11+6+5+4+2+1, 27+18+11+6+5+4+3+1, 27+18+12+1, 27+18+12+2+1 27+18+12+3+1, 27+18+12+4+1, 27+18+12+4+2+1, 27+18+12+4+3+1, 27+18+12+5+4+1 27+18+12+5+4+2+1, 27+18+12+5+4+3+1, 27+18+13+12+1, 27+18+13+12+2+1, 27+18+13+12+3+1 27+18+13+12+4+1, 27+18+13+12+4+2+1, 27+18+13+12+4+3+1, 27+18+13+12+5+4+1 27+18+13+12+5+4+2+1, 27+18+13+12+5+4+3+1, 27+18+14+1, 27+18+14+2+1, 27+18+14+3+1 27+18+14+4+1, 27+18+14+4+2+1, 27+18+14+4+3+1, 27+18+14+12+1, 27+18+14+12+2+1 27+18+14+12+3+1, 27+18+14+12+4+1, 27+18+14+12+4+2+1, 27+18+14+12+4+3+1, 27+18+14+12+5+4+1 27+18+14+12+5+4+2+1, 27+18+14+12+5+4+3+1, 27+18+15+1, 27+18+15+2+1, 27+18+15+3+1 27+18+16+1, 27+18+16+2+1, 27+18+16+3+1, 27+18+16+15+1, 27+18+16+15+2+1, 27+18+16+15+3+1 27+18+17+1, 27+18+17+2+1, 27+18+17+3+1, 27+18+17+4+1, 27+18+17+4+2+1, 27+18+17+4+3+1 27+18+17+5+4+1, 27+18+17+5+4+2+1, 27+18+17+5+4+3+1, 27+18+17+6+1, 27+18+17+6+2+1 27+18+17+6+3+1, 27+18+17+6+4+1, 27+18+17+6+4+2+1, 27+18+17+6+4+3+1, 27+18+17+6+5+4+1 27+18+17+6+5+4+2+1, 27+18+17+6+5+4+3+1, 27+18+17+7+1, 27+18+17+7+2+1, 27+18+17+7+3+1 27+18+17+7+4+1, 27+18+17+7+4+2+1, 27+18+17+7+4+3+1, 27+18+17+7+6+1, 27+18+17+7+6+2+1 27+18+17+7+6+3+1, 27+18+17+7+6+4+1, 27+18+17+7+6+4+2+1, 27+18+17+7+6+4+3+1 27+18+17+7+6+5+4+1, 27+18+17+7+6+5+4+2+1, 27+18+17+7+6+5+4+3+1, 27+18+17+8+1 27+18+17+8+2+1, 27+18+17+8+3+1, 27+18+17+8+4+1, 27+18+17+8+4+2+1, 27+18+17+8+4+3+1 27+18+17+8+5+4+1, 27+18+17+8+5+4+2+1, 27+18+17+8+5+4+3+1, 27+18+17+8+6+1, 27+18+17+8+6+2+1 27+18+17+8+6+3+1, 27+18+17+8+6+4+1, 27+18+17+8+6+4+2+1, 27+18+17+8+6+4+3+1 27+18+17+8+6+5+4+1, 27+18+17+8+6+5+4+2+1, 27+18+17+8+6+5+4+3+1, 27+18+17+8+7+1 27+18+17+8+7+2+1, 27+18+17+8+7+3+1, 27+18+17+8+7+4+1, 27+18+17+8+7+4+2+1
27+18+17+8+7+4+3+1, 27+18+17+8+7+6+1, 27+18+17+8+7+6+2+1, 27+18+17+8+7+6+3+1 27+18+17+8+7+6+4+1, 27+18+17+8+7+6+4+2+1, 27+18+17+8+7+6+4+3+1, 27+18+17+8+7+6+5+4+1 27+18+17+8+7+6+5+4+2+1, 27+18+17+8+7+6+5+4+3+1, 27+18+17+9+1, 27+18+17+9+2+1 27+18+17+9+3+1, 27+18+17+9+4+1, 27+18+17+9+4+2+1, 27+18+17+9+4+3+1, 27+18+17+9+5+4+1 27+18+17+9+5+4+2+1, 27+18+17+9+5+4+3+1, 27+18+17+9+6+1, 27+18+17+9+6+2+1, 27+18+17+9+6+3+L 27+18+17+9+6+4+1, 27+18+17+9+6+4+2+1, 27+18+17+9+6+4+3+1, 27+18+17+9+6+5+4+1 27+18+17+9+6+5+4+2+1, 27+18+17+9+6+5+4+3+1, 27+18+17+10+1, 27+18+17+10+2+1
27+18+17+10+3+1, 27+18+17+10+4+1, 27+18+17+10+4+2+1, 27+18+17+10+4+3+1, 27+18+17+10+5+4+1 27+18+17+10+5+4+2+1, 27+18+17+10+5+4+3+1, 27+18+17+10+6+1, 27+18+17+10+6+2+1 27+18+17+10+6+3+1, 27+18+17+10+6+4+1, 27+18+17+10+6+4+2+1, 27+18+17+10+6+4+3+1 27+18+17+10+6+5+4+1, 27+18+17+10+6+5+4+2+1, 27+18+17+10+6+5+4+3+1, 27+18+17+11+1 27+18+17+11+2+1, 27+18+17+11+3+1, 27+18+17+11+4+1, 27+18+17+11+4+2+1, 27+18+17+11+4+3+L 27+18+17+11+5+4+1, 27+18+17+11+5+4+2+1, 27+18+17+11+5+4+3+1, 27+18+17+11+6+1 27+18+17+11+6+2+1, 27+18+17+11+6+3+1, 27+18+17+11+6+4+1, 27+18+17+11+6+4+2+1 27+18+17+11+6+4+3+1, 27+18+17+11+6+5+4+1, 27+18+17+11+6+5+4+2+1, 27+18+17+11+6+5+4+3+1 27+18+17+12+1, 27+18+17+12+2+1, 27+18+17+12+3+1, 27+18+17+12+4+1 , 27+18+17+12+4+2+1 27+18+17+12+4+3+1, 27+18+17+12+5+4+1, 27+18+17+12+5+4+2+1, 27+18+17+12+5+4+3+1 27+18+17+13+12+1, 27+18+17+13+12+2+1, 27+18+17+13+12+3+1, 27+18+17+13+12+4+1 27+18+17+13+12+4+2+1, 27+18+17+13+12+4+3+1, 27+18+17+13+12+5+4+1, 27+18+17+13+12+5+4+2+1 27+18+17+13+12+5+4+3+1, 27+18+17+14+1, 27+18+17+14+2+1, 27+18+17+14+3+1, 27+18+17+14+4+1 27+18+17+14+4+2+1, 27+18+17+14+4+3+1, 27+18+17+14+12+1, 27+18+17+14+12+2+1
27+18+17+14+12+3+1, 27+18+17+14+12+4+1, 27+18+17+14+12+4+2+1, 27+18+17+14+12+4+3+1 27+18+17+14+12+5+4+1, 27+18+17+14+12+5+4+2+1, 27+18+17+14+12+5+4+3+1, 27+18+17+15+1 27+18+17+15+2+1, 27+18+17+15+3+1, 27+18+17+16+1, 27+18+17+16+2+1, 27+18+17+16+3+1 27+18+17+16+15+1, 27+18+17+16+15+2+1, 27+18+17+16+15+3+1, 27+19+1, 27+19+2+1, 27+ 19+3+1 27+19+4+1, 27+19+4+2+1, 27+19+4+3+1, 27+19+5+4+1, 27+19+5+4+2+1, 27+19+5+4+3+1, 27+19+6+1 27+19+6+2+1, 27+19+6+3+1, 27+19+6+4+1, 27+19+6+4+2+1, 27+19+6+4+3+1, 27+19+6+5+4+1 27+19+6+5+4+2+1, 27+19+6+5+4+3+1, 27+19+7+1, 27+19+7+2+1, 27+19+7+3+1, 27+19+7+4+1 27+19+7+4+2+1, 27+19+7+4+3+1, 27+19+7+6+1, 27+19+7+6+2+1, 27+19+7+6+3+1, 27+19+7+6+4+L 27+19+7+6+4+2+1, 27+19+7+6+4+3+1, 27+19+7+6+5+4+1, 27+19+7+6+5+4+2+1, 27+19+7+6+5+4+3+L 27+19+8+1, 27+19+8+2+1, 27+19+8+3+1, 27+19+8+4+1, 27+19+8+4+2+1, 27+19+8+4+3+1 27+19+8+5+4+1, 27+19+8+5+4+2+1, 27+19+8+5+4+3+1, 27+19+8+6+1, 27+19+8+6+2+1, 27+19+8+6+3+L 27+19+8+6+4+1, 27+19+8+6+4+2+1, 27+19+8+6+4+3+1, 27+19+8+6+5+4+1, 27+19+8+6+5+4+2+1 27+19+8+6+5+4+3+1, 27+19+8+7+1, 27+19+8+7+2+1, 27+19+8+7+3+1, 27+19+8+7+4+1 27+19+8+7+4+2+1, 27+19+8+7+4+3+1, 27+19+8+7+6+1, 27+19+8+7+6+2+1, 27+19+8+7+6+3+1 27+19+8+7+6+4+1, 27+19+8+7+6+4+2+1, 27+19+8+7+6+4+3+1, 27+19+8+7+6+5+4+ L
27+19+8+7+6+5+4+2+1, 27+19+8+7+6+5+4+3+1, 27+19+9+1, 27+19+9+2+1, 27+19+9+3+1, 27+19+9+4+ 1 27+19+9+4+2+1, 27+19+9+4+3+1, 27+19+9+5+4+1, 27+19+9+5+4+2+1, 27+19+9+5+4+3+1, 27+19+9+6+L 27+19+9+6+2+1, 27+19+9+6+3+1, 27+19+9+6+4+1, 27+19+9+6+4+2+1, 27+19+9+6+4+3+1 27+19+9+6+5+4+1, 27+19+9+6+5+4+2+1, 27+19+9+6+5+4+3+1, 27+19+10+1, 27+19+10+2+1 27+19+10+3+1, 27+19+10+4+1, 27+19+10+4+2+1, 27+19+10+4+3+1, 27+19+10+5+4+1 27+19+10+5+4+2+1, 27+19+10+5+4+3+1, 27+19+10+6+1, 27+19+10+6+2+1, 27+19+10+6+3+1 27+19+10+6+4+1, 27+19+10+6+4+2+1, 27+19+10+6+4+3+1, 27+19+10+6+5+4+1, 27+19+10+6+5+4+2+1 27+19+10+6+5+4+3+1, 27+19+11+1, 27+19+11+2+1, 27+19+11+3+1, 27+19+11+4+1, 27+19+11+4+2+1 27+19+11+4+3+1, 27+19+11+5+4+1, 27+19+11+5+4+2+1, 27+19+11+5+4+3+1, 27+19+11+6+1 27+19+11+6+2+1, 27+19+11+6+3+1, 27+19+11+6+4+1, 27+19+11+6+4+2+1, 27+19+11+6+4+3+1 27+19+11+6+5+4+1, 27+19+11+6+5+4+2+1, 27+19+11+6+5+4+3+1, 27+19+12+1, 27+19+12+2+1 27+19+12+3+1, 27+19+12+4+1, 27+19+12+4+2+1, 27+19+12+4+3+1, 27+19+12+5+4+1 27+19+12+5+4+2+1, 27+19+12+5+4+3+1, 27+19+13+12+1, 27+19+13+12+2+1, 27+19+13+12+3+1 27+19+13+12+4+1, 27+19+13+12+4+2+1, 27+19+13+12+4+3+1, 27+19+13+12+5+4+1
27+19+13+12+5+4+2+1, 27+19+13+12+5+4+3+1, 27+19+14+1, 27+19+14+2+1, 27+19+14+3+1 27+19+14+4+1, 27+19+14+4+2+1, 27+19+14+4+3+1, 27+19+14+12+1, 27+19+14+12+2+1 27+19+14+12+3+1, 27+19+14+12+4+1, 27+19+14+12+4+2+1, 27+19+14+12+4+3+1, 27+19+14+12+5+4+1 27+19+14+12+5+4+2+1, 27+19+14+12+5+4+3+1, 27+19+15+1, 27+19+15+2+1, 27+19+15+3+1 27+19+16+1, 27+19+16+2+1, 27+19+16+3+1, 27+19+16+15+1, 27+19+16+15+2+1, 27+19+16+15+3+1 27+19+17+1, 27+19+17+2+1, 27+19+17+3+1, 27+19+17+4+1, 27+19+17+4+2+1, 27+19+17+4+3+1 27+19+17+5+4+1, 27+19+17+5+4+2+1, 27+19+17+5+4+3+1, 27+19+17+6+1, 27+19+17+6+2+1 27+19+17+6+3+1, 27+19+17+6+4+1, 27+19+17+6+4+2+1, 27+19+17+6+4+3+1, 27+19+17+6+5 +4+ 1 27+19+17+6+5+4+2+1, 27+19+17+6+5+4+3+1 , 27+19+17+7+1, 27+19+17+7+2+1, 27+19+17+7+3+1 27+19+17+7+4+1, 27+19+17+7+4+2+1, 27+19+17+7+4+3+1, 27+19+17+7+6+1, 27+19+17+7+6+2+1 27+19+17+7+6+3+1, 27+19+17+7+6+4+1, 27+19+17+7+6+4+2+1, 27+19+17+7+6+4+3+ 1
27+19+17+7+6+5+4+1, 27+19+17+7+6+5+4+2+1, 27+19+17+7+6+5+4+3+1, 27+19+17+8+1 27+19+17+8+2+1, 27+19+17+8+3+1, 27+19+17+8+4+1, 27+19+17+8+4+2+1, 27+19+17+8+4+3+1 27+19+17+8+5+4+1, 27+19+17+8+5+4+2+1, 27+19+17+8+5+4+3+1, 27+19+17+8+6+1, 27+19+17+8+6+2+L 27+19+17+8+6+3+1, 27+19+17+8+6+4+1, 27+19+17+8+6+4+2+1, 27+19+17+8+6+4+3+1
27+19+17+8+6+5+4+1, 27+19+17+8+6+5+4+2+1, 27+19+17+8+6+5+4+3+1, 27+19+17+8+7+1 27+19+17+8+7+2+1, 27+19+17+8+7+3+1, 27+19+17+8+7+4+1, 27+19+17+8+7+4+2+1
27+19+17+8+7+4+3+1, 27+19+17+8+7+6+1, 27+19+17+8+7+6+2+1, 27+19+17+8+7+6+3+1 27+19+17+8+7+6+4+1, 27+19+17+8+7+6+4+2+1, 27+19+17+8+7+6+4+3+1, 27+19+17+8+7+6+5+4+1 27+19+17+8+7+6+5+4+2+1, 27+19+17+8+7+6+5+4+3+1, 27+19+17+9+1, 27+19+17+9+2+1 27+19+17+9+3+1, 27+19+17+9+4+1, 27+19+17+9+4+2+1, 27+19+17+9+4+3+1, 27+19+17+9+5 +4+ 1 27+19+17+9+5+4+2+1, 27+19+17+9+5+4+3+1, 27+19+17+9+6+1, 27+19+17+9+6+2+1, 27+19+17+9+6+3+L 27+19+17+9+6+4+1, 27+19+17+9+6+4+2+1, 27+19+17+9+6+4+3+1, 27+19+17+9+6+5+4+ 1 27+19+17+9+6+5+4+2+1, 27+19+17+9+6+5+4+3+1, 27+19+17+10+1, 27+19+17+10+2+1 27+19+17+10+3+1, 27+19+17+10+4+1, 27+19+17+10+4+2+1, 27+19+17+10+4+3+1, 27+19+17+10+5+4+1, 27+19+17+10+5+4+2+1, 27+19+17+10+5+4+3+1, 27+19+17+10+6+1, 27+19+17+10+6+2+1, 27+19+17+10+6+3+1, 27+19+17+10+6+4+1, 27+19+17+10+6+4+2+1, 27+19+17+10+6+4+3+1, 27+19+17+10+6+5+4+1 , 27+19+17+10+6+5+4+2+1, 27+19+17+10+6+5+4+3+1, 27+19+17+11+1, 27+19+17+11+2+1, 27+19+17+11+3+1, 27+19+17+11+4+1, 27+19+17+11+4+2+1, 27+19+17+11+4+3+1, 27+19+17+11+5+4+1, 27+19+17+11+5+4+2+1, 27+19+17+11+5+4+3+1, 27+19+17+11+6+1, 27+19+17+11+6+2+1, 27+19+17+11+6+3+1, 27+19+17+11+6+4+1, 27+19+17+11+6+4+2+1, 27+19+17+11+6+4+3+1, 27+19+17+11+6+5+4+1, 27+19+17+11+6+5+4+2+1, 27+19+17+11+6+5+4+3+1, 27+19+17+12+1, 27+19+17+12+2+1, 27+19+17+12+3+1, 27+19+17+12+4+1, 27+19+17+12+4+2+1, 27+19+17+12+4+3+1, 27+19+17+12+5+4+1, 27+19+17+12+5+4+2+1, 27+19+17+12+5+4+3+1, 27+19+17+13+12+1, 27+19+17+13+12+2+1, 27+19+17+13+12+3+1, 27+19+17+13+12+4+1, 27+19+17+13+12+4+2+1, 27+19+17+13+12+4+3+1, 27+19+17+13+12+5+4+1, 27+19+17+13+12+5+4+2+1, 27+19+17+13+12+5+4+3+1, 27+19+17+14+1, 27+19+17+14+2+1, 27+19+17+14+3+1, 27+19+17+14+4+1, 27+19+17+14+4+2+1, 27+19+17+14+4+3+1, 27+19+17+14+12+1, 27+19+17+14+12+2+1, 27+19+17+14+12+3+1, 27+19+17+14+12+4+1, 27+19+17+14+12+4+2+1, 27+19+17+14+12+4+3+1, 27+19+17+14+12+5+4+1, 27+19+17+14+12+5+4+2+1, 27+19+17+14+12+5+4+3+1, 27+19+17+15+1, 27+19+17+15+2+1, 27+19+17+15+3+1, 27+19+17+16+1, 27+19+17+16+2+1, 27+19+17+16+3+1, 27+19+17+16+15+1, 27+19+17+16+15+2+1, 27+19+17+16+15+3+1, 27+20+1, 27+20+2+1, 27+20+3+1, 27+21+20+1, 27+21+20+2+1, 27+21+20+3+1, 27+22+20+1, 27+22+20+2+1, 27+22+20+3+1, 27+23+20+1, 27+23+20+2+1, 27+23+20+3+1, 27+23+21+20+1, 27+23+21+20+2+1, 27+23+21+20+3+1, 27+23+22+20+1, 27+23+22+20+2+1, 27+23+22+20+3+1, 27+24+20+1, 27+24+20+2+1, 27+24+20+3+1, 27+24+21+20+1, 27+24+21+20+2+1, 27+24+21+20+3+1, 27+24+22+20+1, 27+24+22+20+2+1, 27+24+22+20+3+1 and 28.
In the list above, the numbers refer to the embodiments according to their numbering provided hereinabove whereas "+" indicates the dependency from another embodiment. The different individualised embodiments are separated by commas. In other words, "5+4+1" for example refers to embodiment 5) depending on embodiment 4), depending on embodiment 1), i.e. embodiment "5+4+1" corresponds to embodiment 1) further limited by the features of embodiments 4) and 5). Likewise, "18+16+3+1" refers to embodiment 18) depending mutatis mutandis on embodiments 16) and 13), depending on embodiment 1), i.e. embodiment "18+16+3+1" corresponds to embodiment 1) further limited by the features of embodiment 3), further limited by the features of embodiments 16) and 18).
The compounds of formula I can be manufactured in accordance with the present invention using the procedures described hereafter. PREPARATION OF COMPOUNDS OF FORMULA I
General preparation methods:
The compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures. Sections a) to f) hereafter describe general methods for preparing compounds of formula I. If not indicated otherwise, the generic groups K (Ka, Kb, Kc and Kd), Rla, Rlb, Rlc, Rld, Ua, Va, Wa, Ub, Vb, Wb, Vc, Wc, Vd, Wd, Xa, Ra, A, Rb, G (Ga, Gb, Gc and Gd), M, Q and Q' are as defined for formula I. General synthetic methods used repeatedly throughout the text below are referenced to and described in the section entitled "General reaction techniques" in the experimental section below. In some instances generic groups might be incompatible with the assembly illustrated in the procedures and schemes below and so will require the use of protecting groups. The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-Interscience, 1999).
The compounds of formula I can be manufactured by a) reacting a compound of formula II
Figure imgf000028_0001
II with an alkene derivative of formulae Ilia or Illb
Figure imgf000029_0001
Illb
using general reaction technique 1 ; or b) reacting a compound of formula II with an epoxide of formula IVa, IVb or IVc
Figure imgf000029_0002
IVa IVb IVc using general reaction technique 2; or c) reacting a compound of formula II with an aldehyde of formula V
Figure imgf000029_0003
wherein K is as defined in formula I, provided that when K is Ka, A is CH2, using general reaction technique 3; or d) reacting a compound of formula II with a compound of formula VI
K— CH2— LG VI
wherein LG represents chloro, bromo, iodo, OTf, OTs or OMs. The reaction can be performed in various solvents such as DMF, DMA, NMP, in presence of a base such as DIPEA or TEA at a temperature ranging between 20°C and 100°C; or e) reacting a compound of formula VII
Figure imgf000030_0001
VII wherein when K is Ka A is CH2, with a carbonic acid derivative of formula VIII,
Figure imgf000030_0002
VIII wherein L and L both represent chloro, OCCl3, imidazolyl or succinimidyloxy, or L represents chloro and L00 represents OCCI3 using general reaction technique 4; or f) deprotecting a compound of formula IX
Figure imgf000030_0003
IX wherein PG represents 4-methoxybenzyl or 2,4- dimethoxybenzyl or 3,4-dimethoxybenzyl. The deprotection reaction can be performed using acidic conditions such as TFA, TfOH, or a combination of TFA and TfOH at a temperature ranging between 20°C and 100°C. The compounds of formula I thus obtained may be, if desired, converted into their salts, and notably into their pharmaceutically acceptable salts.
Besides, whenever the compounds of formula I are obtained in the form of mixtures of diastereomers, the diastereomers can be separated using methods known to one skilled in the art, e.g. by HPLC over a chiral stationary phase such as a Regis Whelk-Ol(R,R) (10 μηι) column, a Daicel ChiralCel OD-H (5-10 μηι) column, or a Daicel ChiralPak IA (10 μηι) or AD-H (5 μηι) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as TEA or diethylamine) and eluent B (Hex), at a flow rate of 0.8 to 150 mL/min. The mixtures of diasteromers may also be separated by an appropriate combination of silica gel chromatography, HPLC and crystallization techniques. Preparation of the intermediates used in the preparation the compounds of formula I:
Compounds .f formuja.II:
The compounds of formula II can be prepared as summarised in Scheme 1 hereafter.
Figure imgf000031_0001
I!
Scheme 1 In Scheme 1, PG1 is an amine protecting group, such as a Boc, Cbz, Alloc or Fmoc and L1 represents CI, Br, I or OTf.
The compounds of formula I-l are reacted with compounds of formula 1-3 using general reaction technique 5 to give the intermediates of formula 1-2. Removal of the protecting group using general reaction technique 6 provides the compounds of formula II. Compounds f^fprm^
The compounds of formula Ilia can be prepared as described in WO 02/08224, WO 2004/058144, WO 2006/021448, WO 2007/016610, WO 2007/107965 and WO 2010/041194 or by analogy to these reported methods. The compounds of formula Illb can be prepared as described in WO 2007/071936 and WO 2010/041194 or by analogy to these reported methods. C ompounds of formulae I V _¾ I Vb _and IV c
The compounds of formulae IVa, IVb and IVc can be prepared as described in WO 00/78748, WO 02/08224, WO 2006/02047, WO 2006/21448 and WO 2006/032466.
Compounds P.f formula, V: The compounds of formula V wherein K represents Ka, A represents CH2, U is CH and V or W is N can be prepared as described in WO 2005/16916 and WO 2005/108389. The other azaisosters can be prepared by analogy to these reported methods.
The compounds of formula V wherein K represents Kb can be prepared as described in WO 2006/137485, WO 2007/138974, WO 2009/09700 and WO 2009/69589. The compounds of formula V wherein K represents Kc can be prepared by oxidation of the corresponding primary alcohols using general reaction technique 7. The precursors (Vc = N and Wc = CH) can be obtained as described in WO 2008/125594 and WO 2010/041194.
The compounds of formula V wherein K represents Kd can be prepared by oxidation of the corresponding primary alcohols using general reaction technique 7. The precursors (Vd = N and Wd = CH) can be obtained as described in WO 2009/104147. The azaisosters (e.g. Vd = CH and Wd = N) can be obtained in analogy to the reported methods.
Compounds. pf^formula.VL
The compounds of formula VI can be prepared as summarised in Scheme 2 hereafter.
Figure imgf000032_0001
VI
Scheme 2
In Scheme 2, LG represents OTf, OMs, OTf or halogen such as bromine, chlorine or iodine.
The compounds of formula VI can be prepared from compounds of formula II- 1 using general reaction technique 8. Compounds .f formula VII:
The compounds of formula VII can be prepared as summarised in Scheme 3 hereafter.
Figure imgf000033_0001
Scheme 3
In Scheme 3, G is as defined in formula VII, PG1 is an amine protecting group, such as a Boc, Cbz, Alloc or Fmoc and K is as defined in formula I, provided that A represents CH2.
The compounds of formula III-l can be deprotected (Scheme 3) using general reaction technique 6, leading to the intermediates of formula III-2. The formation of the compounds of formula VII can then be achieved using methods which have been described for the preparation of compounds of formula I wherein A is CH2, section a), c), d) and f) using respectively precursors of formulae Ilia, Illb, V and VI.
Compounds of formula VIII:
The compounds of formula VIII are commercially available.
Compounds of .formula IX:
The compounds of formula IX can be prepared as summarised in Scheme 4 hereafter.
Figure imgf000034_0001
1-1 IV-1 IV-2
Figure imgf000034_0002
IV-3 IX
Scheme
Figure imgf000034_0003
In Scheme 4, PG represents 4-methoxybenzyl, 2,4-dimethoxybenzyl or 3,4-dimethoxybenzyl,
PG 1 is an amine protecting group, such as a Boc, Cbz, Alloc or Fmoc, L 2 represents OTf or a halogen such as CI, Br or I.
The compounds of formula 1-1 can be reacted (Scheme 4) with the compounds of formula IV-1, wherein L represents OTf or a halogen such as CI, Br or I using general reaction technique 5. The protecting group PG1 in the intermediates of formula IV-2 is removed using general reaction technique 6 affording the intermediates of formula IV-3 which are further transformed into the derivatives of formula IX using methods which have been described for the preparation of compounds of formula I wherein A is CH2, section a), c), d) and f), using respectively precursors of formulae Ilia, Illb, V and VI. Synthesis of building blocks:
C omp unds p.f formula. I - 1 :
The compounds of formula 1-1 can be prepared as summarised in Scheme 5 hereafter.
Figure imgf000035_0001
Scheme 5
In Scheme 5, PG1 represents an amino protecting group such Boc or Cbz.
The derivatives of formula V-1 (commercially available when PG1 represents Cbz or Boc) can be reacted with the derivatives of formula VIII using general reaction technique 4.
C omppunds p.f formula.1.-3 : The compounds of formula 1-3 are either commercially available (G represents Ga) or can be made according to WO 2008/009700 (G represents Gc), WO 2009/71890, WO 2010/30782, WO 2010/41194 or WO 2011/057892 (G represents Gd).
Comppunds pf. formula. II:_1
The compounds of formula II- 1 wherein K represents Ka can be obtained by reduction of the corresponding aldehydes using general reaction technique 9. The required aldehydes can be made according to J. Chem. Soc. (1957), 3066-3071, WO 02/089749, WO 2003/050132, WO 2005/108389, WO 2005/016916 or in analogy to methods reported therein.
The compounds of formula II- 1 wherein K represents Kb can be obtained according to WO 2006/137485, WO 2007/138974, WO 2008/009700 and WO 2009/069589. The compounds of formula II- 1 wherein K represents Kc are obtained by reduction of the corresponding aldehydes using general reaction technique 9. The required aldehydes are made according to WO 2010/41194 or in analogy to the method reported therein.
The compounds of formula II- 1 wherein K represents Kd can be obtained by reduction of the corresponding aldehydes using general reaction technique 9. The required aldehydes can be made according to WO 2008/03690 and WO 2009/104147 or in analogy to the methods reported therein.
Compounds of form
The compounds of formula III- 1 can be prepared as summarised in Scheme 6 hereafter.
Figure imgf000036_0001
Scheme 6
In Scheme 6, G is as defined in formula I. PG 1 and PG 2 are orthogonal amine protecting groups, such as a Boc, alloc, Cbz or Fmoc. L is CI, Br, I, OMs, OTs or OTf.
The compounds of formula VI-2 can be obtained (Scheme 6) from the compounds of formula VI-1 (commercially available when PG1 represents Cbz or Boc) using general technique reaction 8. The sodio anion of compounds of formula VI-3 which are formed by reacting the compounds of formula VI-3 with sodium hydride in an appropriate solvent such as DMF are subsequently reacted with the compound of formula VI-2 at a temperature ranging between 25 °C and 100°C and especially at 60°C to afford directly the compounds of formula III- 1. If required, the protecting group PG can be removed using general reaction technique 6.
C ompounds of formula IV- 1 :
The compounds of formula IV- 1 can be prepared as summarised in Scheme 7 hereafter.
Figure imgf000036_0002
Scheme 7
In Scheme 7, L2 is CI, Br or I. PG is an amine protecting group such as a 4-methoxybenzyl or 3,4-dimethoxybenzyl, Q' represents O or S and M is N or CH. The compounds of formula VII- 1 can be reacted with 4-methoxybenzyl, 2,4-dimethoxybenzyl or 3,4-dimethoxybenzyl chloride in the presence of a base such as CS2CO3 in a solvent such as DMF at a temperature ranging between 20°C and 100°C, affording the compound of formula IV- 1. Compounds of formul.a V-l.:.
The compound of formula V-l wherein PG1 is Boc is commercially available. The other analogues can be made from (3R,4R)-4-(aminomethyl)-3-piperidinol (prepared according to WO 2005/000838) using general reaction technique 10.
Compounds of formula. yi-3; Compounds of formula VI-3 can be prepared according to WO2004/09562, WO2007/ 107965, WO 2008/126024 and WO 2009/104159 or prepared (when PG2 represents Boc) as described in Scheme 8 hereafter.
Boc G
H02C-G ► ^N^ G— NH2
H
Vlli-1 VI-3 Viii-2
Scheme 8 In Scheme 8, G represents Ga, Gb or Gc.
The compound of formula VI-3, wherein G represents Gc and PG represents Boc can be prepared from the corresponding acids of formula VIII- 1 via a Curtius reaction. The compounds of formula VIII- 1 can for instance be reacted with DPPA in 2-methyl-2-propanol in presence of TEA at a temperature between 50°C and reflux. Alternatively the compounds of formula VI-3 can be prepared from the compounds of formula VIII-2 using general reaction technique 10.
Comp.ounds .o.f form^
The compounds of formula VII- 1 are commercially available or can be prepared according to WO 2010/041194 and WO 2010/30782. Compounds of formula Vni-1 :
The compounds of formula VIII- 1 are either commercially available or can be prepared according to WO 2004/58144, WO 02/56882, WO 2006/105289, WO 2007/16610 or J. Org. Chem. (1968), 33(1), 456-457. In case G represents Gc, they can also be obtained by saponification of the corresponding ester using general reaction technique 1 1 as shown in Scheme 9 hereafter. The required esters can be prepared according to WO 2007/081597.
Figure imgf000038_0001
!X-1 VI!M
Scheme 9
In scheme 9, Q is O or S and R is alkyl. Compounds of form
Compounds of formula VIII-2 are either commercially available or prepared according to WO 2007/100758, WO 2007/107905 or WO 2010/30782.
EXPERIMENTAL PART Abbreviations: The following abbreviations are used throughout the specification and the examples:
Ac acetyl
AcOH acetic acid
Alloc allyloxycarbonyl
aq. aqueous
ΒΓΝΑΡ (±)-(!, 1 '-binaphthalene-2,2'-diyl)bis(diphenylphosphine)
Boc tert-butoxycarbonyl
BrettPhos 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl-
1 , 1 '-biphenyl
Cbz benzyloxycarbonyl
CC column chromatography over silica gel Cy cyclopentyl
CDI carbonyldiimidazole
Dba dibenzylideneacetone
DCE 1 ,2-dichloroethane
DCM dichloromethane
DIPEA N,N-diisopropylethylamine
DMA dimethylacetamide
DMAP 4-dimethylaminopyridine
DME 1.2- dimethoxyethane
DMF N,N-dimethylformamide
DMSO dimethylsulfoxide
EA ethyl acetate
ESI Electron Spray Ionisation
eq. equivalent
ether diethyl ether
Et ethyl
EtOH ethanol
Fmoc 9-fluorenylmethoxycarbonyl
h hour(s)
Hex hexane
Hept heptanes
HPLC high pressure liquid chromatography
IPr 1.3- bis(2,6-diisopropylphenyl)-l,3-dihydro-2H-imidazol-2-ylidene
JosiPhos ligands (R)-l-[(SP)-2-(di-tert-butylphosphino)ferrocenyl]ethylbis(2-methyl- phenyl)phosphine or (R)-l-[(SP)-2-(di-tert-butyl- phosphino)ferrocenyl]ethyldiphenylphosphine or
(R)-l-[(SP)-2-(dicyclohexylphosphino)ferrocenyl]ethyl- di-tert-butylphosphine
KHMDS potassium hexamethyldisilazide
LAH lithium aluminium hydride
LC liquid chromatography
LiHMDS lithium hexamethyldisilazide
Me methyl MeCN acetonitrile
MEK methyl ethyl ketone
MeOH methanol
min minute(s)
MS Mass Spectroscopy
Ms methanesulfonyl (mesyl)
ft-BuLi ft-butyl lithium
NMO N-methylmorpholine oxide
NMP N-methyl-2-pyrrolidone
org. organic
Pd/C palladium on carbon
Pd/CaC03 palladium dihydroxide on calcium carbonate
Pd(OH)2/C palladium dihydroxide on carbon
PEPPSI™-IPr [ 1 ,3-bis(2,6-diisopropylphenyl)imidazol- 2-ylidene](3-chloropyridyl)palladium(II) di chloride
Ph phenyl
PMB para-methoxybenzyl
Pyr pyridine
Q-phos l,2,3,4,5-pentaphenyl-r-(di-tert-butylphosphino)ferrocene quant. quantitative
rac racemic
rt room temperature
sat. saturated
SK-CC01 -A 2'-(dimethylamino)-2-biphenylyl-palladium(II) chloride
dinorbornylphosphine complex
SK-CC02-A 2-(dimethylaminomethyl)ferrocen- 1 -yl-palladium(II) chloride dinorbornylphosphine complex
S-Phos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
TBAF tetrabutylammonium fluoride
TBDMS tert-butyldimethylsilyl
TBDPS tert-butyldiphenylsilyl
TBME tert-butylmethylether
tBu tert-butyl TEA triethylamine
Tf trifluoromethanesulfonyl (triflyl)
TFA trifluoroacetic acid
THF tetrahydrofuran
TMG 1 , 1 ,3,3-tetramethylguanidine
TMS trimethylsilyl
tR retention time
Ts ?ara-toluenesulfonyl
T3P propylphosphonic anhydride
XantPhos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
X-Phos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
General reaction techniques:
General, reaction .technique .1. (addition of .piperidine derivative onto .an a.lkene) :
The addition of a piperidine derivative onto an alkene can be accomplished in various solvents such as DMF, DMA or NMP in presence of a promoter such a TMG at a temperature ranging between 60°C and 100°C.
General reaction technique .2. (addition of. peridine derivative onto .an .epoxide).:.
The addition of a piperidine derivative onto an epoxide can be accomplished in various solvent such as DMF, DMA, NMP in presence of a mineral base such as K2CO3 and a Lewis acid such as LiC104 at a temperature ranging between 60°C and 100°C.
General, reaction technique.3. (reductive. amination) :
The reaction between an amine and an aldehyde is performed in a solvent system allowing the removal of the formed water through physical or chemical means (e.g. distillation of the solvent-water azeotrope or presence of drying agents such as molecular sieves, MgS04 or Na2S04). Such solvent is typically toluene, Hex, THF, NMP, DCM or DCE or a mixture of solvents such as DCE/MeOH. The reaction can be catalyzed by traces or a stoichiometric amount of acid (usually AcOH or /?-TsOH). The intermediate imine is reduced with a suitable reducing agent (e.g. NaBH4, NaBH3CN, or NaBH(OAc)3) or by hydrogenation over a noble metal catalyst such as Pd/C. The reaction is carried out between -10° and +110°C, preferably between 0°C and 60°C. The reaction can also be carried out in one pot. It can also be performed in protic solvents such as MeOH or water in the presence of a picoline-borane complex (Tetrahedron (2004), 60, 7899-7906).
General, reaction technique .4. (cy.cl ic carbamate for mat on)_:_
The aminoalcohol derivative was reacted with phosgene, diphosgene, triphosgene, carbonyldiimidazole or di-O-succinyl carbonate. The reaction is preferably carried out in a dry aprotic solvent such as DCM or THF in presence of an organic base such as TEA or pyridine and at a temperature range between -78°C and +80°C.
General, reaction .technique .5. (Buchwald-Hartwi^ coupling);.
The halide or triflate aromatic partner is reacted with the required 7-protected octahydro- 2H-pyrido[4,3-e][l,3]oxazin-2-one derivative in the presence of a palladium catalyst in a solvent such as toluene, THF, dioxane, DME or DMF. Examples of typical palladium catalysts are triarylphosphine palladium complexes such as Pd(PPh3)4. These catalysts can also be prepared in situ from a common palladium source such as Pd(OAc)2 or Pd2(dba)3 and a ligand such as trialkylphosphines (e.g. PCy3 or P(tBu)3), dialkylphosphinobiphenyls (e.g. X-Phos or BrettPhos), chelating diphosphines (e.g. ΒΓΝΑΡ, XantPhos) or ferrocenylphosphines (e.g. Q-phos). One can also use instead, a commercially available precatalyst based on palladacycle (e.g. SK-CC02-A) or N-heterocyclic carbene complexes (e.g. PEPPSI™-IPr). Alternatively, a copper catalysed coupling reaction between the above mentioned partners can be performed using a copper (I) source such as copper iodide, a ligand such as trans-N,N'-dimethyl-l,2-cyclohexanediamine, a base such as K2CO3 in a solvent such as dioxane at a temperature ranging between 50°C and reflux.
General, reaction technique .6. (removal, of amine .protecting .groups).:.
The benzyl carbamates are deprotected by hydrogenolysis over a noble metal catalyst (e.g. Pd/C or Pd(OH)2/C). The Boc group is removed under acidic conditions such as HC1 in an organic solvent such as MeOH or dioxane, or TFA neat or diluted in a solvent such DCM. The Alloc group is removed by the action of tetrakis(triphenylphosphine)palladium(0) in presence of an allyl cation scavenger such as morpholine, dimedone or tributyltin hydride between 0°C and +50°C in a solvent such as THF. The Fmoc group is removed under mild basic conditions such as piperidine in DMF. The N-acetyl protecting group is removed under basic conditions such as Na2CO3, LiOH or NaOH in aq. MeOH or THF, or under acidic conditions such as aq. HC1 in THF. The N-benzyl protected amines are deprotected by hydrogenolysis over a noble catalyst (e.g. Pd(OH)2). The 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl or 4-methoxybenzyl protecting group can be removed by reaction with TFA. Further general methods to remove amine protecting groups have been described in Protecting Groups in Organic Synthesis, 3rd Ed 1999, 494-653; T.W. Greene, P.G.M. Wuts (Publisher: John Wiley and Sons, Inc., New York).
General, reaction technique .7. (alcohol .oxidation) :
A primary allylic or benzylic alcohol dissolved in an organic solvent such as DCM or THF is oxidized into the corresponding aldehyde with Mn02. Further methods can be found in Comprehensive Organic Transformations. A guide to Functional Group Preparations; 2nd Edition, R. C. Larock, Wiley- VC; New York, Chichester, Weinheim, Brisbane, Singapore, Toronto, 1999; Section aldehydes and ketones, p. 1234-1236
General, reaction .technique .8. (alcohol .activation):
The alcohol is reacted with MsCl, TfCl or TsCl in presence of a base such as TEA in a dry aprotic solvent such as Pyr, THF or DCM between -30°C and +50°C. In the case of the triflate or mesylate, Tf20 or Ms20 can also be used. These sulfonates can be reacted with a sodium halogenide such as Nal or NaBr in MeCN or DMF between 40°C and 120°C delivering the corresponding iodide derivatives. Alternatively the corresponding bromides or chlorides can also be obtained by reaction of the corresponding alcohol derivatives with PBr3 or PC13 respectively.
General reaction .technique .9. (aldehyde .and ketone reduction) ;
A ketone or an aldehyde is reduced with a boron or aluminium hydride reducing agent such as LiBH4, NaBH4 or LAH in a solvent such as THF between -20°C and +40°C. Further general methods to reduce carbonyl groups as well as asymmetric reduction methods have been described in Comprehensive Organic Transformations. A guide to Functional Group Preparations, 2nd Edition, R. C. Larock, Wiley- VC, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto 1999, Section alcohols and phenols, p. 1075-1087 and p. 1097-1110. General reaction .technique 1 Q (p otection of an amine):.
Amines are usually protected as carbamates such as Alloc, Cbz, Boc or Fmoc. They are obtained by reacting the amine with allyl- or benzyl- chloroformate, di tert-butyl dicarbonate or Fmoc chloride in presence of a base such as NaOH, TEA, DMAP or imidazole. Further strategies to introduce other amine protecting groups have been described in Protecting Groups in Organic Synthesis, 3rd Ed (1999), 494-653; T.W. Greene, P.G.M. Wuts; (Publisher: John Wiley and Sons, Inc., New York, N.Y.).
General, reaction .technique .11. (ester hydrolysis);
The methyl and ethyl esters are deprotected by saponification with an alkali hydroxide such as NaOH, LiOH or KOH, benzyl ester by hydrogeno lysis over a noble metal catalyst such as Pd/C. The tert-butyl esters are deprotected by treatment with TFA (neat or diluted in an organic solvent such as DCM) or a solution of HC1 in an organic solvent such as dioxane.
Detailed Synthetic Procedures
1H NMR spectra were recorded on a 300 MHz VARIAN GEMINI spectrometer and are reported relative to the indicated deuterated solvent signals (δ CDC13: 7.26 ppm and δ DMSO: 2.54 ppm). Multiplicities: s = singlet, d = doublet, t = triplet, q = quadruplet, p = pentuplet, hex = hexet, hep = heptet, m = multiplet, br. = broad; coupling constants are given in Hz.
Preparative HPLCs were performed on XBridge Prep CI 8 columns from Waters. The following conditions were used:
- Eluents: A: H2O + 0.1% acidic or basic additive; B: MeCN + 0.1% acidic or basic additive;
- Gradient: 5% B→ 95% B over 5 min.
- Detection: UV/Vis and/or MS and/or ELSD.
- Method A: Prep-HPLC (basic conditions): additive in A and B is 0.1% NH4OH.
- Method B: Prep-HPLC (acidic conditions): additive in A and B is 0.1% HCO2H. Preparation A: rac-(4aR*,8aR*)-tert-but l 2-oxohexahydro- 2H-pyrido[4,3-e] [l,3]oxazine-7(3H)-carboxylate:
To a mixture of rac-(3R*,4R*)-tert-buty\ 4-(aminomethyl)-3-hydroxypiperidine- 1-carboxylate (3.39 g, 14.72 mmol; prepared according to Tetrahedron (2008), 64, 2456-2464) in MEK (40 mL) heated to 60°C was added CDI (3.58 g, 22.08 mmol, 1.5 eq). The mixture was stirred for 3 h. Na2CO3 (5% aq., 4 mL) was added. The reaction proceeded at rt for 70 min. The two layers were decanted and the aq. layer was extracted with EA (10 mL). The combined org. layers were washed with brine (8 mL), dried over Na2S04, filtered and concentrated to dryness. The residue was purified by CC (DCM to DCM/MeOH 9: 1) to afford the title compound as a white solid (2.59 g).
1H NMR (d6-DMSO) δ : 7.23 (d, J = 3.7 Hz, 1H); 4.111 (m, 1H); 3.94 (m, 1H); 3.79 (td, J = 5.0, 10.4 Hz, 1H); 3.14 (td, J = 5.0, 11.2 Hz, 1H); 2.87 (t, J = 11.2 Hz, 1H); 2.55-2.80 (m, 2H); 1.64-1.76 (m, 2H); 1.38 (s, 9H), 1.12 (m, 1H). MS (ESI, m/z): 257.2 [M+H+] for C12H2oN204. Preparation B: r c-( R*,5 R*)-3-(2,3-dihydrobenzo[6] [l,4]dioxin-6-yl)octahydro- 2H-pyrido [4,3-e] [1,3] oxazin-2-one:
B.i. Rac-(4aR*,8aR*)-tert-butyl 3-(2,3-dihydrobenzo[b] [1 ,4] 1 dioxin-6-yl)-2-oxohexahydro- 2H-pyrido[4, 3-e] [1 ,3] oxazine- 7 (3H)-carboxylate:
A vial was charged with K2C03 (0.22 g, 1.56 mmol, 2 eq.), Cul (0.01 g, 0.08 mmol, 0.1 eq.) and trafts-l,2-cyclohexane diamine (0.01 g, 0.08 mmol, 0.1 eq.), rac-(4aR*,8aR*)-tert-butyl 2-oxohexahydro-2H-pyrido[4,3-e][l,3]oxazine-7(3H)-carboxylate (Preparation A, 0.2 g, 0.78 mmol) and flushed with nitrogen for 5 min. A solution of 6-iodo- 2,3-dihydrobenzo[b][l,4]dioxine (0.21 g, 0.78 mmol, 1.01 eq.) in dry dioxane (0.78 mL) was added and the resulting suspension was at 110°C for 40 h. The reaction mixture was cooled to rt and filtered over Celite. The solid was washed by EA (2 x 10 mL). The filtrate was concentrated to dryness and the residue was purified by CC (DCM/MeOH 49: 1 to 19: 1) to give the title compound as a beige foam (0.19 g).
MS (ESI, m/z): 391.2 [M+H+] for C20H26N2O6. B. ii. Rac-(4aR * 8aR *)-3-(2, 3-dihydrobenzofbJ [1 ,4Jdioxin-6-yl)octahydro- 2H-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
A solution of intermediate B.i (0.18 g, 0.47 mmol) in TFA (1.8 mL) was stirred at rt for 20 min. The volatiles were removed in vacuo and the residue was partitioned between aq. sat. sodium carbonate (5 mL) and DCM/MeOH (9: 1, 8 mL). The aq. layer (pH = l l) was extracted four times with DCM/MeOH (9: 1, 4 x 10 mL). The combined org. layers were dried over Na2SO4, filtered and concentrated. The residue was purified by CC (DCM/MeOH 19: 1 containing 1% aq. NH4OH) to give the title amine as a white foam (0.07 g).
1H NMR (d6-DMSO) δ : 6.84 (d, J = 2.3 Hz, 1H); 6.81 (d, J = 8.4 Hz, 1H); 6.76 (dd, J = 2.3, 8.4 Hz, 1H); 4.21 (s, 4H); 3.96 (td, J = 4.7, 10.2 Hz, 1H); 3.43 (dd, J = 5.4, 11.0 Hz, 1H); 3.35 (t, J = 11.0 Hz, 1H); 3.11 (dd, J = 4.7, 11.4 Hz, 1H); 2.87 (m, 1H); 2.31-2.44 (m, 2H); 1.88 (m, 1H); 1.68 (m, 1H); 1.12 (m, 1H). MS (ESI, m/z): 291.2 [M+H+] for Ci5H18N2O4.
Preparation C: r c-( R*,5 R*)-3-(3-oxo-3,4-dihydro-2H-benzo[6] [l,4]oxazin- 6-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
C. i. Rac-(4aR*,8aR*)-tert-butyl 3-(4-(4-methoxybenzyl)-3-oxo-3,4-dihydro- 2H-benzo[b] [1, 4]oxazin-6-yl)-2-oxohexahydro-2H-pyrido[4, 3-e] [1, 3]oxazine- 7(3H)-carboxylate:
In a 7 mL sealed vial were introduced 6-iodo-4-(4-methoxybenzyl)-2H-benzo[b][l,4]thiazin- 3(4H)-one (0.2 g, 0.486 mmol), rac-{4aR*,8ciR*)-tert-buty\ 2-oxohexahydro- 2H-pyrido[4,3-e][l,3]oxazine-7(3H)-carboxylate (Preparation A, 0.15 g, 0.584 mmol, 1.2 eq.), potassium carbonate (0.134 g, 2 eq.), (R,R)-(-)-N,N'-dimethyl- 1 ,2-cyclohexanediamine (0.01 g, 0.06 mmol, 0.1 eq.), Cul (0.11 g, 0.57 mmol, 1 eq.) and dioxane (2.3 mL). The suspension was stirred at 100°C for 2 days. The mixture was cooled to rt, diluted with DCM/MeOH (9: 1, 2 mL) and filtered. The yellow salt obtained was washed with DCM/MeOH (9: 1, 2 x 10 mL). The combined filtrates were concentrated under reduced pressure. The residue was purified (DCM/MeOH 9: 1) to afford the title compound as a greenish foam (0.15 g).
MS (ESI, m/z): 524.2 [M+H+] for C28H33N3O7. C. ii. rac-(4aR * 8aR *)-3-(3-oxo-3, 4-dihydro-2H-benzo[b] [1, 4] oxazin-6-yl)octahydro- 2H-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
A solution of intermediate C.i (0.14 g, 0.26 mmol) in TFA (99%, 1.06 mL) was stirred at 60°C for 1 h, then 3 h at 70°C. More TFA (1.06 mL) was added and the mixture was stirred at 80°C overnight. The volatiles were removed in vacuo and the residue was partitioned between aq. sat. sodium carbonate (4 mL) and DCM/MeOH (9: 1, 8 mL). The pH of the aq. layer was adjusted to 12 using 32% aq. NaOH and the aq. layer was extracted with DCM/MeOH (9: 1, 4 x 10 mL). The combined org. layers were dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by CC (DCM/MeOH 19: 1 containing 0.5% aq. NH4OH) to give the title compound as a beige foam (0.041 g, 49% yield).
1H NMR (d6-DMSO) δ: 10.7 (s, 1H); 6.84-6.94 (m, 3H); 4.54 (s, 2H); 4.01 (td, J = 4.3, 10.2 Hz, 1H); 3.33-3.49 (m, 2H); 3.35 (t, J = 11.0 Hz, 1H); 3.12 (dd, J = 4.7, 11.4 Hz, 1H); 2.87 (m, 1H); 2.31-2.44 (m, 2H); 1.89 (m, 1H); 1.68 (m, 1H); 1.12 (m, 1H). MS (ESI, m/z): 304.2 [M+H+] for C15Hi7N3O4. Preparation D: r c-( R*,5 R*)-3-(4-(4-methoxybenzyl)-3-oxo-3,4-dihydro- 2H-benzo[6] [l,4]thiazin-6-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
D. i. Rac-(4aR*,8aR*)-tert-butyl 3-(4-(4-methoxybenzyl)-3-oxo-3,4-dihydro- 2H-benzo[b] [1, 4]thiazin-6-yl)-2-oxohexahydro-2H-pyrido[4,3-e] [1 , 3]oxazine- 7(3H)-carboxylate:
In a 7 mL sealed vial were introduced 6-iodo-4-(4-methoxybenzyl)-2H-benzo[b][l,4]oxazin- 3(4H)-one (0.2 g, 0.57 mmol), rac-(4aR*,8aR*)-tert-butyl 2-oxohexahydro- 2H-pyrido[4,3-e][l,3]oxazine-7(3H)-carboxylate (Preparation A, 0.18 g, 0.69 mmol, 1.2 eq.), potassium carbonate (0.16 g, 1.15 mmol, 2 eq.), (R,R)-(-)-N,N -dimethyl - 1 ,2-cyclohexanediamine (0.008 mL, 0.1 eq.), Cul (0.09 g, 0.1 eq.) and dioxane (2 mL). The suspension was stirred at 100°C for 2 days. The mixture was cooled to rt, diluted with DCM/MeOH (2 mL) and filtered. The yellow salt obtained was washed with DCM/MeOH (9: 1, 2 x l0 mL). The combined filtrates were concentrated under reduced pressure. The residue was purified by CC (DCM/MeOH 9: 1) to afford the title compound as a greenish foam (0.231 g).
MS (ESI, m/z): 540.0 [M+H+] for C28H33N3O6S. D.ii. Rac-(4aR*,8aR*)-3-(3-oxo-3,4-dihydro-2H-benzo[b] [1 ,4] 1 oxazin-6-yl)octahydro- 2H-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
A solution of intermediate D.i (0.2 g, 0.38 mmol) in TFA (1.5 mL) was stirred at rt for 10 min. The volatiles were removed in vacuo and the residue was partitioned between aq. sat. sodium carbonate (4 mL) and DCM/MeOH (9: 1, 8 mL). The pH of the aq. layer was adjusted to 12 adding 32% NaOH, and then extracted with DCM/MeOH (9: 1, 4 x l0 mL). The combined org. layers were dried over MgSO4, filtered and concentrated to dryness. The residue was purified by CC (DCM/MeOH 9: 1 containing 10% of aq. NH4OH) to give the title compound as a yellow foam (0.134 g, 80%> yield).
1H NMR (d6-DMSO) δ: 7.38 (d, J = 8.3 Hz, 1H); 7.33 (d, J = 2.0 Hz, 1H); 7.16 (d, J = 8.6 Hz, 2H); 7.01 (dd, J = 2.0, 8.3 Hz, 1H); 6.84 (d, J = 8.6 Hz, 2H); 5.15 (br. s, 2H); 4.01 (td, J = 4.6, 10.2 Hz, 1H); 3.70 (s, 3H); 3.63 (s, 2H); 3.37 (m, 1H); 3.35 (d, J = 3.5 Hz, 1H); 3.13 (dd, J = 4.7, 11.5 Hz, 1H); 2.90 (m, 1H); 2.33-2.50 (m, 2H); 1.90 (m, 1H); 1.70 (m, 1H); 1.17 (m, 1H). MS (ESI, m/z): 440.0 [M+H+] for C23H25N3O4S. Preparation E: (R)-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine and
(S)-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine:
The two title enantiomers of 7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine were separated by chiral HPLC. Rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine obtained as described in WO 2004/058144 (0.33 g), was separated using the following chiral HPLC conditions: ChiralPak IC (Daicel, 30 x 250 mm, 5 μιτι) column, using a ratio of 1/1 of eluent A (EtOH, in the presence of 0.1 % diethylamine) and eluent B (MeCN), at rt, at a flow rate of 34 niL/min. The relevant fractions were pooled and concentrated to afford each enantiomer (0.15 g). The absolute stereochemistry of both enantiomers was assigned by comparison with the chiral HPLC analysis of an authentic sample of the (R)-enantiomer synthetized as described in WO 2007/016610.
(R)-enantiomer: tR = 8.5 min (ChiralPak IA (Daicel, 4.6 x 250 mm, 5 μιτι), same gradient as before at a flow rate of 0.8 mL/min). MS (ESI, m/z): 221.2 [M+H+] for C11H9N2O2F.
(S)-enantiomer: tR = 11.0 min (ChiralPak IA (Daicel, 4.6 x 250 mm, 5 μιτι), same gradient as before at a flow rate of 0.8 mL/min). MS (ESI, m/z): 221.2 [M+H+] for C11H9N2O2F. Preparation F: r c-7-fluoro-2-methoxy-8-(oxiran-2-yl)quinoline
F. i. 7-fluoro-2-methoxy-8-vinylquinoline:
A solution of 8-bromo-7-fluoro-2-methoxyquinoline and (PPh3)4Pd in DME (155 mL) was flushed with N2. K2C03 (2.66 g, 19.3 mmol), water (47 mL) and 2,4,6-trivinylcyclotriboroxane-pyridine (2.31 g) were added at rt and the mixture was heated at 85°C overnight. After cooling to rt, water (50 mL) was added and the mixture was extracted with TBME (2 x 100 mL). The combined org. layers were washed with water (30 mL) and brine (30 mL), dried over MgS04 and concentrated to dryness. The residue was purified by CC (Hept/EA 4:1) to afford the title alkene as an orange solid (3.97 g, quant. yield).
MS (ESI, m/z): 204.2 [M+H+] for C12Hi0NOF.
F.ii. Rac- l-(7-fluoro-2-methoxyquinolin-8-yl)ethane-l,2-diol:
To a solution of intermediate F.i (1.88 g, 9.25 mmol) in DCM (40 mL) and water (5 mL) were added NMO (137 mg, 10.2 mmol) and potassium osmate (VI) dihydrate (0.035 g, 0.1 mmol). The resulting mixture was vigorously stirred at rt for 2 h. The phases were separated, the aq. layer was extracted with a DCM/MeOH mixture (9: 1, 100 mL) and the combined org. layers were washed with 10% Na2S203, dried over MgS04 and concentrated to dryness. The residue was purified by CC (Hept/EA 1: 1 then EA) to afford the title diol as a yellowish oil (1.85 g, 85% yield).
MS (ESI, m/z): 238.0 [M+H+] for Ci2Hi2N03F.
F.iii. Rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)quinoline:
To an ice-chilled solution of intermediate F.ii (1.18 g, 4.97 mmol) and trimethyl orthoacetate (0.75 mL, 5.92 mmol) in DCM (45 mL) was added TMSC1 (0.763 mL, 5.97 mmol). The mixture was stirred 10 min. and was concentrated under reduced pressure. The residue was taken up in MeOH (30 mL) and K2C03 (1.72 g, 12.4 mmol) was added. The suspension was vigorously stirred at rt for 1 h. Water (50 mL) and DCM (300 mL) were added and the two phases were separated. The aq. layer was extracted once more with DCM (100 mL). The combined org. layers were dried over MgS04, filtered and concentrated to dryness to afford the title epoxide as a yellowish oil (0.98 g, 90% yield). 1H NMR (d6-DMSO) δ: 7.95 (d, J = 9.5 Hz, 1H); 7.66 (dd, J = 5.8, 8.9 Hz, 1H); 7.12 (dd, J = 8.9, 10.4 Hz, 1H); 6.89 (d, J = 8.8 Hz, 1H); 4.74 (dd, J = 2.9, 4.2 Hz, 1H); 4.08 (s, 3H); 3.59 (ddd, J = 0.7, 2.9, 5.5 Hz, 1H); 3.28 (ddd, J = 2.9, 5.5, 8.4 Hz, 1H). MS (ESI, m/z): 219.9 [M+H+] for Ci2Hi0NO2F. Preparation G: r c-7-fluoro-2-methoxy-8-(oxiran-2-yl)quinoxaline:
G. i. 7-fluoro-2-methoxy-8-vinylquinoxaline:
Methyl triphenyl phosphonium bromide (154 g, 430 mmol) was suspended in THF (1 L) and cooled to 0°C. KOtBu (44.4 g, 400 mmol) was added in one portion and the yellow suspension was stirred at 0°C for 15 min before a solution of 6-fluoro-3-methoxyquinoxaline- 5-carbaldehyde (71 g, 340 mmol) in THF (550 mL) was added dropwise over 70 min. The mixture was stirred at 0°C for 60 min. Sat. NH4C1 solution (250 mL) and water (250 mL) were added and the phases were separated. The org. layer was dried over MgSO4, filtered and concentrated to dryness. The residue was purified by two filtrations over a plug of silica gel (2 x 250 g) using an Hept/EA (2: 1) mixture as eluent to afford the title alkene as an orange solid (62.7 g, 89% yield).
1H NMR (CDCI3) δ: 8.43 (s, 1H), 7.88 (dd, J = 5.6, 9.1 Hz, 1H), 7.49 (dd, J = 12.1, 18.2 Hz, 1H), 6.38 (dd, J = 1.3, 18.2 Hz, 1H), 5.73 (dt, J = 1.8, 12.1 Hz, 1H), 4.12 (s, 3H).
G.ii. Rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)quinoxaline:
Starting from intermediate G.i (60.2 g, 295 mmol), the title epoxide was obtained as a colourless solid (39.8 g) using the procedures described in Preparation F, steps F.ii and F.iii (dihydroxylation: 84% yield, epoxide formation: 86% yield).
1H NMR (CDCI3) δ: 8.45 (s, 1H), 7.97 (dd, J = 5.5, 9.1 Hz, 1 H), 7.30 (dd, J = 9.4, 10.1 Hz, 1H) 4.66 (dd, J = 2.9, 4.2 Hz, 1H), 4.12 (s, 3H); 3.59 (ddd, J = 0.5, 2.9, 5.5 Hz, 1H), 3.28 (m, 1 H). Preparation H: r c-( R*,5 R*)-3-(4-(4-methoxybenzyl)-3-oxo-3,4-dihydro- 2H-pyrido[3,2-6] [l,4]oxazin-6-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 6-bromo-4-(4-methoxybenzyl)-2H-pyrido[3,2-b][l,4]oxazin-3(4H)-one (prepared as described in WO 2010/041194, 0.35 g, 1 mmol) and rac-(4aR *,8aR*)-tert-butyl 2-oxohexahydro-2H-pyrido[4,3-e][l,3]oxazine-7(3H)-carboxylate (Preparation A, 0.308 g, 1.2 mmol, 1.2 eq.), the title compound was obtained as an orange foam (0.255 g) using the procedures described in Preparation D, steps D.i and D.ii (Buchwald coupling: 95% yield, Boc deprotection: 63% yield).
MS (ESI, m/z): 425.0 [M+H+] for C22H24N405. Preparation I: r c-( S*,5 S*)-3-(4-(4-methoxybenzyl)-3-oxo-3,4-dihydro- 2H-pyrido[3,2-6][l,4]thiazin-6-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
Li. 6-chloro-4-(4-methoxybenzyl)-2H-pyrido[3,2-b][l,4]thiazin-3(4H)-one:
A suspension of 6-chloro-2H-pyrido[3,2-b][l,4]thiazin-3(4H)-one (prepared as described in WO 2010/041194, 0.8 g, 3.99 mmol), Cs2CO3 (1.56 g, 4.78 mmol) and PMB-C1 (0.61 mL, 4.39 mmol) in DMF (8 mL) was stirred at rt for 4 h. The solvent was evaporated to dryness and the residue was partitioned between EA (20 mL) and water (25 mL). The aq. layer was extracted once with EA (15 mL) and the combined org. layers were washed with brine (20 mL), dried over Na2SO4 and concentrated to dryness. The residue (1.39 g) was crystallized in a mixture of ether/Hept (2:3). After filtration, the title compound was obtained as an orange solid (1.2 g, 93% yield).
1H NMR (ί 6-DMSO) δ: 7.88 (d, J = 8.0 Hz, 1H), 7.13-7.20 (m, 3H); 6.79-6.85 (m, 2H); 5.16 (s, 2H), 3.71 (s, 2H); 3.67 (s, 3H). MS (ESI, m/z): 321.1 [M+H+] for Ci5Hi3N2O2ClS.
Lit Rac-(4aS^,8aS^)-3-(4-(4-methoxybenzyl)-3-oxo-3,4-di ydro- 2H-pyrido[3,2-bJfl,4Jthiazin-6-yl)octahydro-2H-pyrido[4,3-eJfl,3Joxazin-2-one: Starting from intermediate Li (171 mg, 0.53 mmol), the title compound, was obtained as a yellowish foam (0.132 g) using the procedures described in Preparation D, steps D.i and D.ii (Buchwald coupling: 73% yield, Boc deprotection: 79% yield).
1H NMR (ί 6-DMSO) δ: 7.79 (d, J = 8.5 Hz, 1H); 7.51 (d, J = 8.5 Hz, 1H); 7.09-7.14 (m, 2H); 6.78-6.83 (m, 2H); 5.19 (s, 2H); 3.94 (td, J = 4.8, 10.2 Hz, 1H); 3.75 (overlapped dd, J = 5.3, 11.9 Hz, 1H); 3.72 (s, 2H); 3.67 (s, 3H); 3.08-3.16 (m, 2H); 2.88 (m, 1H); 2.28-2.44 (m, 3H); 1.65-1.86 (m, 2H); 1.16 (m, 1H). MS (ESI, m/z): 441.2 [M+H+] for C22H24N4O4S. Preparation J: r c-( R*,5 R*)-3-(2,3-dihydro-[l,4]dioxino[2,3-6]pyridin- 7-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from commercial 7-bromo-2,3-dihydro-[l,4]dioxino[2,3-b]pyridine (81 mg, 0.37 mmol), the title compound was obtained as a beige foam (73 mg) using the procedures described in Preparation D, steps D.i and D.ii (Buchwald coupling: 67% yield, Boc deprotection: 100%> yield).
1H NMR (ί 6-DMSO) δ: 7.74 (d, J = 2.3 Hz, 1H), 7.35 (d, J = 2.3 Hz, 1H); 4.36-4.40 (m, 2H); 4.21-4.26 (m, 2H); 4.02 (td, J = 4.7, 10.3 Hz, 1H); 3.36-3.50 (m, 2H); 3.13 (dd, J = 4.8, 11.6 Hz, 1H), 2.89 (m, 1H); 2.75 (br. s, 1H); 2.36-2.47 (m, 2H); 1.94 (m, 1H); 1.70 (m, 1H); 1.16 (m, 1H). MS (ESI, m/z): 291.9 [M+H+] for Ci4Hi7N304.
Preparation K: r c-( S*,5 S*)-3-(6,7-dihydro-[l,4]dioxino[2,3-c]pyridazin- 3-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 3-bromo-6,7-dihydro-[l,4]dioxino[2,3-c]pyridazine (180 mg, 1.04 mmol), the title compound was obtained as a white solid (33 mg) using the procedures described in Preparation D, steps D.i and D.ii (Buchwald coupling: 18% yield, Boc deprotection: 62% yield).
1H NMR (ί 6-DMSO) δ: 7.44 (s, 1H); 4.47-4.52 (m, 2H); 4.35-4.41 (m, 2H); 3.98-4.09 (m, 2H); 3.45 (t, J = 11.7 Hz, 1H); 3.13 (dd, J = 4.8, 11.6 Hz, 1H), 2.89 (m, 1H); 2.42-2.47 (m, 2H); 1.90 (m, 1H); 1.76 (m, 1H); 1.20 (m, 1H). MS (ESI, m/z): 293.3 [M+H+] for C13H16N404.
Preparation L: r c-( R*,5 R*)-3-(2,3-dihydro-[l,4]dioxino[2,3-c]pyridin- 7-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
L. i. Rac-(3R * 4R *)-tert-butyl 4-(( (2, 3-dihydro-[l ,4Jdioxino[2, 3-cJpyridin- 7-yl)amino)methyl)-3-hydroxypiperidine-l-carboxylate: A mixture of rac-(3R*,4R*)-tert-buty\ 3-hydroxy-4-((tosyloxy)methyl)piperidine- 1-carboxylate (prepared as described in Tetrahedron (2008), 64, 2456-2464, 0.26 g, 0.67 mmol) and tert-butyl (2,3-dihydro-[l,4]dioxino[2,3-c]pyridin-7-yl)carbamate (prepared as described in WO 2009/104159, 0.17 g, 0.67 mmol, 1 eq.) was dissolved in DMF (2.5 mL). NaH (60%) dispersion in oil, 0.04 g, 0.88 mmol, 1.3 eq.) was added and the mixture was vigorously stirred at rt for 2 h. More NaH (0.03 g, 0.67 mmol, 1 eq.) was added. After two more hours, sat. aq. NaHCO3 (5 mL) was added and the mixture was extracted with EA (3 x 10 mL). The combined org. phases were dried over MgS04 and concentrated under reduced pressure. The residue was purified by CC (DCM/MeOH 19:1) to afford the title compound as a white solid (0.15 g, 62% yield).
MS (ESI, m/z): 366.4 [M+H+] for Ci8H27N305.
L. ii. Rac-(4aR * 8aR *)-tert-butyl 3-(2, 3-dihydro-fl ,4] dioxino[2, 3-cJpyridin- 7-yl)- 2-oxohexahydro-2H-pyrido[4, 3-e] [1, 3]oxazine- 7(3H)-carboxylate:
To a suspension of intermediate L.i (0.15 g, 0.4 mmol) in DCM (3 mL) was added TEA (0.12 mL, 0.87 mmol, 2.2 eq.). The mixture was cooled to -78°C and a solution of triphosgene (0.06 g, 0.21 mmol, 0.54 eq.) in DCM (0.8 mL) was added dropwise. The solution was stirred at this temperature for 1 h. Water (6 mL) and DCM (10 mL) were added. The aq. layer was extracted once with DCM (10 mL). The combined org. layers were washed with brine, dried over MgS04, filtered and concentrated down. The crude product was purified by CC (DCM/MeOH 19:1) to afford the title product as a white foam (0.12 g, 78% yield).
MS (ESI, m/z): 392.3 [M+H+] for C19H25N3O6.
L. in. Rac-(4aR * 8aR *)-3-(2, 3-dihydro-fl, 4] dioxino[2, 3-cJpyridin- 7-yl)octahydro- 2H-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
A solution of intermediate L.ii (0.12 g, 0.3 mmol) in 4N HC1 in dioxane (3.3 mL) was stirred at rt for 2 h. The mixture was concentrated to dryness. The residue was partitioned between sat. aq. NaHCO3 (6 mL) and DCM/MeOH (9:1, 30 mL). The aq. layer was extracted with the same mixture twice more (2 x 15 mL). The combined org. layers were washed with brine (8 mL), dried over MgSO4, filtered and concentrated to dryness. The residue was purified by CC (DCM/MeOH 19:1 + 0.5% aq. NH4OH) to afford the title compound as a beige solid (0.06 g, 73% yield).
1H NMR (ί 6-DMSO) δ: 7.92 (s, 1H); 7.19 (s, 1H); 4.31-4.35 (m, 2H); 4.24-4.29 (m, 2H); 3.87-4.01 (m, 2H); 3.31 (overlapped t, J = 11.5 Hz, 1H); 3.13 (dd, J = 4.6, 11.5 Hz, 1H), 2.87 (m, 1H); 2.34-2.47 (m, 2H); 1.71-1.91 (m, 2H); 1.18 (m, 1H). MS (ESI, m/z): 292.3 [M+H+] for C14Hi7N3O4. Preparation M: rac-(4aR *,8aR *)-3-(6,7-dihydro-[l,4] oxathiino [2,3-c] pyridazin- 3-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 3-chloro-6,7-dihydro-[l,4]oxathiino[2,3-c]pyridazine (prepared as described in WO 2007/071936, 200 mg, 1.06 mmol), the title compound was obtained as a beige solid (76 mg) using the procedures described in Preparation D, step D.i (Buchwald coupling: 70% yield), and Preparation L, step L.ii (Boc deprotection: 32% yield). The residue was purified by CC (DCM/MeOH 19: 1 + 0.5% aq. NH4OH).
1H NMR (ί 6-DMSO) δ: 7.80 (s, 1H); 4.55-4.60 (m, 2H); 3.97-4.08 (m, 2H); 3.44 (t, J = 11.6 Hz, 1H); 3.26-3.31 (m, 2H); 3.14 (dd, J = 4.6, 11.4 Hz, 1H), 2.89 (m, 1H); 2.36-2.50 (m, 2H); 2.34 (br. s, 1H); 1.90 (m, 1H); 1.76 (m, 1H); 1.20 (m, 1H). MS (ESI, m/z): 309.0 [M+H+] for Ci3Hi6N4O3S.
Examples 1 and 2: ( R,5 R)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro- 6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one and ( S,5 S)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy- [l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one:
1/2. i. Rac-(4aR * 8aR *)-3-(2, 3-dihydro-benzofl, 4 ] dioxin-6-yl)- 7-[2-(3-fluoro-6-methoxy- [1, 5] naphthyridin-4-yl)-ethyl] -octahydro-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
Typical procedure for the addition of the oxazinone moiety onto an alkene
To a solution of 7-fluoro-2-methoxy-8-vinyl-l ,5-naphthyridine (0.062 g, 0.3 mmol) and intermediate B.ii (0.09 g, 0.3 mmol) in DMF (0.26 mL) was added one drop of TMG. The mixture was stirred at 90°C for 24 h. The mixture was cooled to rt and concentrated to dryness. The residue was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH to 19: 1 + 0.5%) aq. NH4OH) to afford the desired compound as a yellowish foam (0.06 g, 40% yield).
1H NMR (d6-DMSO) δ: 8.76 (d, J = 0.4 Hz, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.23 (d, J = 9.1 Hz, 1H); 6.83 (d, J = 2.3 Hz, 1H); 6.81 (d, J = 8.4 Hz, 1H); 6.74 (dd, J = 2.3, 8.4 Hz, 1H); 4.20 (s, 4H); 4.04 (s, 3H); 4.02 (overlapped m, 1H); 3.25-3.45 (m, 5H); 2.96 (m, 1H); 2.76-2.84 (m, 2H); 2.05-2.20 (m, 2H); 1.68-1.88 (m, 2H); 1.20 (m, 1H). MS (ESI, m/z): 495.4 [M+H+] for C26H27N4O5F. 1/2. ii. (4aR,8aR)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy- [1, 5] naphthyridin-4-yl)-ethyl] -octahydro-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one and
(4aS, 8aS)-3-(2, 3-dihydro-benzofl, 4] dioxin-6-yl)- 7-[2-(3-fluoro-6-methoxy- [1, 5] naphthyridin-4-yl)-ethyl] -octahydro-pyrido[4, 3-e] [l,3]oxazin-2-one: Compounds 1/2. i (0.06 g), were separated using the following chiral HPLC conditions: ChiralPak IA (Daicel, 30 x 250 mm, 5 μιη) column, using a ratio of 4/1 of eluent A (EtOH, in the presence of 0.1% diethylamine) and eluent B (MeCN), at rt, at a flow rate of 0.8 mL/min. The relevant fractions were pooled and concentrated to afford each enantiomer (0.02 g).
Enantiomer 1: 1R = 10.56 min (ChiralPak IA (Daicel, 4.6 x 250 mm, 5 μηι), same gradient as before). 1H NMR (d6-DMSO) δ: 8.76 (d, J = 0.4 Hz, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.23 (d, J = 9.1 Hz, 1H); 6.83 (d, J = 2.3 Hz, 1H); 6.81 (d, J = 8.4 Hz, 1H); 6.74 (dd, J = 2.3, 8.4 Hz, 1H); 4.20 (s, 4H); 4.04 (s, 3H); 4.02 (overlapped m, 1H); 3.25-3.45 (m, 5H); 2.96 (m, 1H); 2.76-2.84 (m, 2H); 2.05-2.20 (m, 2H); 1.68-1.88 (m, 2H); 1.20 (m, 1H). MS (ESI, m/z): 495.2 [M+H+] for C26H27N4O5F.
Enantiomer 2: tR = 12.55 min (ChiralPak IA (Daicel, 4.6 x 250 mm, 5 μηι), same gradient as before). MS (ESI, m/z): 495.2 [M+H+] for C26H27N4O5F.
Example 3: (4aR*, « R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(2RS)-2-hydroxy- 2-(6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one (mixture of stereoisomers): Typical procedure for an epoxide opening with an oxazinone moiety
To a solution of intermediate B.ii (0.03 g, 0.11 mmol) and rac-2-methoxy-8-(oxiran-2-yl)- 1,5-naphthyridine (0.02 g, 0.11 mmol, 1.05 eq.) in DMF (0.38 mL) were added K2C03 (0.02 g, 0.15 mmol, 1.4 eq.) and lithium perchlorate (0.01 g, 0.11 mmol, 1.05 eq.). The reaction mixture was stirred at 80°C for 18 h. The mixture was cooled to rt and filtered over Celite. The solid was washed by EA (2 x 15 mL). The filtrate was concentrated. The residue was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH) to afford the title compound as an off-white foam (0.037 g, 71% yield).
1H NMR (d6-DMSO) δ: 8.77 (d, J = 4.5 Hz, 1H); 8.25 (d, J = 9.1 Hz, 1H); 7.76 (d, J = 4.5 Hz, 1H); 7.25 (d, J = 9.1 Hz, 1H); 6.80-6.85 (m, 2H); 6.76 (m, 1H); 5.81 (m, 1H); 5.33 (dd, J = 2.4, 4.5 Hz, 1H); 4.21 (s, 4H); 4.07 (m, 1H); 4.01 (s, 3H); 3.34-3.48 (m, 2H); 3.24 (m, 1H); 3.12 (m, 1H); 2.81-2.95 (m, 1H); 2.61 (m, 1H); 2.15-2.32 (m, 2H); 1.68-1.89 (m, 2H); 1.25 (m, 1H). MS (ESI, m/z): 493.2 [M+H+] for C26H28N406.
Example 4 : rac-(4aR *,8aR *)-3-(2,3-dih dro-benzo [1,4] dioxin-6-yl)-7- [2-(6-methoxy- [l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one: Starting from 2-methoxy-8-vinyl-l,5-naphthyridine (0.0215 g, 0.115 mmol) and intermediate B.ii. (0.0335 g, 0.115 mmol), the title compound was obtained as an off-white foam (0.017 g, 31% yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 19: 1 + 0.5% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.66 (d, J = 4.4 Hz, 1H); 8.23 (d, J = 9.0 Hz, 1H); 7.59 (d, J = 4.4 Hz, 1H); 7.24 (d, J = 9.1 Hz, 1H); 6.73-6.83 (m, 3H); 4.21 (s, 4H); 4.07 (m, 1H); 4.01 (s, 3H); 3.25-3.49 (m, 5H); 2.97 (m, 1H); 2.79-2.88 (m, 2H); 2.04-2.21 (m, 2H); 1.70-1.89 (m, 2H); 1.23 (m, 1H). MS (ESI, m/z): 477.2 [M+H+] for C26H28N405.
Example 5: r c-( R*,5 R*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]- 3-(3-oxo-3,4-dihydro-2H-benzo [1,4] oxazin-6-yl)-octahydro-pyrido [4,3-e] [1,3] oxazin- 2-one:
Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (25 mg, 0.122 mmol) and intermediate C.ii (37 mg, 0.122 mmol), the title compound was obtained as an off-white foam (54 mg, 9%) yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 10.76 (s, 1H); 8.80 (s, 1H); 8.30 (d, J = 9.1 Hz, 1H); 7.26 (d, J = 9.1 Hz, 1H); 6.85-6.96 (m, 3H); 4.57 (s, 2H); 4.10 (m, 1H); 4.07 (s, 3H); 3.29-3.50 (m, 5H); 2.99 (m, 1H); 2.80-2.87 (m, 2H); 2.19 (m, 1H); 2.12 (t, J = 10.2 Hz, 1H); 1.86 (m, 1H); 1.76 (m, 1H); 1.25 (m, 1H). MS (ESI, m/z): 508.1 [M+H+] for C26H26N505F.
Example 6: ( R*,« R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(2RS)-2-(3-fluoro- 6-methoxy- [1,5] naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido [4,3-e] [1,3] oxazin- 2-one (mixture of stereoisomers):
Starting from rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine (0.025 g, 0.112 mmol) and intermediate B.ii. (0.031 g, 0.107 mmol), the title compound was obtained as a gum (containing still some residual DMF; 0.041 g, 76% yield) using the procedure described in Example 3. The crude material was purified by CC (DCM/MeOH 13: 1 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.80 (app. d, J = 1.3 Hz, 1H); 8.31 (app. dd, J = 1.3, 9.1 Hz, 1H); 7.28 (app. d, J = 3.1, 9.1 Hz, 1H); 6.73-6.84 (m, 3H); 6.03 (m, 1H); 5.56 (t, J = 5.5 Hz, 1H); 4.22 (s, 4H); 4.07 (s, 1.5H); 4.05 (s, 1.5H); 3.95 (td, J = 4.2, 9.5 Hz, 0.5H); 3.88 (td, J = 4.2, 9.5 Hz, 0.5H); 3.29-3.46 (m, 3.5H); 3.16 (dd, J = 4.4, 10.4 Hz, 0.5H); 3.00-3.10 (m, 2H); 2.96 (dd, J = 6.2, 12.7 Hz, 0.5H); 2.86 (m, 0.5H); 2.07-2.27 (m, 2H); 1.64-1.85 (m, 2H); 1.10 (m, 1H). MS (ESI, m/z): 511.1 [M+H+] for C26H27N406F.
Example 7: r c-( R*,5 R*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]- 3-(3-oxo-3,4-dihy dro-2H-benzo [ 1,4] thiazin-6-yl)-octahy dro-py rido [4,3-e] [ 1,3 ] oxazin-
2- one:
7.i. Rac-(4aR^,8aR^)-7-(2-(3-fluoro-6-methoxy-l ,5-naphthyridin-4-yl)ethyl)-
3- (4-(4-methoxybenzyl)-3-oxo-3,4-dihydro-2H-benzo[b] [1 ,4]thiazin-6-yl)octahydro- 2H-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one: Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.033 g, 0.161 mmol) and intermediate D.ii (0.070 g, 0.161 mmol), the title compound was obtained as a beige foam (0.053 g, 52% yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 19: 1 + 0.5% aq. NH4OH).
MS (ESI, m/z): 644.1 [M+H+] for C34H34N5O5FS. 7.ii. Rac-(4aR*,8aR*)-7-[2-(3-fluoro-6-methoxy-fl,5Jnaphthyridin-4-yl)-ethylJ-3-(3-oxo- 3, 4-dihydro-2H-benzo[l,4]t iazin-6-yl)-octahydro-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
To a solution of intermediate 7.i (0.05 g, 0.1 mmol) in TFA (99%, 0.38 mL, 4.97 mmol, 50 eq.) was added concentrated HC1 (0.003 mL).The reaction mixture was stirred at 80°C for 2 h. The volatiles were removed in vacuo and the residue was partitioned between aq. sat. sodium carbonate (4 mL) and DCM/MeOH (9: 1, 8 mL). The aq. layer (pH = 12, adjusted using 8NNaOH) was extracted with DCM/MeOH (9: 1, 2 x 10 mL). The combined org. layers were dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by CC (DCM/MeOH 49: 1+ 0.2% aq. NH4OH to DCM/MeOH 97:3 + 0.3% aq.NH4OH) to give the title compound as an off-white foam (0.038 g, 74% yield). 1H NMR (d6-DMSO) δ: 10.57 (s, 1H); 8.76 (s, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.30 (d, J = 9.1 Hz, 1H); 7.24 (d, J = 8.7 Hz, 1H); 6.91-6.98 (m, 2H); 4.09 (overlapped m, 1H); 4.05 (s, 3H); 3.44 (s, 2H); 3.28-3.54 (m, 5H); 2.97 (m, 1H); 2.77-2.85 (m, 2H); 2.06-2.23 (m, 2H); 1.70-1.89 (m, 2H); 1.23 (m, 1H). MS (ESI, m/z): 524.1 [M+H+] for C26H26N504FS. Example 8: r c-(^aR*,*aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(7-methoxy- 2-oxo-2H-quinolin- l-yl)-ethyl] -octahy dro-py rido [4,3-e] [ 1,3] oxazin-2-one :
To a solution of intermediate B.ii (0.048 g, 0.167 mmol) in DCE (1 mL) and THF (0.1 mL) was added 2-(7-methoxy-2-oxoquinolin-l(2H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.038 g, 0.175 mmol, 1.05 eq.). The reaction mixture was stirred at rt for 2 h. NaBH(OAc)3 (0.053 g, 0.25 mmol, 1.5 eq.) was added and the mixture was stirred at rt overnight. Further NaBH(OAc)3 (0.035 g, 0.167 mmol, 1 eq.) was added and the mixture was stirred 2 more hours. Sat. aq. NaHCO3 (10 mL) and DCM/MeOH (9: 1, 25 mL) were added. The aq. layer was extracted with DCM/MeOH (9: 1, 2 x 25 mL). The combined org. layers were washed with brine, dried over MgSO4, filtered and concentrated to dryness. The crude product was purified via a preparative HPLC (Method A) to afford the title product as a white foam (0.042 g, 51% yield).
1H NMR (d6-DMSO) δ: 7.80 (d, J = 8.4 Hz, 1H); 7.63 (d, J = 8.6 Hz, 1H); 6.96 (d, J = 2.1 Hz, 1H); 6.74-6.90 (m, 4H); 6.40 (d, J = 9.4 Hz, 1H); 4.29-4.49 (m, 2H), 4.22 (s, 4H); 4.07 (m, 1H); 3.89 (s, 3H); 3.31-3.49 (m, 3H), 2.99 (m, 1H), 2.62-2.71 (m, 2H); 2.04-2.20 (m, 2H), 1.70-1.89 (m, 2H); 1.25 (m, 1H). MS (ESI, m/z): 492.0 [M+H+] for C27H29N3O6.
Example 9 : rac-(4aR *,8aR *)-3-(2,3-dihy dro-benzo [1,4] dioxin-6-yl)-7- [2-(7-methoxy- 2-oxo-2H-quinoxalin-l-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 2-(7-methoxy-2-oxoquinoxalin-l(2H)-yl)acetaldehyde (0.04 g, 0.161 mmol) and intermediate B.ii (0.050 g, 0.172 mmol), the title compound was obtained as a yellowish foam (0.039 g, 46% yield) using the procedure described in Example 8. The crude material was purified by a preparative HPLC (Method A).
1H NMR (d6-DMSO) δ : 8.03 (s, 1H); 7.74 (d, J = 8.4 Hz, 1H); 6.95-7.04 (m, 2H); 6.73-6.85 (m, 3H); 4.28-4.48 (m, 2H), 4.21 (s, 4H); 4.01 (m, 1H); 3.91 (s, 3H); 3.30-3.48 (m, 3H); 2.93 (m, 1H); 2.66-2.75 (m, 2H); 2.01-2.19 (m, 2H), 1.68-1.89 (m, 2H); 1.19 (m, 1H). MS (ESI, m/z): 493.0 [M+H+] for C26H28N4O6. Example 10: rac-(4aR*, 5 R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(7-methoxy-
2- OXO-2H- [1,8] naphthy ridin- l-yl)-ethyl] -octahy dro-py rido [4,3-e] [ 1,3 ] oxazin-2-one :
Starting from 2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.04 g, 0.161 mmol) and intermediate B.ii (0.050 g, 0.172 mmol), the title compound was obtained as a yellowish foam (0.057 g, 67% yield) using the procedure described in Example 8. The crude material was purified by a preparative HPLC (Method A).
1H NMR (d6-DMSO) δ : 8.0 (d, J = 8.5 Hz, 1H); 7.85 (d, J = 9.5 Hz, 1H); 6.70-6.84 (m, 4H); 6.49 (d, J = 9.5 Hz, 1H); 4.43-4.60 (m, 2H), 4.21 (s, 4H); 4.03 (m, 1H); 3.98 (s, 3H); 3.30-3.49 (m, 3H); 2.98 (m, 1H); 2.69-2.80 (m, 2H); 2.05-2.20 (m, 2H), 1.68-1.89 (m, 2H); 1.19 (m, 1H). MS (ESI, m/z): 493.2 [M+H+] for C26H28N4O6.
Example 11: r c-( R*,5 R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(6-methoxy-
3- oxo-3H-pyrido [2,3-6] pyrazin-4-yl)-ethyl] -octahy dro-pyrido [4,3-e] [1,3] oxazin-2-one:
Starting from 2-(6-methoxy-3-oxopyrido[2,3-b]pyrazin-4(3H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.04 g, 0.161 mmol) and intermediate B.ii (0.050 g, 0.172 mmol), the title compound was obtained as a yellowish foam (0.053 g, 63% yield) using the procedure described in Example 8. The crude material was purified by a preparative HPLC (Method A).
1H NMR (d6-DMSO) δ: 8.11-8.14 (m, 2H); 6.72-6.85 (m, 4H); 4.37-4.52 (m, 2H), 4.20 (s, 4H); 4.00 (m, 1H); 4.00 (s, 3H); 3.25-3.46 (m, 3H); 2.96 (m, 1H); 2.69-2.85 (m, 2H); 2.03-2.19 (m, 2H), 1.68-1.88 (m, 2H); 1.17 (m, 1H). MS (ESI, m/z): 494.2 [M+H+] for C25H27N5O6.
Example 12: r c-( R*,5 R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-methoxy- 6-oxo-6H-pyrido [2,3-6] pyrazin-5-yl)-ethyl] -octahy dro-pyrido [4,3-e] [1,3] oxazin-2-one: Starting from 2-(3-methoxy-6-oxopyrido[2,3-b]pyrazin-5(6H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.04 g, 0.161 mmol) and intermediate B.ii (0.050 g, 0.172 mmol), the title compound was obtained as a yellowish foam (0.046 g, 54% yield) using the procedure described in Example 8. The crude material was purified by a preparative HPLC (Method A). 1H NMR (d6-DMSO) δ: 8.23 (s, 1H), 7.93 (d, J = 9.7 Hz, 1H); 6.68-6.83 (m, 4H); 4.37-4.53 (m, 2H), 4.20 (s, 4H); 4.05 (s, 3H); 3.99 (m, 1H); 3.26-3.48 (m, 3H); 2.96 (m, 1H); 2.69-2.81 (m, 2H); 2.03-2.19 (m, 2H), 1.67-1.90 (m, 2H); 1.18 (m, 1H). MS (ESI, m/z): 494.2 [M+H+] for C25H27N506. Example 13: (4aR*, « R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(R)-2-(3-fluoro-
6- methoxy- [1,5] naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido [4,3-e] [1,3] oxazin- 2-one:
Starting from fRy)-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine (Preparation E, (R)-enantiomer, 0.048 g, 0.21 mmol) and intermediate B.ii (0.060g , 0.207 mmol), the title compound was obtained as an off-white foam (0.059 g, 56% yield) using the procedure described in Example 3. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.80 (app. d, J = 1.3 Hz, 1H); 8.31 (app. dd, J = 1.3, 9.1 Hz, 1H); 7.28 (app. d, J = 3.1, 9.1 Hz, 1H); 6.73-6.84 (m, 3H); 6.03 (m, 1H); 5.56 (dd, J = 4.1, 5.7 Hz, 1H); 4.22 (s, 4H); 4.07 (s, 1.5H); 4.05 (s, 1.5H); 3.95 (td, J = 4.2, 9.5 Hz, 0.5H); 3.88 (td, J = 4.2, 9.5 Hz, 0.5H); 3.29-3.46 (m, 3.5H); 3.16 (dd, J = 4.4, 10.4 Hz, 0.5H); 3.00-3.10 (m, 2H); 2.96 (dd, J = 6.2, 12.7 Hz, 0.5H); 2.86 (m, 0.5H); 2.07-2.27 (m, 2H); 1.64-1.85 (m, 2H); 1.10 (m, 1H). MS (ESI, m/z): 511.1 [M+H+] for C26H27N406F.
Examples 14 and 15: (4 S,# S -3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)- 7-[(S)-2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one and ( R,5 R)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-
7- [(S)-2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
14/15. i. (4aR * 8aR *)-3-(2, 3-dihydro-benzo[l ,4] dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy- [1, 5] naphthyridin-4-yl)-2-hydroxy-ethyl] -octahydro-pyrido[4, 3-e] [1, 3] οχαζίη-2-one:
Starting from fS)-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine (Preparation E, (S)-enantiomer, 0.048 g, 0.21 mmol) and intermediate B.ii (0.060 g, 0.207 mmol), the title compound (0.064 g, 61 % yield) was prepared as off-white foam using the procedure described in Example 3. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH). 1H NMR (d6-DMSO) δ: 8.80 (app. d, J = 1.3Hz, 1H); 8.31 (app. dd, J = 1.3, 9.1 Hz, 1H); 7.28 (app. d, J = 3.1, 9.1 Hz, 1H); 6.73-6.84 (m, 3H); 6.03 (m, 1H); 5.56 (dd, J = 4.1, 5.7 Hz, 1H); 4.22 (s, 4H); 4.07 (s, 1.5H); 4.05 (s, 1.5H); 3.95 (td, J = 4.2, 9.5 Hz, 0.5H); 3.88 (td, J = 4.2, 9.5 Hz, 0.5H ); 3.29-3.46 (m, 3.5H); 3.16 (dd, J = 4.4, 10.4 Hz, 0.5H); 3.00-3.10 (m, 2H); 2.96 (dd, J = 6.2, 12.7 Hz, 0.5H); 2.86 (m, 0.5H); 2.07-2.27 (m, 2H); 1.64-1.85 (m, 2H); 1.10 (m, 1H). MS (ESI, m/z): 511.1 [M+H+] for C26H27N406F.
14/ 15. ii. (4aS,8aS)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy- [1, 5] naphthyridin-4-yl)-2-hydroxy-ethyl] -octahydro-pyrido[4, 3-e] [1, 3] οχαζίη-2-one and (4aR,8aR)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy- [1, 5] naphthyridin-4-yl)-2-hydroxy-ethyl] -octahydro-pyrido[4, 3-e] [1, 3] οχαζίη-2-one:
Intermediates 14/15. i (0.052 g) were separated using the following chiral HPLC conditions: ChiralPak IA (Daicel, 30 x 250 mm, 5 μηι) column, using a ratio of 1/9 of eluent A (EtOH, in the presence of 0.1% diethylamine) and eluent B (MeCN), at rt, at a flow rate of 34 niL/min. The relevant fractions were pooled and concentrated to afford each enantiomer (0.022 g). Enantiomer 1: tR = 8.90 min (ChiralPak IA (Daicel, 4.6 x 250 mm, 5 μηι), same gradient as before at a flow rate of 0.8 mL/min).
1H NMR (d6-DMSO) δ: 8.80 (app. d, J = 1.3 Hz, 1H); 8.31 (app. dd, J = 1.3, 9.1 Hz, 1H); 7.28 (app. d, J = 9.1 Hz, 1H); 6.73-6.84 (m, 3H); 6.03 (m, 1H); 5.56 (d, J = 5.7 Hz, 1H); 4.22 (s, 4H); 4.05 (s, 3H); 3.95 (td, J = 4.2, 9.5 Hz, 1H); 3.42 (m, 1H); 3.30 (m, 1H); 3.16 (dd, J = 4.4, 10.4 Hz, 1H); 3.00-3.10 (m, 2H); 2.96 (dd, J = 6.2, 12.7 Hz, 1H); 2.17 (t, J = 10.3 Hz, 2H); 1.64-1.83 (m, 2H); 1.10 (m, 1H). MS (ESI, m/z): 511.1 [M+H+] for C26H27N406F.
Enantiomer 2: tR = 13.10 min (ChiralPak IA (Daicel, 4.6 x 250 mm, 5 μηι), same gradient as before at a flow rate of 0.8 mL/min).
1H NMR (d6-DMSO) δ: 8.80 (app. d, J = 1.3 Hz, 1H); 8.31 (app. dd, J = 1.3, 9.1 Hz, 1H); 7.28 (app. d, J = 9.1 Hz, 1H); 6.73-6.84 (m, 3H); 6.03 (m, 1H); 5.56 (d, J = 5.7 Hz, 1H); 4.22 (s, 4H); 4.07 (s, 3H); 3.87 (td, J = 4.2, 9.5Hz, 1H); 3.27-3.44 (m, 3H); 3.00 (d, J = 6.9 Hz, 2H); 2.84 (m, 1H); 2.21 (m, 1H); 2.07 (t, J = 10.7 Hz, 1H); 1.64-1.83 (m, 2H); 1.10 (m, 1H). MS (ESI, m/z): 511.1 [M+H+] for C26H27N406F. Example 16 : (4aR *,8aR *)-3-(2,3-dihydro-benzo [1,4] dioxin-6-yl)-7-[(2RS)-2-(7-fluoro- 2-methoxy-quinolin-8-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one (mixture of stereoisomers):
Starting from rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)quinoline (Preparation F, 0.040 g, 0.18 mmol) and intermediate B.ii (0.050 g, 0.17 mmol), the title compound was obtained as a beige foam (0.065 g, 74% yield) using the procedure described in Example 3. The crude material was purified by CC (DCM/MeOH 13: 1 + 0.3% aq. NH4OH).
MS (ESI, m/z): 510.4 [M+H+] for C27H28N3O6F.
Example 17 : (4aR *,8aR *)-3-(2,3-dihydro-benzo [1,4] dioxin-6-yl)-7-[(2RS)-2-(6-fluoro- 3-methoxy-quinoxalin-5-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one (mixture of stereoisomers):
Starting from rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)quinoxaline (0.014 g, 0.06 mmol) and intermediate B.ii (0.018 g, 0.06 mmol), the title compound was obtained as a yellowish foam (0.013 g, 43%) yield) using the procedure described in Example 3. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.58 (s, 1H), 7.96 (dd, J = 5.5, 9.1 Hz, 1H), 7.49 (m, 1H); 6.69-6.82 (m, 3H); 5.94 (m, 1H); 5.25 (t, J = 5.5 Hz, 1H); 4.19 (s, 4H); 4.06 (s, 1.5H); 4.05 (s, 1.5H); 3.90 (m, 1H ); 3.32-3.43 (m, 2H); 2.78-3.16 (m, 4H); 2.07-2.27 (m, 2H); 1.64-1.85 (m, 2H); 1.10 (m, 1H). MS (ESI, m/z): 511.4 [M+H+] for C26H27N4O6F. Example 18: (4aR*, « R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(2RS)-2-hydroxy- 2-(3-methoxy-quinoxalin-5-yl)-ethyl]-octahydro-pyrido[4,3-e] [l,3]oxazin-2-one (mixture of stereoisomers):
Starting from 2-methoxy-8-(oxiran-2-yl)quinoxaline (prepared as described in WO 2010/041194, 0.028 g, 0.14 mmol) and intermediate B.ii (0.040 g, 0.14 mmol), the title compound was obtained as a yellowish foam (0.042 g, 62% yield) using the procedure described in Example 3. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.60 (s, 1H); 7.88 (app. d, J = 8.3 Hz, 2H); 7.63 (dd, J = 7.3, 8.3 Hz, 1H); 6.73-6.84 (m, 3H); 5.80 (m, 1H); 5.16 (dd, J = 2.1, 4.5 Hz, 1H); 4.21 (s, 4H); 4.07 (m, 1H); 4.05 (s, 3H); 3.32-3.49 (m, 2.5H); 3.25 (m, 0.5H); 3.11 (m, 0.5H); 2.95 (m, 0.5H); 2.74-2.81 (m, 1H); 2.54-2.64 (m, 1H); 2.12-2.30 (m, 2H); 1.66-1.87 (m, 2H); 1.26 (m, 1H). MS (ESI, m/z): 493.4 [M+H+] for C26H28N4O6.
Example 19: r c-(^aR*,*aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]- 3-(3-oxo-3,4-dihydro-2H-pyrido [3,2-6] [1,4] oxazin-6-yl)-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
19. i. (4aS, 8aS)- 7-(2-(3-fluoro-6-methoxy-l , 5-naphthyridin-4-yl)ethyl)- 3-(4-(4-methoxybenzyl)-3-oxo-3 ,4-dihydro-2H-pyrido[3 ,2-b] [1 ,4] oxazin-6-yl)octahydro- 2H-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one: Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.040 g, 0.19 mmol) and intermediate H.ii (0.070 g, 0.161 mmol), the title compound was obtained as an off-white foam (0.079 g, 64% yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 49: 1 + 0.2% aq. NH4OH).
MS (ESI, m/z): 493.4 [M+H+] for C33H33N6O6F. 19. ii. Rac-(4aR * 8aR *)- 7-[2-(3-fluoro-6-methoxy-[l , 5] naphthyridin-4-yl)-ethyl] -3-(3-oxo- 3, 4-dihydro-2H-pyrido[3 ,2-b] [1, 4] oxazin-6-yl)-octahydro-pyrido[4, 3-e] [ 1 ,3] οχαζίη-2-one:
To a solution of intermediate 17. i (0.08 g, 0.13 mmol) in DCM (4 mL) was added TFA (0.49 mL, 6.28 mmol, 50 eq.) and trifluoromethanesulfonic acid (0.1 1 mL, 1.26 mmol, 10 eq.). The reaction mixture was stirred at rt for 1 h. Aq. sat. Na2CO3 (6 mL) and DCM/MeOH (9: 1, 8 mL) were added carefully. The two layers were separated. The pH of the aq. layer was adjusted to 12 adding 32% NaOH. The aq. layer was extracted with DCM/MeOH (9: 1, 2 x 10 mL). The combined org. layers were dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by CC (DCM/MeOH 97:3 + 0.3%) NH4OH) to give the title compound as a white solid (0.06 g).
1H NMR (d6-DMSO) δ: 11.1 (br. s, 1H); 8.76 (s, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.37 (d, J = 9.1 Hz, 1H); 7.24 (d, J = 7.3 Hz, 1H); 7.22 (d, J = 7.3 Hz, 1H); 4.61 (s, 2H); 4.05 (overlapped m, 1H); 4.05 (s, 3H); 3.89 (m, 1H); 3.27-3.38 (m, 5H); 2.78-2.85 (m, 2H); 2.02-2.24 (m, 2H); 1.74-1.84 (m, 2H); 1.26 (m, 1H). MS (ESI, m/z): 493.4 [M+H+] for C25H25N6O5F Examples 20 and 21: ( R,5 R)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)- ethyl]-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-6] [l,4]thiazin-6-yl)-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one and ( S,5 S)-7-[2-(3-fluoro-6-methoxy- [l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-6] [l,4]thiazin-6-yl)- octahydro-pyrido[4,3-e] [l,3]oxazin-2-one:
20/21. i. Rac-(4aR^,8aR^)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo- 3, 4-dihydro-2H-pyrido[3 ,2-b] [1, 4]thiazin-6-yl)-octahydro-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one:
Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.028 g, 0.13 mmol) and intermediate H.ii (0.060 g, 0.13 mmol), the title compound was obtained as an off-white foam (0.050 g) using the procedure described in Examples 1 and 2, step 1/2. i (alkene addition: 84% yield) and Example 19, step 19.ii (PMB deprotection: 88% yield). The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 10.84 (s, 1 H); 8.77 (s, 1 H); 8.27 (d, J = 9.1 Hz, 1 H); 7.75 (d, J = 8.4 Hz, 1H); 7.40 (d, J = 8.4 Hz, 1H); 7.23 (d, J = 9.0 Hz, 1H); 4.01-4.11 (overlapped m, 2H); 4.05 (s, 3H); 3.52 (s, 2H); 3.28-3.38 (m, 4H); 2.99 (m, 1H); 2.70-2.86 (m, 2H); 2.07-2.26 (m, 2H); 1.72-1.86 (m, 2H); 1.26 (m, 1H). MS (ESI, m/z): 525.2 [M+H+] for C25H25N604FS.
20/21. ii. (4aR,8aR)-7-[2-(3-fluoro-6-methoxy-[ 1 ,5] naphthyridin-4-yl)-ethyl] -3-(3-oxo- 3, 4-dihydro-2H-pyrido[3 ,2-b] [1, 4]thiazin-6-yl)-octahydro-pyrido[4, 3-e] [1 ,3] οχαζίη-2-one and (4aS, 8aS)- 7-[2-(3-fluoro-6-methoxy-[l , 5] naphthyridin-4-yl)-ethyl] -3-(3-oxo-3 ,4-dihydro- 2H-pyrido[3 ,2-b] [ 1 ,4j 1thiazin-6-yl)-octahydro-pyrido[4,3-e] [1 ,3] Όχαζίη-2-one:
Intermediates 20/21. i (0.042 g) were separated using the following chiral HPLC conditions: ChiralPak IB (Daicel, 30 x 250 mm, 5 μιη) column, using a ratio of 1/9 of eluent A (EtOH, in the presence of 0.1% diethylamine ) and eluent B (MeCN), at rt, at a flow rate of 34 niL/min. The relevant fractions were pooled and concentrated to afford each enantiomer (0.006 g).
Enantiomer 1: tR = 7.45 min (ChiralPak IB (Daicel, 4.6 x 250 mm, 5 μιη) same gradient as before at a flow rate of 0.8 mL/min).
1H NMR (d6-DMSO) δ: 10.84 (s, 1H); 8.77 (s, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.75 (d, J = 8.4 Hz, 1H); 7.40 (d, J = 8.4 Hz, 1H); 7.23 (d, J = 9.0 Hz, 1H); 4.01-4.11 (overlapped m, 2H); 4.05 (s, 3H); 3.52 (s, 2H); 3.28-3.38 (m, 4H); 2.99 (m, 1H); 2.70-2.86 (m, 2H); 2.07-2.26 (m, 2H); 1.72-1.86 (m, 2H); 1.26 (m, 1H). MS (ESI, m/z): 525.3 [M+H+] for C25H25N604FS.
Enantiomer 2: tR = 13.10 min (ChiralPak IB (Daicel, 4.6 x 250 mm, 5 μιη) same gradient as before at a flow rate of 0.8 mL/min).
1H NMR (d6-DMSO) δ: 10.84 (s, 1H); 8.77 (s, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.75 (d, J = 8.4 Hz, 1H); 7.40 (d, J = 8.4 Hz, 1H); 7.23 (d, J = 9.0 Hz, 1H); 4.01-4.11 (overlapped m, 2H); 4.05 (s, 3H); 3.52 (s, 2H); 3.28-3.38 (m, 4H); 2.99 (m, 1H); 2.70-2.86 (m, 2H); 2.07-2.26 (m, 2H); 1.72-1.86 (m, 2H); 1.26 (m, 1H). MS (ESI, m/z): 525.2 [M+H+] for C25H25N604FS. Example 22: r c-(^aR*,«aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-6]pyridin-7-yl)- 7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.048 g, 0.23 mmol) and intermediate J (0.072 g, 0.24 mmol), the title compound was obtained as a beige foam (0.078 g, 67% yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.77 (s, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.72 (d, J = 2.3 Hz, 1H); 7.34 (d, J = 2.3 Hz, 1H); 7.23 (d, J = 9.1 Hz, 1H); 4.35-4.40 (m, 2H); 4.15-4.21 (m, 2H); 4.07 (overlapped m, 1H), 4.05 (s, 3H); 3.26-3.50 (m, 5H); 2.97 (m, 1H); 2.77-2.85 (m, 2H), 2.15 (m, 1H); 2.10 (t, J = 10.0 Hz, 1H); 1.84 (m, 1H); 1.74 (m, 1H); 1.20 (m, 1H). MS (ESI, m/z): 496.3 [M+H+] for C25H26N505F.
Example 23: r c-( R*,5 R*)-3-(6,7-dihydro-[l,4]dioxino[2,3-c]pyridazin-3-yl)- 7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one: Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.023 g, 0.11 mmol) and intermediate K (0.033 g, 0.11 mmol), the title compound was obtained as a yellowish foam (0.037 g, 66%o yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.76 (s, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.43 (s, 1H); 7.23 (d, J = 9.1 Hz, 1H); 4.47-4.51 (m, 2H); 4.36-4.40 (m, 2H); 4.05-4.15 (m, 2H), 4.05 (s, 3H); 3.46 (t, J = 11.3 Hz, 1H); 3.28-3.36 (m, 3H); 2.98 (m, 1H); 2.77-2.86 (m, 2H); 2.08-2.26 (m, 2H); 1.77-1.90 (m, 2H); 1.25 (m, 1H). MS (ESI, m/z): 497.3 [M+H+] for C24H25N605F.
Example 24: r c-(^aR*,«aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-c]pyridin-7-yl)- 7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.041 g, 0.2 mmol) and intermediate L (0.061 g, 0.21 mmol), the title compound was obtained as an off- white foam (0.047 g, 48% yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.76 (d, J = 0.3 Hz, 1H); 8.27 (d, J = 9.1 Hz, 1H); 7.92 (s, 1H), 7.23 (d, J = 9.1 Hz, 1H); 7.18 (s, 1H); 4.31-4.35 (m, 2H); 4.25-4.29 (m, 2H); 4.05 (s, 3H); 4.03 (m, 1H); 3.93 (dd, J = 5.1, 11.6 Hz, 1H); 3.26-3.37 (m, 4H); 2.97 (m, 1H); 2.76-2.83 (m, 2H); 2.17 (m, 1H); 2.10 (t, J = 10.1 Hz, 1H); 1.69-1.84 (m, 2H); 1.25 (m, 1H). MS (ESI, m/z): 496.3 [M+H+] for C25H26N505F. Example 25: r c-(^aR*,*aR*)-7-[2-(7-methoxy-2-oxo-2H-[l,8]naphthyridin-l-yl)-ethyl]- 3-(3-oxo-3,4-dihydro-2H-pyrido [3,2-6] [1,4] oxazin-6-yl)-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.038 g, 0.18 mmol) and intermediate H (0.072 g, 0.17 mmol), the title compound was obtained as a colourless foam (0.060 g) using the procedures described in Example 7 (reductive amination: 85% yield) and Example 19, step 19.ii (PMB deprotection: 82% yield). The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 11.18 (s, 1H); 8.04 (d, J = 8.5 Hz, 1H); 7.85 (d, J = 9.4 Hz, 1H); 7.37 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 9.4 Hz, 1H); 4.61 (s, 2H), 4.44-4.56 (m, 2H); 4.06 (m, 1H); 3.98 (s, 3H); 3.88 (m, 1H); 3.30-3.39 (m, 2H); 2.98 (m, 1H); 2.68-2.78 (m, 2H); 2.18 (m, 1H), 2.11 (t, J = 10.1 Hz, 1H); 1.71-1.86 (m, 2H); 1.27 (m, 1H). MS (ESI, m/z): 507.2 [M+H+] for C^H^NeOe. Example 26: rac-(4aR*, 5 R*)-7-[2-(7-methoxy-2-oxo-2H-[l,8]naphthyridin-l-yl)-ethyl]-
3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-6] [l,4]thiazin-6-yl)-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.028 g, 0.12 mmol) and intermediate I (0.053 g, 0.12 mmol), the title compound was obtained as a colourless foam (0.024 g) using the procedures described in Example 7 (reductive amination: 56% yield) and Example 19, step 19.ii (PMB deprotection: 69%> yield). The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 10.85 (s, 1H), 8.04 (d, J = 8.5 Hz, 1H); 7.85 (d, J = 9.4 Hz, 1H); 7.75 (d, J = 8.4 Hz, 1H); 7.41 (d, J = 8.4 Hz, 1H); 6.72 (d, J = 8.4 Hz, 1H); 6.49 (d, J = 9.4 Hz, 1H); 4.44-4.58 (m, 2H); 3.98-4.12 (m, 2H); 3.98 (s, 3H); 3.52 (s, 2H); 3.27-3.38 (m, 2H); 2.98 (m, 1H); 2.69-2.78 (m, 2H); 2.19 (m, 1H), 2.11 (t, J = 10.1 Hz, 1H); 1.72-1.86 (m, 2H); 1.28 (m, 1H). MS (ESI, m/z): 523.0 [M+H+] for C25H26N6O5S. Example 27: r c-( R*,5 R*)-3-(6,7-dihydro-8-oxa-5-thia-l,2-diaza-naphthalen-3-yl)- 7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro- pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 7-fluoro-2-methoxy-8-vinyl-l,5-naphthyridine (0.030 g, 0.147 mmol) and intermediate M (0.046 g, 0.147 mmol), the title compound was obtained as a yellowish foam (0.036 g, 48%o yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 8.76 (d, J = 0.5 Hz, 1H), 8.27 (d, J = 9.1 Hz, 1H), 7.79 (s, 1H), 7.23 (d, J = 9.1 Hz, 1H); 4.55-4.60 (m, 2H); 3.99-4.13 (m, 2H); 4.05 (s, 3H); 3.25-3.37 (m, 6H); 2.97 (m, 1H); 2.77-2.85 (m, 2H); 2.18 (m, 1H); 2.12 (t, J = 10.2 Hz, 1H); 1.76-1.84 (m, 2H); 1.25 (m, 1H). MS (ESI, m/z): 512.9 [M+H+] for C24H25N6O4FS. Example 28: r c-( R*,5 R*)-3-(6,7-dihydro-8-oxa-5-thia-l,2-diaza-naphthalen-3-yl)- 7- [2-(6-methoxy-3-oxo-3H-py rido [2,3-6] p razin-4-yl)-ethyl] -octahy dr o- pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from 2-(6-methoxy-3-oxopyrido[2,3-b]pyrazin-4(3H)-yl)acetaldehyde (prepared as described in WO 2008/009700, 0.02 g, 0.08 mmol) and intermediate M (0.025 g, 0.08 mmol), the title compound was obtained as a white solid (0.020 g, 50% yield) using the procedure described in Example 8. The crude material was purified by a preparative HPLC (Method A). 1H NMR (d6-DMSO) δ: 8.12 (d, J = 8.6 Hz, 1H); 8.11 (s, 1H); 7.79 (s, 1H); 6.84 (d, J = 8.6 Hz, 1H); 4.55-4.60 (m, 2H); 4.38-4.53 (m, 2H); 4.01 (s, 3H); 3.99-4.11 (m, 2H); 3.44 (t, J = 11.4 Hz, 1H); 3.25-3.35 (m, 3H); 2.97 (m, 1H); 2.74-2.86 (m, 2H); 2.18 (m, 1H); 2.12 (t, J = 10.2 Hz, 1H); 1.76-1.84 (m, 2H); 1.25 (m, 1H). MS (ESI, m/z): 512.2 [M+H+] for C23H25N7O5S.
Example 29: (R)-2-[(4aR*, « R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-2-oxo- octahydro-pyrido [4,3-e] [1,3] oxazin-7-ylmethyl] -9-fluoro-l,2-dihydro- pyrrolo[3,2,l-//']quinolin-4-one(mixture of stereoisomers):
To a solution of intermediate B.ii (0.057 g, 0.20 mmol) in DMF (1.6 mL) were added (R)-(9-fluoro-4-oxo-2,4-dihydro-lH-pyrrolo[3,2,l- ]quinolin-2-yl)methyl methanesulfonate (prepared as described in WO 2009/104147, 0.068 g, 0.23 mmol) and DIPEA (0.067 mL, 0.39 mmol). The mixture was stirred at 80°C for 48 h. The solvent was removed in vacuo. The residue was partitioned between sat. aq. NaHCO3 (5 mL) and DCM/MeOH (9: 1, 10 mL). The phases were separated and the aq. layer was extracted twice with the same mixture (2 x 10 mL). The combined org. layers were dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by a preparative HPLC (Method A) to give the title compound formate salt as a white solid (0.007 g, 6% yield).
MS (ESI, m/z): 492.25 [M+H+] for C24H25N6O4FS.
Example 30: (RS)-4-[( R*,« R*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-2-oxo- octahydro-pyrido [4,3-e] [1,3] oxazin-7-ylmethyl] -3-fluoro-4,5-dihydro- pyrrolo[3,2,l-ife] [l,5]naphthyridin-7-one (mixture of stereoisomers):
Starting from 3-fluoro-4-methylene-4H-pyrrolo[3,2,l-<ie][l,5]naphthyridin-7(5H)-one (prepared as described in WO 2007/071936, 0.058 g, 0.29 mmol) and intermediate B.ii (0.041 g, 0.14 mmol), the title compound was obtained as a yellow solid (0.012 g, 18% yield) using the procedure described in Examples 1 and 2, step 1/2. i. The crude material was purified by CC (DCM/MeOH 19: 1 + 0.5% aq. NH4OH).
MS (ESI, m/z): 512.9 [M+H+] for C26H25N4O5F. Example 31: rac-(4aR*, 5 R*)-7-(2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)ethyl)- 3-(3-oxo-3,4-dihydro-2H-benzo[6] [l,4]thiazin-6-yl)octahydro- 2H-pyrido [4,3-e] [1,3] oxazin-2-one:
Starting from 2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)acetaldehyde (prepared as described in WO 2008/009700; 0.030 g; 0.14 mmol) and intermediate D (0.058 g, 0.13 mmol), the title compound was obtained as a colourless foam (0.040 g) using the procedures described in Example 7 (reductive amination: 77% yield) and Example 19, step 19.ii (PMB deprotection: 76% yield). The crude material was purified by CC (DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 10.5 (s, 1H); 8.04 (d, J = 8.5 Hz, 1H); 7.86 (d, J = 9.4 Hz, 1H); 7.30 (d, J = 8.4 Hz, 1H), 6.94-6.97 (m, 2H); 6.73 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 9.4 Hz, 1H); 4.44-4.56 (m, 2H); 4.08 (m, 1H); 3.98 (s, 3H); 3.38-3.51 (m, 2H); 3.45 (s, 2H); 3.31 (m, 1H); 2.98 (m, 1H); 2.69-2.79 (m, 2H); 2.17 (m, 1H), 2.10 (t, J = 10.1 Hz, 1H); 1.71-1.86 (m, 2H); 1.24 (m, 1H). MS (ESI, m/z): 522.0 [M+H+] for C26H27N5O5S.
Example 32: (4aR*, « R*)-7-((^RS)-2-(3-fluoro-6-methoxy-l,5-naphthyridin-4-yl)- 2-hydroxyethyl)-3-(3-oxo-3,4-dihydro-2H-benzo [b] [1,4] oxazin-6-yl)octahydro- 2H-pyrido [4,3-e] [1,3] oxazin-2-one:
Starting from rac-7-fluoro-2-methoxy-8-(oxiran-2-yl)-l,5-naphthyridine (prepared as described in WO 2004/058144; 0.044 g; 0.2 mmol) and intermediate C.i (0.080 g, 0.19 mmol), the title compound was obtained as a yellow foam (0.033 g) using the procedures described in Example 3 (epoxide opening, 74% yield) and Example 19, step 19.Π (PMB deprotection, 44% yield). The crude material was purified by CC (DCM/MeOH 13: 1 + 0.3% aq. NH4OH).
MS (ESI, m/z): 524.4 [M+H+] for C^H^NsOeF. Example 33 : (4aR *,8aR *)-7-(((R)-9-fluoro-4-oxo-2,4-dih dro- lH-pyrrolo[3,2,l- /]quinolin-2-yl)methyl)-3-(3-oxo-3,4-dihydro-
2H-pyrido[3,2-6] [l,4]oxazin-6-yl)octahydro-2H-pyrido[4,3-e] [l,3]oxazin-2-one:
Starting from intermediate H (0.110 g, 0.336 mmol) and (R)-(9-fluoro-4-oxo-2,4-dihydro- lH-pyrrolo[3,2,l- ]quinolin-2-yl)methyl methanesulfonate (prepared as described in WO 2009/104147; 0.110 g, 0.26 mmol), the title compound was obtained as a yellow foam (0.061 g) using the procedure described in Example 29 (mesylate displacement, 54% yield) and Example 19, step 19.ii (PMB deprotection, 90%> yield). The crude material was purified by CC (DCM/MeOH 13: 1 + 0.3% aq. NH4OH).
MS (ESI, m/z): 506.2 [M+H+] for C26H24N5O5F.
Example 34: rac-(4aR*, 5 R*)-7-(2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)ethyl)-
3-(3-oxo-3,4-dihydro-2H-benzo[6] [l,4]oxazin-6-yl)octahydro-
2H-pyrido [4,3-e] [1,3] oxazin-2-one:
Starting from 2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)acetaldehyde (prepared as described in WO 2008/009700; 0.030 g; 0.14 mmol) and intermediate C.i (0.057 g,
0.135 mmol), the title compound was obtained as a colourless foam (0.029 g) using the procedures described in Example 7 (reductive amination: 50%> yield) and Example 19, step 19.ii (PMB deprotection: 85% yield). The crude material was purified by CC
(DCM/MeOH 97:3 + 0.3% aq. NH4OH).
1H NMR (d6-DMSO) δ: 10.7 (s, 1H); 8.04 (d, J = 8.5 Hz, 1H); 7.85 (d, J = 9.4 Hz, 1H);
6.83-6.93 (m, 3H); 6.73 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 9.4 Hz, 1H); 4.54 (s, 2H);
4.44-4.56 (m, 2H); 4.08 (m, 1H); 3.98 (s, 3H); 3.38-3.49 (m, 2H); 3.32 (m, 1H); 2.98 (m, 1H);
2.68-2.80 (m, 2H); 2.16 (m, 1H), 2.09 (t, J = 10.1 Hz, 1H); 1.71-1.86 (m, 2H); 1.22 (m, 1H).
MS (ESI, m/z): 506.2 [M+H+] for C26H27N5O6. Pharmacological properties of the invention compounds
In vitro assays
Bacterial growth minimal inhibitory concentrations: Experimental methods: Minimal inhibitory concentrations (MICs; mg/1) were determined in cation-adjusted Mueller- Hinton Broth by a microdilution method following the description given in "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically", Approved standard, 7th ed., Clinical and Laboratory Standards Institute (CLSI) Document M7-A7, Wayne, PA, USA, 2006. All Example compounds were tested against several Gram positive and Gram negative bacteria. Typical antibacterial test results are given in the table hereafter (MIC in mg/1).
Example No. MIC for Example No. MIC for
S. aureus 29213 S. aureus 29213
1 ≤ 0.031 2 ≤ 0.031
3 0.125 4 0.063
5 ≤ 0.031 6 0.063
7 ≤ 0.031 8 ≤ 0.031
9 ≤ 0.031 10 ≤ 0.031
11 ≤ 0.031 12 ≤ 0.031
13 0.063 14 ≤ 0.031
15 0.063 16 0.125
17 0.063 18 0.063
19 ≤ 0.031 20 ≤ 0.031
21 ≤ 0.031 22 ≤ 0.031
23 ≤ 0.031 24 ≤ 0.031
25 ≤ 0.031 26 ≤ 0.031
27 ≤ 0.031 28 ≤ 0.031
29 0.25 30 0.5
31 ≤ 0.031 32 0.125 Example No. MIC for Example No. MIC for S. aureus 29213 S. aureus 29213
33 0.125 34 0.25

Claims

Claims
1. A compound of formula I wherein the relative configuration of the octahydro pyrido[4,3-e][l,3]oxazinone moiet is trans
Figure imgf000073_0001
wherein
K represents the group Ka
Figure imgf000073_0002
wherein Rla represents alkoxy, halogen or cyano;
one or two of Ua, Va, Wa represent(s) N and the remaining each represent CH;
Xa represents CRa wherein Ra represents hydrogen or halogen;
A represents CHRb wherein Rb represents hydrogen or hydroxyl; or K represents the group Kb
Figure imgf000073_0003
Kb
wherein R represents hydrogen, alkoxy, halogen or cyano;
one or two of Ub, Vb, and Wb represent(s) N and the remaining each represent CH; or K represents the roup Kc or Kd wherein
Figure imgf000074_0001
Kc Kd wherein Rlc and Rld independently represent H or F;
Vc, Vd, Wc and Wd independently represent CH or N; and
G represents one of the groups Ga, Gb, Gc and Gd
Figure imgf000074_0002
Ga Gb Gc Gd wherein M represents CH or N; and Q and Q' independently represent O or S; or a salt of such a compound.
2. A compound of formula I according to claim 1, wherein K represents the group Ka or Kb; or a salt of such a compound.
3. A compound of formula I according to claim 2, wherein K represents the group Ka wherein Rla represents methoxy, or wherein K represents the group Kb wherein Rlb represents methoxy; or a salt of such a compound.
4. A compound of formula I according to claim 2, wherein K represents the group Ka; or a salt of such a compound.
5. A compound of formula I according to claim 4, wherein A represents CHRb wherein Rb represents hydrogen; or a salt of such a compound.
6. A compound of formula I according to claim 4, wherein A represents CHRb wherein Rb represents hydroxyl, and the absolute configuration of the carbon atom to which Rb is attached to is (R); or a salt of such a compound.
7. A compound of formula I according to claim 2, wherein K represents the group Kb; or a salt of such a compound.
8. A compound of formula I according to one of claims 1 to 7, wherein G represents a group selected from the groups consisting of
Figure imgf000075_0001
(Ga) (Gb) (Gc)
wherein
• M represents CH and Q' represent O or S; or
• M represents N and Q' represents S; and
• Q represents O or S; or a salt of such a compound.
9. A compound of formula I according to claim 1 , wherein:
• K represents the group Ka
Figure imgf000075_0002
wherein Rla represents methoxy;
Ua and Wa each represent N and Va and Xa each represent CH;
Xa represents CRa wherein Ra represents fluorine;
A represents CHRb wherein Rb represents hydrogen or hydroxyl;
or K represents the group Kb
Figure imgf000076_0001
Kb
wherein R represents methoxy;
Ub represents N, Vb represents CH and Wb represents CH or N; and
· G represents one of the groups Gb and Gc
Figure imgf000076_0002
wherein Q represents O or S; or a salt of such a compound.
10. A compound of formula I according to claim 1, which is selected from the following:
• (^aR,5aR)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy- [1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aS,Sa>S)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-hydroxy-2-(6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
· (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(6-methoxy-[ 1 ,5]naphthyridin- 4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one; • (^aR*,5aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-benzo[ 1 ,4]oxazin-6-yl)-octahydro-pyrido[4,3-e] [1 ,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-fluoro-6-methoxy-
[ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
· (^aR*,5aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-
3,4-dihydro-2H-benzo[ 1 ,4]thiazin-6-yl)-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(7-methoxy-2-oxo-2H-quinolin- l-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(7-methoxy-2-oxo- 2H-qumoxalin-l-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(7-methoxy-2-oxo- 2H- [ 1 , 8]naphthyridin- 1 -yl)-ethyl] -octahydro-pyrido [4,3 -e] [ 1 ,3 ] oxazin-2-one ;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(6-methoxy-3-oxo- 3H-pyrido[2,3-b]pyrazin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
· (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(3-methoxy-6-oxo-
6H-pyrido[2,3-b]pyrazin-5-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(R)-2-(3-fluoro-6-methoxy-
[ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aS,SaS)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR,5aR)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[(S)-2-(3-fluoro-6-methoxy-
[ 1 ,5]naphthyridin-4-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-(7-fluoro-2-methoxy-quinolin- 8-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
· (4aR *,8aR *)-3-(2,3-dihydro-benzo[ 1 ,4]dioxin-6-yl)-7-[2-(6-fluoro-3-methoxy- quinoxalin-5-yl)-2-hydroxy-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-7-[2-hydroxy-2-(3-methoxy- quinoxalin-5-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazm-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR,5aR)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-3,4-dihydro- 2H-pyrido[3,2-b] [ 1 ,4]thiazin-6-yl)-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one; • (^aS,5aS)-7-[2-(3-fluoro-6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-3-(3-oxo-3,4-dihydro 2H-pyrido[3,2-b] [ 1 ,4]thiazin-6-yl)-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-b]pyridin-7-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ l,3]oxazin-2-one;
· (^aR^5aR*)-3-(6,7-dihydro-[l,4]dioxino[2,3-c]pyridazin-3-yl)-7-[2-(3-fluoro-
6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (4aR*, 5aR*)-3-(2,3-dihydro-[l,4]dioxino[2,3-c]pyridin-7-yl)-7-[2-(3-fluoro-6-methoxy- [ 1 ,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (^aR^5aR*)-7-[2-(7-methoxy-2-oxo-2H-[l,8]naphthyridin-l-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR^5aR*)-7-[2-(7-methoxy-2-oxo-2H-[l,8]naphthyridin-l-yl)-ethyl]-3-(3-oxo- 3,4-dihydro-2H-pyrido[3,2-b][l,4]thiazin-6-yl)-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (^aR*,5aR*)-3-(6,7-dihydro-8-oxa-5-thia-l,2-diaza-naphthalen-3-yl)-7-[2-(3-fluoro- 6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one; · (^aR*,5aR*)-3-(6,7-dihydro-8-oxa-5-thia-l,2-diaza-naphthalen-3-yl)-7-[2-(6-methoxy-
3- oxo-3H-pyrido[2,3-b]pyrazm-4-yl)-ethyl]-octahydro-pyrido[4,3-e][l,3]oxazin-2-one;
• (R)-2-[(4aR* SaR*)-3-(2,3-dihydro-benz
pyrido[4,3-e][l,3]oxazin-7-ylmethyl]-9-fl^^
4- one;
· 4-[(^aR*,5aR*)-3-(2,3-dihydro-benzo[l,4]dioxin-6-yl)-2-oxo-octahydro- pyrido[4,3-e][l,3]oxazin-7-ylmethyl]-3-fluoro-4,5-dihydro- pyrrolo[3 ,2, 1 -de] [ 1 ,5]naphthyridin-7-one;
• (^aR*,5aR*)-7-(2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)ethyl)-3-(3-oxo- 3,4-dihydro-2H-benzo[b][l,4]thiazin-6-yl)octahydro-2H-pyrido[4,3-e][l,3]oxazin-2-one; · (4aR *,8aR *)-7-((2RS)-2-(3-fluoro-6-methoxy- 1 ,5-naphthyridin-4-yl)-2-hydroxyethyl)- 3-(3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl)octahydro- 2H-pyrido[4,3-e] [ 1 ,3]oxazin-2-one;
• (4aR *,8aR *)-7-(((R)-9-fluoro-4-oxo-2,4-dihydro- lH-pyrrolo[3,2, 1 - /']quinolin- 2-yl)methyl)-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-6-yl)octahydro- 2H-pyrido[4,3-e][l,3]oxazin-2-one; and
• (^aR*,5aR*)-7-(2-(7-methoxy-2-oxo-l,8-naphthyridin-l(2H)-yl)ethyl)-3-(3-oxo- 3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl)octahydro-2H-pyrido[4,3-e][l,3]oxazin-2-one; or a salt of such a compound.
11. As a medicament, a compound of formula I as defined in one of claims 1 to 10, or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
13. A compound of formula I as defined in one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for the prevention or treatment of a bacterial infection.
14. A compound or pharmaceutically acceptable salt according to claim 13, which is for the prevention or treatment of a bacterial infection selected from the group consisting of respiratory tract infections, otitis media, meningitis, skin and soft tissue infections, pneumonia, bacteremia, endocarditis, intraabdominal infections, gastrointestinal infections, Clostridium difficile infections, urinary tract infections, sexually transmitted infections, foreign body infections, osteomyelitis, lyme disease, topical infections, opthalmological infections, tuberculosis and tropical diseases.
15. A compound or pharmaceutically acceptable salt according to claim 14, which is for the prevention or treatment of a bacterial infection selected from the group consisting of respiratory tract infections, otitis media, meningitis, skin and soft tissue infections, pneumonia and bacteremia.
PCT/IB2012/056829 2011-11-30 2012-11-29 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics WO2013080156A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201280058091.3A CN103958525A (en) 2011-11-30 2012-11-29 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
CA2854266A CA2854266A1 (en) 2011-11-30 2012-11-29 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
US14/362,026 US9029368B2 (en) 2011-11-30 2012-11-29 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics
JP2014544023A JP2014533747A (en) 2011-11-30 2012-11-29 3,7-Disubstituted octahydro-2H-pyrido [4,3-e] [1,3] oxazin-2-one antibiotic
EP12813981.3A EP2785721A1 (en) 2011-11-30 2012-11-29 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011055383 2011-11-30
IBPCT/IB2011/055383 2011-11-30

Publications (1)

Publication Number Publication Date
WO2013080156A1 true WO2013080156A1 (en) 2013-06-06

Family

ID=47557414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/056829 WO2013080156A1 (en) 2011-11-30 2012-11-29 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics

Country Status (7)

Country Link
US (1) US9029368B2 (en)
EP (1) EP2785721A1 (en)
JP (1) JP2014533747A (en)
CN (1) CN103958525A (en)
CA (1) CA2854266A1 (en)
TW (1) TW201326180A (en)
WO (1) WO2013080156A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096686A1 (en) 2014-12-17 2016-06-23 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Antibacterial compounds having broad spectrum of activity
WO2017137743A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Antibacterial compounds
WO2017137742A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Antibacterial compounds
WO2017137744A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
WO2017211759A1 (en) 2016-06-08 2017-12-14 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. New antibacterial compounds
JP2018523675A (en) * 2015-08-16 2018-08-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Antibacterial agents comprising pyrazino [2,3-b] [1,4] oxazin-3-one or related ring systems
US10369130B2 (en) 2014-12-17 2019-08-06 AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Antibacterial compounds

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164118A (en) * 2013-05-08 2015-12-16 埃科特莱茵药品有限公司 Antibacterial phthalide derivatives
SG11202012222TA (en) * 2018-08-13 2021-01-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
MX2021001433A (en) 2018-08-13 2021-04-12 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors.
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078748A1 (en) 1999-06-21 2000-12-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
WO2002008224A1 (en) 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2002056882A1 (en) 2001-01-22 2002-07-25 Smithkline Beecham P.L.C. Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents
WO2002089749A2 (en) 2001-05-10 2002-11-14 Abbott Gmbh & Co.Kg Arylsulfonamide ethers, and methods of use thereof
WO2003050132A1 (en) 2001-12-05 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. 6-o-acyl ketolide derivatives of erythromycine useful as antibacterials
WO2004009562A1 (en) 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
WO2004058144A2 (en) 2002-12-18 2004-07-15 Glaxo Group Limited Antibacterial agents
WO2005000838A1 (en) 2003-06-19 2005-01-06 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
WO2005016916A2 (en) 2003-08-08 2005-02-24 Novexel Substituted quinolines serving as antimicrobial agents
WO2005108389A1 (en) 2004-05-12 2005-11-17 Eisai R & D Management Co., Ltd. Indole derivatives having piperidine rings
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
WO2006021448A1 (en) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel compounds having an anti-bacterial activity
WO2006032466A2 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
WO2006105289A1 (en) 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
WO2006137485A1 (en) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. Novel nitrogenated heterocyclic compound and salt thereof
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
WO2007071936A1 (en) 2005-12-22 2007-06-28 Glaxo Group Limited Heterocyclic compounds, their preparation and their use as antibacterials
WO2007081597A2 (en) 2005-10-21 2007-07-19 Glaxo Group Limited Peri condensed tricyclic compounds useful as antibacterial agents
WO2007100758A2 (en) 2005-02-28 2007-09-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007107965A1 (en) 2006-03-23 2007-09-27 Actelion Pharmaceuticals Ltd Cyclohexyl or piperidinyl carboxamide antibiotic derivatives
WO2007107905A2 (en) 2006-03-17 2007-09-27 Koninklijke Philips Electronics N.V. Protection of software from piracy
WO2007138974A1 (en) 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
WO2008003690A1 (en) 2006-07-03 2008-01-10 Glaxo Group Limited Azatricyclic compounds and their use
WO2008009700A1 (en) 2006-07-20 2008-01-24 Glaxo Group Limited Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
WO2008026172A1 (en) * 2006-08-30 2008-03-06 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
WO2008125594A1 (en) 2007-04-13 2008-10-23 Glaxo Group Limited Pyrrolo (3, 2, 1-ij) quinoline-4-one derivatives for treating tuberculosis
WO2008126024A2 (en) 2007-04-11 2008-10-23 Actelion Pharmaceuticals Ltd Oxazolidinone antibiotic derivatives
WO2009009700A2 (en) 2007-07-10 2009-01-15 Timothy Adams Heimlich or abdominal thrust maneuver teaching aid for choking relief or rescue
WO2009069589A1 (en) 2007-11-26 2009-06-04 Toyama Chemical Co., Ltd. Novel naphthyridine derivative monohydrate and method for producing the same
WO2009071890A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009104159A1 (en) 2008-02-22 2009-08-27 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
WO2009104147A2 (en) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Azatricyclic antibiotic compounds
WO2010030782A1 (en) 2008-09-12 2010-03-18 Nellcor Puritan Bennett Llc Low power isolation design for a multiple sourced power bus
WO2010041194A1 (en) 2008-10-07 2010-04-15 Actelion Pharmaceuticals Ltd Tricyclic oxazolidinone antibiotic compounds
WO2011057892A1 (en) 2009-10-27 2011-05-19 Elara Pharmaceuticals Gmbh 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivates as hif-inhibitors for the treatment of cancer and inflammatory diseases

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078748A1 (en) 1999-06-21 2000-12-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
WO2002008224A1 (en) 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2002056882A1 (en) 2001-01-22 2002-07-25 Smithkline Beecham P.L.C. Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents
WO2002089749A2 (en) 2001-05-10 2002-11-14 Abbott Gmbh & Co.Kg Arylsulfonamide ethers, and methods of use thereof
WO2003050132A1 (en) 2001-12-05 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. 6-o-acyl ketolide derivatives of erythromycine useful as antibacterials
WO2004009562A1 (en) 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
WO2004058144A2 (en) 2002-12-18 2004-07-15 Glaxo Group Limited Antibacterial agents
WO2005000838A1 (en) 2003-06-19 2005-01-06 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
WO2005016916A2 (en) 2003-08-08 2005-02-24 Novexel Substituted quinolines serving as antimicrobial agents
WO2005108389A1 (en) 2004-05-12 2005-11-17 Eisai R & D Management Co., Ltd. Indole derivatives having piperidine rings
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
WO2006021448A1 (en) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel compounds having an anti-bacterial activity
WO2006032466A2 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
WO2007100758A2 (en) 2005-02-28 2007-09-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2006105289A1 (en) 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
WO2006137485A1 (en) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. Novel nitrogenated heterocyclic compound and salt thereof
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
WO2007081597A2 (en) 2005-10-21 2007-07-19 Glaxo Group Limited Peri condensed tricyclic compounds useful as antibacterial agents
WO2007071936A1 (en) 2005-12-22 2007-06-28 Glaxo Group Limited Heterocyclic compounds, their preparation and their use as antibacterials
WO2007107905A2 (en) 2006-03-17 2007-09-27 Koninklijke Philips Electronics N.V. Protection of software from piracy
WO2007107965A1 (en) 2006-03-23 2007-09-27 Actelion Pharmaceuticals Ltd Cyclohexyl or piperidinyl carboxamide antibiotic derivatives
WO2007138974A1 (en) 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
WO2008003690A1 (en) 2006-07-03 2008-01-10 Glaxo Group Limited Azatricyclic compounds and their use
WO2008009700A1 (en) 2006-07-20 2008-01-24 Glaxo Group Limited Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
WO2008026172A1 (en) * 2006-08-30 2008-03-06 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
WO2008126024A2 (en) 2007-04-11 2008-10-23 Actelion Pharmaceuticals Ltd Oxazolidinone antibiotic derivatives
WO2008125594A1 (en) 2007-04-13 2008-10-23 Glaxo Group Limited Pyrrolo (3, 2, 1-ij) quinoline-4-one derivatives for treating tuberculosis
WO2009009700A2 (en) 2007-07-10 2009-01-15 Timothy Adams Heimlich or abdominal thrust maneuver teaching aid for choking relief or rescue
WO2009069589A1 (en) 2007-11-26 2009-06-04 Toyama Chemical Co., Ltd. Novel naphthyridine derivative monohydrate and method for producing the same
WO2009071890A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009104147A2 (en) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Azatricyclic antibiotic compounds
WO2009104159A1 (en) 2008-02-22 2009-08-27 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
WO2010030782A1 (en) 2008-09-12 2010-03-18 Nellcor Puritan Bennett Llc Low power isolation design for a multiple sourced power bus
WO2010041194A1 (en) 2008-10-07 2010-04-15 Actelion Pharmaceuticals Ltd Tricyclic oxazolidinone antibiotic compounds
WO2011057892A1 (en) 2009-10-27 2011-05-19 Elara Pharmaceuticals Gmbh 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivates as hif-inhibitors for the treatment of cancer and inflammatory diseases

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Approved standard", 2006, CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI, article "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically"
"Pharmaceutical Preformulation and Formulation", 2001, IHS HEALTH GROUP, ENGLEWOOD, CO
"Remington, The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing"
"Remington, The Science and Practice of Pharmacy", PHILADELPHIA COLLEGE OF PHARMACY AND SCIENCE
"Salt selection for basic drugs", INT. J. PHARM., vol. 33, 1986, pages 201 - 217
J. CHEM. SOC., 1957, pages 3066 - 3071
J. ORG. CHEM., vol. 33, no. 1, 1968, pages 456 - 457
R. C. LAROCK: "Comprehensive Organic Transformations. A guide to Functional Group Preparations", 1999, WILEY-VC, pages: 1075 - 1087,109
R. C. LAROCK: "Comprehensive Organic Transformations. A guide to Functional Group Preparations", 1999, WILEY-VC, pages: 1234 - 1236
T.W. GREENE; P.G.M. WUTS: "Protecting Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS, INC., pages: 494 - 653
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE
TETRAHEDRON, vol. 60, 2004, pages 7899 - 7906
TETRAHEDRON, vol. 64, 2008, pages 2456 - 2464

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096686A1 (en) 2014-12-17 2016-06-23 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Antibacterial compounds having broad spectrum of activity
US10221144B2 (en) 2014-12-17 2019-03-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Antibacterial compounds having broad spectrum of activity
US10369130B2 (en) 2014-12-17 2019-08-06 AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Antibacterial compounds
JP2018523675A (en) * 2015-08-16 2018-08-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Antibacterial agents comprising pyrazino [2,3-b] [1,4] oxazin-3-one or related ring systems
WO2017137743A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Antibacterial compounds
WO2017137742A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Antibacterial compounds
WO2017137744A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
US10487093B2 (en) 2016-02-08 2019-11-26 Redx Pharma Plc Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
WO2017211759A1 (en) 2016-06-08 2017-12-14 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. New antibacterial compounds
WO2017211760A1 (en) 2016-06-08 2017-12-14 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. New antibacterial compounds
US10633366B2 (en) 2016-06-08 2020-04-28 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Antibacterial compounds
US10640488B2 (en) 2016-06-08 2020-05-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Antibacterial compounds

Also Published As

Publication number Publication date
JP2014533747A (en) 2014-12-15
US9029368B2 (en) 2015-05-12
CA2854266A1 (en) 2013-06-06
US20140309218A1 (en) 2014-10-16
CN103958525A (en) 2014-07-30
TW201326180A (en) 2013-07-01
EP2785721A1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
US9029368B2 (en) 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics
DK2344495T3 (en) TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
JP5349500B2 (en) Azatric cyclic antibacterial compounds
CA2744456C (en) 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
EP2346862B1 (en) 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents
AU2009278791A1 (en) Tricyclic alkylaminomethyloxazolidinone derivatives
AU2010233387B2 (en) 2-hydroxyethyl-1H-quinolin-2-one derivatives and their azaisosteric analogues with antibacterial activity
ES2440551T3 (en) [4- (1-Amino-ethyl) -cyclohexyl] -methyl-amine and [6- (1-amino-ethyl) -tetrahydro-pyran-3-yl] -methyl-amine derivatives as antibacterials
US8012961B2 (en) Tricyclic antibiotics
WO2009034546A2 (en) Trans-decahydroisoquinoline derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12813981

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012813981

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2854266

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014544023

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14362026

Country of ref document: US